<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques - Farquhar, C - 2017 | Cochrane Library</title> <meta content="Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques - Farquhar, C - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006109.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques - Farquhar, C - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006109.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006109.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques" name="citation_title"/> <meta content="Cindy Farquhar" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Luk Rombauts" name="citation_author"/> <meta content="Monash University" name="citation_author_institution"/> <meta content="Jan AM Kremer" name="citation_author"/> <meta content="Radboud University Nijmegen Medical Center" name="citation_author_institution"/> <meta content="Anne Lethaby" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="a.lethaby@auckland.ac.nz" name="citation_author_email"/> <meta content="Reuben Olugbenga Ayeleke" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD006109.pub3" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/05/25" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006109.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006109.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006109.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Contraceptives, Oral [*administration &amp; dosage]; Estrogens [*administration &amp; dosage]; Fertilization in Vitro [*methods]; Gonadotropin-Releasing Hormone [antagonists &amp; inhibitors]; Infertility, Female; Live Birth [epidemiology]; Ovarian Hyperstimulation Syndrome [epidemiology]; Ovulation Induction [*methods]; Pregnancy Rate; Pregnancy, Multiple [statistics &amp; numerical data]; Progestins [*administration &amp; dosage]; Randomized Controlled Trials as Topic; Sperm Injections, Intracytoplasmic; Treatment Outcome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006109.pub3&amp;doi=10.1002/14651858.CD006109.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006109.pub3&amp;doi=10.1002/14651858.CD006109.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006109.pub3&amp;doi=10.1002/14651858.CD006109.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006109.pub3&amp;doi=10.1002/14651858.CD006109.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006109.pub3&amp;doi=10.1002/14651858.CD006109.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006109.pub3&amp;doi=10.1002/14651858.CD006109.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006109.pub3&amp;doi=10.1002/14651858.CD006109.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006109.pub3&amp;doi=10.1002/14651858.CD006109.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006109.pub3&amp;doi=10.1002/14651858.CD006109.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006109.pub3&amp;doi=10.1002/14651858.CD006109.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006109.pub3&amp;doi=10.1002/14651858.CD006109.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006109.pub3&amp;doi=10.1002/14651858.CD006109.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006109.pub3&amp;doi=10.1002/14651858.CD006109.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006109.pub3&amp;doi=10.1002/14651858.CD006109.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006109.pub3&amp;doi=10.1002/14651858.CD006109.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006109.pub3&amp;doi=10.1002/14651858.CD006109.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006109.pub3&amp;doi=10.1002/14651858.CD006109.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006109.pub3&amp;doi=10.1002/14651858.CD006109.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006109.pub3&amp;doi=10.1002/14651858.CD006109.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006109.pub3&amp;doi=10.1002/14651858.CD006109.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006109.pub3&amp;doi=10.1002/14651858.CD006109.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006109.pub3&amp;doi=10.1002/14651858.CD006109.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006109.pub3&amp;doi=10.1002/14651858.CD006109.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="STpJR8yz";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006109\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006109\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006109\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006109\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","de","pt","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006109.pub3",title:"Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques",firstPublishedDate:"May 25, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=STpJR8yz&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006109.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006109.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006109.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006109.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006109.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006109.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006109.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006109.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006109.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006109.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>10465 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006109.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006109.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006109.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006109.pub3/full#CD006109-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006109.pub3/full#CD006109-sec-0254"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006109.pub3/full#CD006109-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006109.pub3/full#CD006109-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006109.pub3/full#CD006109-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006109.pub3/full#CD006109-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006109.pub3/full#CD006109-sec-0060"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006109.pub3/full#CD006109-sec-0244"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006109.pub3/appendices#CD006109-sec-0259"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/table_n/CD006109StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/table_n/CD006109StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006109.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006109.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006109.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006109.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006109.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006109.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006109.pub3/information#CD006109-cr-0002">Cindy Farquhar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006109.pub3/information#CD006109-cr-0003">Luk Rombauts</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006109.pub3/information#CD006109-cr-0004">Jan AM Kremer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006109.pub3/information#CD006109-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Anne Lethaby</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006109.pub3/information#CD006109-cr-0006">Reuben Olugbenga Ayeleke</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/information/en#CD006109-sec-0278">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 25 May 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006109.pub3">https://doi.org/10.1002/14651858.CD006109.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006109-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006109-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006109-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006109-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006109-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006109-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006109-abs-0001" lang="en"> <section id="CD006109-sec-0001"> <h3 class="title" id="CD006109-sec-0001">Background</h3> <p>Among subfertile women undergoing assisted reproductive technology (ART), hormone pills given before ovarian stimulation may improve outcomes. </p> </section> <section id="CD006109-sec-0002"> <h3 class="title" id="CD006109-sec-0002">Objectives</h3> <p>To determine whether pretreatment with the combined oral contraceptive pill (COCP) or with a progestogen or oestrogen alone in ovarian stimulation protocols affects outcomes in subfertile couples undergoing ART. </p> </section> <section id="CD006109-sec-0003"> <h3 class="title" id="CD006109-sec-0003">Search methods</h3> <p>We searched the following databases from inception to January 2017: Cochrane Gynaecology and Fertility Group Specialised Register, The Cochrane Central Register Studies Online, MEDLINE, Embase, CINAHL and PsycINFO. We also searched the reference lists of relevant articles and registers of ongoing trials. </p> </section> <section id="CD006109-sec-0004"> <h3 class="title" id="CD006109-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) of hormonal pretreatment in women undergoing ART.</p> </section> <section id="CD006109-sec-0005"> <h3 class="title" id="CD006109-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures recommended by Cochrane. The primary review outcomes were live birth or ongoing pregnancy and pregnancy loss. </p> </section> <section id="CD006109-sec-0006"> <h3 class="title" id="CD006109-sec-0006">Main results</h3> <p>We included 29 RCTs (4701 women) of pretreatment with COCPs, progestogens or oestrogens versus no pretreatment or alternative pretreatments, in gonadotrophin‐releasing hormone (GnRH) agonist or antagonist cycles. Overall, evidence quality ranged from very low to moderate. The main limitations were risk of bias and imprecision. Most studies did not describe their methods in adequate detail. </p> <p><b>Combined oral contraceptive pill versus no pretreatment</b> </p> <p>With antagonist cycles in both groups the rate of live birth or ongoing pregnancy was lower in the pretreatment group (OR 0.74, 95% CI 0.58 to 0.95; 6 RCTs; 1335 women; I<sup>2</sup> = 0%; moderate quality evidence). There was insufficient evidence to determine whether the groups differed in rates of pregnancy loss (OR 1.36, 95% CI 0.82 to 2.26; 5 RCTs; 868 women; I<sup>2</sup> = 0%; moderate quality evidence), multiple pregnancy (OR 2.21, 95% CI 0.53 to 9.26; 2 RCTs; 125 women; I<sup>2</sup> = 0%; low quality evidence), ovarian hyperstimulation syndrome (OHSS; OR 0.98, 95% CI 0.28 to 3.40; 2 RCTs; 642 women; I<sup>2</sup> = 0%, low quality evidence), or ovarian cyst formation (OR 0.47, 95% CI 0.08 to 2.75; 1 RCT; 64 women; very low quality evidence). </p> <p>In COCP plus antagonist cycles versus no pretreatment in agonist cycles, there was insufficient evidence to determine whether the groups differed in rates of live birth or ongoing pregnancy (OR 0.89, 95% CI 0.64 to 1.25; 4 RCTs; 724 women; I<sup>2</sup> = 0%; moderate quality evidence), multiple pregnancy (OR 1.36, 95% CI 0.85 to 2.19; 4 RCTs; 546 women; I<sup>2</sup> = 0%; moderate quality evidence), or OHSS (OR 0.63, 95% CI 0.20 to 1.96; 2 RCTs; 290 women, I<sup>2</sup> = 0%), but there were fewer pregnancy losses in the pretreatment group (OR 0.40, 95% CI 0.22 to 0.72; 5 RCTs; 780 women; I<sup>2</sup> = 0%; moderate quality evidence). There were no data suitable for analysis on ovarian cyst formation. </p> <p>One small study comparing COCP versus no pretreatment in agonist cycles showed no clear difference between the groups for any of the reported outcomes. </p> <p><b>Progestogen versus no pretreatment</b> </p> <p>All studies used the same protocol (antagonist, agonist or gonadotrophins) in both groups. There was insufficient evidence to determine any differences in rates of live birth or ongoing pregnancy (agonist: OR 1.35, 95% CI 0.69 to 2.65; 2 RCTs; 222 women; I<sup>2</sup> = 24%; low quality evidence; antagonist: OR 0.67, 95% CI 0.18 to 2.54; 1 RCT; 47 women; low quality evidence; gonadotrophins: OR 0.63, 95% CI 0.09 to 4.23; 1 RCT; 42 women; very low quality evidence), pregnancy loss (agonist: OR 2.26, 95% CI 0.67 to 7.55; 2 RCTs; 222 women; I<sup>2</sup> = 0%; low quality evidence; antagonist: OR 0.36, 95% CI 0.06 to 2.09; 1 RCT; 47 women; low quality evidence; gonadotrophins: OR 1.00, 95% CI 0.06 to 17.12; 1 RCT; 42 women; very low quality evidence) or multiple pregnancy (agonist: no data available; antagonist: OR 1.05, 95% CI 0.06 to 17.76; 1 RCT; 47 women; low quality evidence; gonadotrophins: no data available). Three studies, all using agonist cycles, reported ovarian cyst formation: rates were lower in the pretreatment group (OR 0.16, 95% CI 0.08 to 0.32; 374 women; I<sup>2</sup> = 1%; moderate quality evidence). There were no data on OHSS. </p> <p><b>Oestrogen versus no pretreatment</b> </p> <p>In antagonist or agonist cycles, there was insufficient evidence to determine whether the groups differed in rates of live birth or ongoing pregnancy (antagonist versus antagonist: OR 0.79, 95% CI 0.53 to 1.17; 2 RCTs; 502 women; I<sup>2</sup> = 0%; low quality evidence; antagonist versus agonist: OR 0.88, 95% CI 0.51 to 1.50; 2 RCTs; 242 women; I<sup>2</sup> = 0%; very low quality evidence), pregnancy loss (antagonist versus antagonist: OR 0.16, 95% CI 0.02 to 1.47; 1 RCT; 49 women; very low quality evidence; antagonist versus agonist: OR 1.59, 95% CI 0.62 to 4.06; 1 RCT; 220 women; very low quality evidence), multiple pregnancy (antagonist versus antagonist: no data available; antagonist versus agonist: OR 2.24, 95% CI 0.09 to 53.59; 1 RCT; 22 women; very low quality evidence) or OHSS (antagonist versus antagonist: no data available; antagonist versus agonist: OR 1.54, 95% CI 0.25 to 9.42; 1 RCT; 220 women). Ovarian cyst formation was not reported. </p> <p><b>Head‐to‐head comparisons</b> </p> <p>COCP was compared with progestogen (1 RCT, 44 women), and with oestrogen (2 RCTs, 146 women), and progestogen was compared with oestrogen (1 RCT, 48 women), with an antagonist cycle in both groups. COCP in an agonist cycle was compared with oestrogen in an antagonist cycle (1 RCT, 25 women). Data were scant but there was no clear evidence that any of the groups differed in rates of live birth or ongoing pregnancy, pregnancy loss or other adverse events. </p> </section> <section id="CD006109-sec-0007"> <h3 class="title" id="CD006109-sec-0007">Authors' conclusions</h3> <p>Among women undergoing ovarian stimulation in antagonist protocols, COCP pretreatment was associated with a lower rate of live birth or ongoing pregnancy than no pretreatment. There was insufficient evidence to determine whether rates of live birth or ongoing pregnancy were influenced by pretreatment with progestogens or oestrogens, or by COCP pretreatment using other stimulation protocols. Findings on adverse events were inconclusive, except that progesterone pretreatment may reduce the risk of ovarian cysts in agonist cycles, and COCP in antagonist cycles may reduce the risk of pregnancy loss compared with no pretreatment in agonist cycles. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006109-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006109-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD006109-abs-0007">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD006109-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006109-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006109-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD006109-abs-0008">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006109-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006109-abs-0005" lang="en"> <h3>Pretreatments in in vitro fertilisation/intra‐cytoplasmic sperm injection cycles</h3> <p><b>Review question</b> </p> <p>The aim of this review was to assess whether pretreatment with a combined oral contraceptive pill (COCP) or with progestogen or oestrogen alone influences pregnancy outcomes in couples with low fertility undergoing assisted reproductive technology (ART) </p> <p><b>Background</b> </p> <p>In vitro fertilisation (IVF; where an egg is mixed with sperm outside the body) and intra‐cytoplasmic sperm injection (ICSI; where one sperm is injected directly into the egg) are important techniques for women who have trouble getting pregnant. IVF and ICSI cycles consist of a few steps. First the woman receives hormone therapy to stimulate her ovaries in producing egg cells (called ovarian stimulation). When a few egg cells are mature enough to be fertilised, the woman receives a single hormone injection. This triggers the ovaries to release the egg cells, so they can be gathered by the clinician. The eggs are then fertilised outside the woman's body and become embryos. One or two embryos are then transferred into the womb. </p> <p>Before the first step in IVF or ICSI cycles (hormone therapy), a pretreatment with a COCP can be given. A COCP contains both progestogen and oestrogen. Pretreatment with a progestogen or oestrogen alone could also be used before the hormone therapy. These pretreatments suppress the woman's own hormone production. This might improve the woman's response to the hormone therapy in IVF/ICSI cycles. In this way, side events such as cyst formation (fluid‐filled sac that develops on a woman's ovary) and the number of pregnancy losses might be reduced and pregnancy outcomes might be improved. </p> <p><b>Study characteristics</b> </p> <p>This Cochrane Review included 30 randomized controlled trials (clinical studies where people are randomly put into one of two or more treatment groups) assessing pretreatment with COCP, progestogen or oestrogen in 5096 women undergoing ART. The evidence is current to January 2017. </p> <p><b>Key results</b> </p> <p>Among women undergoing ovarian stimulation in antagonist protocols, COCP pretreatment was associated with a lower rate of live birth or ongoing pregnancy than no pretreatment. There was insufficient evidence to determine whether rates of live birth or ongoing pregnancy were influenced by pretreatment with progestogens or oestrogens, or by COCP pretreatment using other stimulation protocols. Findings on adverse events were inconclusive, except that progesterone pretreatment may reduce the risk of ovarian cysts in agonist cycles, and COCP in antagonist cycles may reduce the risk of pregnancy loss compared with no pretreatment in agonist cycles. </p> <p><b>Quality of the evidence</b>. </p> <p>Overall evidence quality ranged from very low to moderate. The main problems were risk of bias and imprecision. Most studies did not describe their methods in adequate detail. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006109-sec-0254" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006109-sec-0254"></div> <h3 class="title" id="CD006109-sec-0255">Implications for practice</h3> <section id="CD006109-sec-0255"> <p>Among women undergoing ovarian stimulation in antagonist protocols, COCP pretreatment was associated with a lower rate of live birth or ongoing pregnancy than no pretreatment. There was insufficient evidence to determine whether rates of live birth or ongoing pregnancy were influenced by pretreatment with progestogens or oestrogens, or by COCP pretreatment using other stimulation protocols. Findings on adverse events were inconclusive, except that progesterone pretreatment may reduce the risk of ovarian cysts in agonist cycles, and COCP in antagonist cycles may reduce the risk of pregnancy loss compared with no pretreatment in agonist cycles. </p> </section> <h3 class="title" id="CD006109-sec-0256">Implications for research</h3> <section id="CD006109-sec-0256"> <p>More and larger trials that randomise subfertile women undergoing pretreatments with COCP, progestogen or oestrogen in gonadotrophin‐releasing hormone analogue plus gonadotrophin in in vitro fertilisation/intra‐cytoplasmic sperm injection cycles are needed. Pretreatments with COCP or progestogen should be of particular interest for further research because of their clinical importance. Research should also focus more on assessment of outcomes that are of interest to subfertile women and clinicians; these outcomes include number of live births, formation of ovarian cysts, pregnancy losses and the number of women with ovarian hyperstimulation syndrome. Furthermore, research on women with low response is necessary, because evidence in this area is scant. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006109-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006109-sec-0029"></div> <div class="table" id="CD006109-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Combined oral contraceptive pill compared to no pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Combined oral contraceptive pill compared to no pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> women undergoing ART </p> <p><b>Settings:</b> ART clinic </p> <p><b>Intervention:</b> COCP </p> <p><b>Comparison:</b> no pretreatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk<sup>1</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> No pretreatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> COCP</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth or ongoing pregnancy</b> </p> <p><b>(COCP + Ant vs Ant)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>270 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>215 per 1000</b> <br/> (177 to 260) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.74</b> <br/> (0.58 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1335<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth or ongoing pregnancy</b> </p> <p><b>(COCP + Ant vs Ag)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>296 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>273 per 1000</b> <br/> (212 to 345) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.89</b> <br/> (0.64 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>724<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pregnancy loss</b> </p> <p><b>(COCP + Ant vs Ant)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>64 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>85 per 1000</b> <br/> (53 to 134) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.36</b> <br/> (0.82 to 2.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>868<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pregnancy loss</b> </p> <p><b>(COCP + Ant vs Ag)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>103 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b> <br/> (25 to 76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.40</b> <br/> (0.22 to 0.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>780<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Multiple pregnancy rate (COCP + Ant vs Ant)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>98 per 1000</b> <br/> (25 to 313) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 2.21</b> <br/> (0.53 to 9.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>125<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Multiple pregnancy rate (COCP + Ant vs Ag)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>147 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>189 per 1000</b> <br/> (127 to 273) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.36</b> <br/> (0.85 to 2.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>546<br/> (4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OHSS rate</b> </p> <p><b>(COCP + Ant vs Ant)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>16 per 1000</b> </p> <p>(4 to 52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.98</b> </p> <p>(0.28 to 3.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>642</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OHSS rate</b> </p> <p><b>(COCP + Ant vs Ag)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>35 per 1000</b> </p> <p>(11 to 102)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.63</b> </p> <p>(0.20 to 1.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>290</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Ag:</b> agonist; <b>Ant:</b> antagonist; <b>ART:</b> assisted reproductive techniques; <b>COCP:</b> combined oral contraceptive pill; <b>CI:</b> confidence interval; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Mean baseline risk of control group.<br/> <sup>2</sup> Downgraded one level for serious risk of bias due to poor reporting of sequence generation and allocation concealment.<br/> <sup>3</sup> Downgraded one level for serious imprecision: effect estimate with wide confidence intervals or low event rate (or both).<br/> <sup>4</sup> Downgraded two levels for very serious imprecision: small sample size or very low event rate, and effect estimate with wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006109-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Progestogen compared to placebo or no pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Progestogen compared to placebo or no pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> ovarian stimulation protocols for women undergoing ART </p> <p><b>Settings:</b> </p> <p><b>Intervention:</b> progestogen </p> <p><b>Comparison:</b> placebo or no pretreatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk<sup>1</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo or no pretreatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Prog</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth or ongoing pregnancy</b> </p> <p><b>(Prog + Ag vs Ag)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>170 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>217 per 1000</b> <br/> (124 to 352) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.35</b> <br/> (0.69 to 2.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>222<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth or ongoing pregnancy (Prog + Ant vs Ant)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>292 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>217 per 1000</b> <br/> (69 to 512) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.67</b> <br/> (0.18 to 2.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pregnancy loss</b> </p> <p><b>(Prog + Ag vs Ag)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b> <br/> (24 to 220) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.26</b> <br/> (0.67 to 7.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>222<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pregnancy loss</b> </p> <p><b>(Prog + Ant vs Ant)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>208 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>86 per 1000</b> <br/> (16 to 354) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.36</b> <br/> (0.06 to 2.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Multiple pregnancy rate</b> </p> <p><b>(Prog + Ag vs Ag)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Multiple pregnancy rate</b> </p> <p><b>(Prog + Ant vs Ant)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>42 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>44 per 1000</b> <br/> (3 to 438) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.05</b> <br/> (0.06 to 17.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OHSS rate</b> </p> <p><b>(Prog + Ag vs Ag)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OHSS rate</b> </p> <p><b>(Prog + Ant vs Ant)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Ag:</b> agonist; <b>Ant:</b> antagonist; <b>ART:</b> assisted reproductive techniques; <b>CI:</b> confidence interval; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>OR:</b> odds ratio; <b>Prog:</b> progestogen. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Mean baseline risk of control group.<br/> <sup>2</sup> Downgraded two levels for very serious imprecision: small sample size and effect estimate with wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006109-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oestrogen compared to no pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Oestrogen<b>compared to no p</b> retreat<b>ment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> ovarian stimulation protocols for women undergoing ART </p> <p><b>Settings:</b> </p> <p><b>Intervention:</b> oestrogen </p> <p><b>Comparison:</b> no pretreatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk<sup>1</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> No pretreatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Oestr</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth or ongoing pregnancy</b> </p> <p><b>(Oestr + Ant vs Ant)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>299 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>252 per 1000</b> <br/> (184 to 333) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.79</b> <br/> (0.53 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>502<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth or ongoing pregnancy</b> </p> <p><b>(Oestr + Ant vs Ag)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>350 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>322 per 1000</b> <br/> (215 to 447) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.88</b> <br/> (0.51 to 1.5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>242<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pregnancy loss</b> </p> <p><b>(Oestr + Ant vs Ant)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>208 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> <br/> (5 to 279) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.16</b> <br/> (0.02 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pregnancy loss</b> </p> <p><b>(Oestr + Ant vs Ag)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>72 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>110 per 1000</b> <br/> (46 to 240) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.59</b> <br/> (0.62 to 4.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Multiple pregnancy rate</b> </p> <p><b>(Oestr + Ant vs Ant)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Multiple pregnancy rate</b> </p> <p><b>(Oestr + Ant vs Ag)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not calculable ‐ see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 2.24</b> <br/> (0.09 to 53.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 2 events (both in oestrogen group)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OHSS rate</b> </p> <p><b>(Oestr + Ant vs Ant)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OHSS rate</b> </p> <p><b>(Oestr + Ant vs Ag)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>18 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>27 per 1000</p> <p>(5 to 147)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.54</p> <p>(0.25 to 9.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>220</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Ag:</b> agonist; <b>Ant:</b> antagonist; <b>ART:</b> assisted reproductive techniques; <b>CI:</b> confidence interval; <b>Oestr:</b> oestrogen; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Mean baseline risk of control group.<br/> <sup>2</sup> Downgraded one level for serious imprecision: effect estimate with wide confidence intervals.<br/> <sup>3</sup> Downgraded one level for serious risk of bias due to poor reporting on allocation concealment or high attrition (or both).<br/> <sup>4</sup> Downgraded two levels for very serious imprecision: small sample size and effect estimate with wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006109-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006109-sec-0030"></div> <p>For definitions of terminology see our Glossary (<a href="./appendices#CD006109-sec-0260">Appendix 1</a>). </p> <section id="CD006109-sec-0031"> <h3 class="title" id="CD006109-sec-0031">Description of the condition</h3> <p>For subfertile women, assisted reproductive techniques (ART) such as in vitro fertilisation (IVF) and intra‐cytoplasmic sperm injection (ICSI) can be a way to achieve pregnancy. Pregnancy and live birth rates are higher with IVF than with expectant management (<a href="./references#CD006109-bbs2-0140" title="PandianZ , BhattacharyaS , ValeL , TempletonA . In vitro fertilisation for unexplained subfertility. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD003357.pub2] ">Pandian 2005</a>). </p> <p>An IVF cycle has the following stages: ovarian stimulation, oocyte retrieval, fertilisation of the egg and transfer of the embryo. Ovarian stimulation involves the administration of gonadotrophins. These hormones stimulate growth and maturation of the follicle. Gonadotrophins include follicle‐stimulating hormone (FSH) and luteinising hormone (LH). There are two different gonadotrophin preparations; human menopausal gonadotrophin (hMG) which consists of both FSH and LH, and a more recent therapy, recombinant follicle‐stimulating hormone (rFSH). There is insufficient evidence of a difference between these treatments in ongoing pregnancy or live birth rate and other aspects with relation to IVF (<a href="./references#CD006109-bbs2-0144" title="VanWelyM , WestergaardLG , BossuytPM , Van derVeenF . Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews2003, Issue 1. [DOI: 10.1002/14651858.CD003973] ">Van Wely 2003</a>). </p> <p>There are a number of undesirable events associated with gonadotrophin therapy that can complicate treatment and outcomes: ovarian hyperstimulation syndrome (OHSS), premature LH‐surge and multiple pregnancy (<a href="./references#CD006109-bbs2-0124" title="DodsonWC . Role of gonadotropin releasing hormone agonists in ovulation induction. Journal of Reproductive Medicine1989;34(1):76‐9. ">Dodson 1989</a>). In some women undergoing IVF therapy, these problems occur because the endogenous FSH and LH production is too dominant (<a href="./references#CD006109-bbs2-0119" title="AwadallaSG , FriedmanCI , ChinNW , DoddsW , ParkJM , KimMH . Follicular stimulation for in vitro fertilization using pituitary suppression and human menopausal gonadotropins. Fertility and Sterility1987;48(5):811‐5. ">Awadalla 1987</a>). Gonadotrophin‐releasing hormone analogues (GnRHa) are administered to inhibit the production of endogenous FSH and LH (<a href="./references#CD006109-bbs2-0119" title="AwadallaSG , FriedmanCI , ChinNW , DoddsW , ParkJM , KimMH . Follicular stimulation for in vitro fertilization using pituitary suppression and human menopausal gonadotropins. Fertility and Sterility1987;48(5):811‐5. ">Awadalla 1987</a>; <a href="./references#CD006109-bbs2-0124" title="DodsonWC . Role of gonadotropin releasing hormone agonists in ovulation induction. Journal of Reproductive Medicine1989;34(1):76‐9. ">Dodson 1989</a>). Gonadotrophin‐releasing hormone (GnRH) is a hormone that occurs naturally in the woman's body and that regulates the production of gonadotrophins. There are two different types of GnRHa: agonists or antagonists. The difference lies in their mechanism of action. GnRH agonists bind to the GnRH receptors in the pituitary gland and initially stimulate the release of gonadotrophins ('flare‐up'). Negative feedback causes a decrease in the number of GnRH receptors, which results in the release of fewer gonadotrophins. In a traditional treatment protocol, GnRH agonists are administered prior to commencing gonadotrophins, ensuring that the flare‐up will be over by the time gonadotrophins are injected. Conversely, GnRH antagonists can be started after gonadotrophin therapy has been administered because they bind competitively to the receptor, causing immediate suppression of the endogenous production of FSH and LH (<a href="./references#CD006109-bbs2-0143" title="TarlatzisBC , FauserBC , KolibianakisEM , DiedrichK , RombautsL , DevroeyP . GnRH antagonists in ovarian stimulation for IVF. Human Reproduction Update2006;12(4):333‐40. [DOI: 10.1093/humupd/dml001] ">Tarlatzis 2006</a>). Therefore, GnRHa can prevent a premature LH‐surge and synchronise the follicle cohort. </p> <p>The authors of one Cochrane Review comparing GnRH agonist cycles with GnRH antagonist cycles concluded that GnRH antagonists are associated with a substantial reduction in OHSS without reducing the likelihood of achieving live birth (<a href="./references#CD006109-bbs2-0117" title="Al‐InanyHG , YoussefMA , AyelekeRO , BrownJ , LamWS , BroekmansFJ . Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD001750.pub4] ">Al‐Inany 2016</a>). </p> <p>When a few follicles reach maturity after gonadotrophin stimulation and GnRHa treatment, human chorionic gonadotrophin (hCG) is administered to trigger ovulation and 34 to 36 hours later, oocyte retrieval is undertaken and the egg is fertilised outside the body. Following fertilisation, the embryos are either transferred on day two or three (cleavage stage) or on day five or six (blastocyst stage). Luteal phase support is typically provided as a progestogen or a hCG treatment, or as a combination. </p> </section> <section id="CD006109-sec-0032"> <h3 class="title" id="CD006109-sec-0032">Description of the intervention</h3> <p>Oral contraceptive pills (OCP) are widely used by women of different ages to prevent pregnancy. They are also indicated for a range of menstrual and gynaecological conditions, such as acne vulgaris, polycystic ovary syndrome (PCOS) and menorrhagia (<a href="./references#CD006109-bbs2-0118" title="ArowojoluAO , GalloMF , LopezLM , GrimesDA , GarnerSE . Combined oral contraceptive pills for treatment of acne. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD004425.pub3] ">Arowojolu 2007</a>; <a href="./references#CD006109-bbs2-0132" title="HarwoodK , VuguinP , DiMartino‐NardiJ . Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. Hormone Research2007;68(5):209‐17. [DOI: 10.1159/000101538] ">Harwood 2007</a>; <a href="./references#CD006109-bbs2-0135" title="IrvineGA , CameronIT . Medical management of dysfunctional uterine bleeding. Best Practice and Research in Clinical Obstetrics and Gynaecology1999;13(2):189‐202. ">Irvine 1999</a>). Combined oral contraceptive pills (COCP) consisting of oestrogen and progestogen reduce the women's own production of FSH and LH by way of a negative feedback (<a href="./references#CD006109-bbs2-0122" title="CohenBL , KatzM . Pituitary and ovarian function in women receiving hormonal contraception. Contraception1979;20(5):475‐87. ">Cohen 1979</a>; <a href="./references#CD006109-bbs2-0128" title="GaspardUJ , DuboisM , GillainD , FranchimontP , DuvivierJ . Ovarian function is effectively inhibited by a low‐dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel. Contraception1984;29(4):305‐18. ">Gaspard 1984</a>). The COCP suppresses gonadal function and, in the absence of an LH‐surge, no flare‐up or premature ovulation will occur. Only progestogen has a contraceptive effect (<a href="./references#CD006109-bbs2-0126" title="ErkkolaR . Recent advances in hormonal contraception. Obstetrics and Gynecology2007;19:547‐53. ">Erkkola 2007</a>). Progestogen has the ability to slow GnRH pulsatility of the pituitary gland, thereby reducing gonadotrophin surges and, according to dose, inhibiting ovulation (<a href="./references#CD006109-bbs2-0032" title="AndersonRE , SteinAL , PaulsonRJ , StanczykFZ , VijodAG , LoboRA . Effects of norethindrone on gonadotropin and ovarian‐steroid secretion when used for cycle programming during in vitro fertilization. Fertility and Sterility1990;54(1):96‐101. ">Anderson 1990</a>; <a href="./references#CD006109-bbs2-0126" title="ErkkolaR . Recent advances in hormonal contraception. Obstetrics and Gynecology2007;19:547‐53. ">Erkkola 2007</a>; <a href="./references#CD006109-bbs2-0136" title="LeNestourE , MarraouiJ , LahlouN , RogerM , DeZieglerD , BouchardP . Role of estradiol in the rise in follicle‐stimulating hormone levels during the luteal‐follicular transition. Journal of Clinical Endocrinology and Metabolism1993;77(2):439‐42. ">Le Nestour 1993</a>; <a href="./references#CD006109-bbs2-0139" title="MoudgalRN , Jagannadha RaoA , MurthyGSRC , NeelakantaR , BanavarSR , KotagiSG , et al. Effect of intranasal administration of norethisterone and progesterone on pituitary and gonadal function in adult male and female bonnet monkeys (Macaca radiata). Fertility and Sterility1985;44(1):120‐4. ">Moudgal 1985</a>). Oestrogen is added to the COCP to regulate the bleeding patterns, though it is also capable of reducing FSH levels (<a href="./references#CD006109-bbs2-0123" title="DeZieglerD , JaaskelainenAS , BrioschiPA , FanchinR , BullettiC . Synchronization of endogenous and exogenous FSH stimuli in controlled ovarian hyperstimulation (COH). Human Reproduction1998;13(3):561‐4. ">De Ziegler 1998</a>; <a href="./references#CD006109-bbs2-0136" title="LeNestourE , MarraouiJ , LahlouN , RogerM , DeZieglerD , BouchardP . Role of estradiol in the rise in follicle‐stimulating hormone levels during the luteal‐follicular transition. Journal of Clinical Endocrinology and Metabolism1993;77(2):439‐42. ">Le Nestour 1993</a>). </p> <p>Most of progestogen‐only pills do not inhibit ovulation although higher doses of progestogen may do so (<a href="./references#CD006109-bbs2-0126" title="ErkkolaR . Recent advances in hormonal contraception. Obstetrics and Gynecology2007;19:547‐53. ">Erkkola 2007</a>). </p> </section> <section id="CD006109-sec-0033"> <h3 class="title" id="CD006109-sec-0033">How the intervention might work</h3> <p>The COCP given prior to gonadotrophin in an IVF cycle assists synchronisation of follicular development and prevents occurrence of spontaneous LH‐surges (<a href="./references#CD006109-bbs2-0067" title="GonenY , JacobsonW , CasperRF . Gonadotropin suppression with oral contraceptives before in vitro fertilization. Fertility and Sterility1990;53(2):282‐7. ">Gonen 1990</a>). Huirne reported similar data as well as a reduction of the occurrence of large follicles prior to day eight (<a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>). In another study, both the COCP and progestogen had a suppressive effect on LH and FSH secretion. However, oestrogen administration (at 4 mg/day) did not suppress serum LH and FSH concentrations (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>). </p> <p>The resulting pituitary suppression of COCPs in GnRH antagonist cycles is associated with slower follicular growth and lower serum oestradiol levels than in antagonist cycles with no pretreatment in the early part of the cycle. This results in a longer duration of rFSH stimulation and a higher total rFSH consumption than in antagonist cycles without pretreatment (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>). </p> <p>COCP pretreatment in an ovarian stimulation protocol before IVF can reduce cyst formation, shorten the length of GnRHa treatment and reduce the amount of gonadotrophin needed, without negatively affecting the pregnancy rate (<a href="./references#CD006109-bbs2-0121" title="BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF , TanSL . Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin‐releasing hormone analogues and on subsequent implantation and pregnancy rates. Fertility and Sterility1998;70(6):1063‐9. ">Biljan 1998a</a>). Pituitary suppression seems to occur earlier with progestogen pretreatment and fewer ovarian cysts are formed, when compared with no pretreatment (<a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>). COCP pretreatment can be used for scheduling oocyte retrieval on days of the working week, which is important with antagonist cycles (<a href="./references#CD006109-bbs2-0120" title="BarmatLI , ChantilisSJ , HurstBS , DickeyRP . A randomized prospective trial comparing gonadotropin‐releasing hormone (GnRH) antagonist/ recombinant follicle‐stimulating hormone (rFSH) versus GnRH‐agonist/ rFSH in women pretreated with oral contraceptives before in vitro fertilization. Fertility and Sterility2005;83(2):321‐30. [DOI: 10.1016/j.fertnstert.2004.06.076] ">Barmat 2005</a>; <a href="./references#CD006109-bbs2-0067" title="GonenY , JacobsonW , CasperRF . Gonadotropin suppression with oral contraceptives before in vitro fertilization. Fertility and Sterility1990;53(2):282‐7. ">Gonen 1990</a>; <a href="./references#CD006109-bbs2-0134" title="HuirneJA , HuguesJN , PirardC , FischlF , SageJC , PoulyJL , et al. Cetrorelix in an oral contraceptive‐pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r‐hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction2006;21(6):1408‐15. [10.1093/humrep/del030] ">Huirne 2006b</a>). Scheduling is of benefit for the clinicians and people in the laboratory, since these people usually do not work on weekends. </p> </section> <section id="CD006109-sec-0034"> <h3 class="title" id="CD006109-sec-0034">Why it is important to do this review</h3> <p>There is some debate regarding the effects of the COCP upon pregnancy rate. Higher rates of clinical pregnancy and live birth have been reported when dual suppression protocols and GnRHa were compared to a GnRHa protocol without the use of oral contraceptives in non‐randomised studies (<a href="./references#CD006109-bbs2-0046" title="DamarioMA , BarmatL , LiuHC , DavisOK , RosenwaksZ . Dual suppression with oral contraceptives and gonadotrophin releasing‐hormone agonists improves in‐vitro fertilization outcome in high responder patients. Human Reproduction1997;12(11):2359‐65. ">Damario 1997</a>; <a href="./references#CD006109-bbs2-0075" title="KeltzMD , GeraPS , SkorupskiJ , SteinDE . Comparison of FSH flare with and without pretreatment with oral contraceptive pills in poor responders undergoing in vitro fertilization. Fertility and Sterility2007;88(2):350‐3. [DOI: 10.1016/j.fertnstert.2006.11.123] KeltzMD , SharmaP , SteinDE . Comparison of FSH flare in poor responders undergoing in vitro fertilization (IVF) with and without prior oral contraceptive suppression. Fertility and Sterility2003; Vol. 80:S107. ">Keltz 2007</a>). However, other non‐randomised studies have found no evidence of effect with regard to pregnancy rate (<a href="./references#CD006109-bbs2-0034" title="BellverJ , AlbertC , LabartaE , PellicerA . Early pregnancy loss in women stimulated with gonadotropin‐releasing hormone antagonist protocols according to oral contraceptive pill pretreatment. Fertility and Sterility2007;87(5):1098‐101. [DOI: 10.1016/j.fertnstert.2006.08.098] ">Bellver 2007</a>; <a href="./references#CD006109-bbs2-0062" title="GaleraF , VerduV , VillafañexV , GarijoE , RaywardJ , BajoJM . Comparison of plasmatic steroid levels with and without previous oral contraceptive administration in GnRH antagonist IVF cycles. Fertility and Sterility2004; Vol. Suppl 2, 82:S32. ">Galera 2004</a>). </p> <p>There is a lack of consensus regarding whether pretreatment with COCP in ovarian stimulation protocols improves rates of pregnancy and live birth. Furthermore, the effects of pretreatment with progestogen or oestrogen alone on IVF outcomes is unclear. The results of many small RCTs can be pooled in a systematic review and may provide a more definitive answer regarding the role of the COCP, progestogens or oestrogens in ART. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006109-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006109-sec-0035"></div> <p>To determine whether pretreatment with the combined oral contraceptive pill or with a progestogen or oestrogen alone in ovarian stimulation protocols affects outcomes in subfertile couples undergoing ART. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006109-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006109-sec-0036"></div> <section id="CD006109-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006109-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included only randomized controlled trials (RCTs) in this review. We included both published and unpublished studies and we excluded trials with quasi‐randomisation. </p> <p>We excluded cross‐over trials unless pre‐crossover data were available; this type of design is inappropriate in this context. </p> </section> <section id="CD006109-sec-0039"> <h4 class="title">Types of participants</h4> <p>Women of any age with subfertility, regardless of any cause, undergoing ART.</p> <p>We only excluded two types of participants from this review. The first was women with premature ovarian failure, because these women require a different ovarian stimulation protocol. The second was women who participated in ovarian stimulation protocols as oocyte donors. </p> </section> <section id="CD006109-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Pretreatment with COCPs, progestogens or oestrogens versus no pretreatment or alternative pretreatments, in GnRH agonist or antagonist cycles. We excluded studies that compared different doses of the same pretreatment. </p> </section> <section id="CD006109-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD006109-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD006109-list-0001"> <li> <p>Live birth or ongoing pregnancy (in studies not reporting live birth) per woman randomized.</p> <ul id="CD006109-list-0002"> <li> <p>Live birth defined as the delivery of a foetus with signs of life after 20 completed weeks of gestational age, counted as live birth event. When there were multiple live births (e.g. twins or triplets), we counted these as one live birth event (<a href="./references#CD006109-bbs2-0131" title="GriffinPD , RowePJ , VayenaE , editor(s) . Medical, ethical and social aspects of assisted reproduction. Current practices and controversies in assisted reproduction: report of a WHO meeting. Geneva, Switzerland: World Health Organization2002. [ISBN 92 4 159030 0] ">Griffin 2002</a>). </p> </li> <li> <p>Ongoing pregnancy defined as evidence of a gestational sac with foetal heart motion at 12 weeks or later, confirmed with ultrasound. When there were multiple gestational sacs in one woman, we counted these as one ongoing pregnancy (<a href="./references#CD006109-bbs2-0131" title="GriffinPD , RowePJ , VayenaE , editor(s) . Medical, ethical and social aspects of assisted reproduction. Current practices and controversies in assisted reproduction: report of a WHO meeting. Geneva, Switzerland: World Health Organization2002. [ISBN 92 4 159030 0] ">Griffin 2002</a>). </p> </li> </ul> </li> <li> <p>Pregnancy loss (miscarriage) per woman randomized ‐ defined as the sum of the number of spontaneous abortions (pregnancy loss before 20 completed weeks of gestation) and the number of stillbirths (pregnancy loss after 20 completed weeks of gestation) (<a href="./references#CD006109-bbs2-0131" title="GriffinPD , RowePJ , VayenaE , editor(s) . Medical, ethical and social aspects of assisted reproduction. Current practices and controversies in assisted reproduction: report of a WHO meeting. Geneva, Switzerland: World Health Organization2002. [ISBN 92 4 159030 0] ">Griffin 2002</a>). </p> </li> </ul> </p> </section> <section id="CD006109-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD006109-list-0003"> <li> <p>Clinical pregnancy rate per woman randomized ‐ defined as evidence of a gestational sac with foetal heart motion at six weeks or later, confirmed with ultrasound. When there were multiple gestational sacs in one woman, we counted these as one clinical pregnancy (<a href="./references#CD006109-bbs2-0131" title="GriffinPD , RowePJ , VayenaE , editor(s) . Medical, ethical and social aspects of assisted reproduction. Current practices and controversies in assisted reproduction: report of a WHO meeting. Geneva, Switzerland: World Health Organization2002. [ISBN 92 4 159030 0] ">Griffin 2002</a>). </p> </li> <li> <p>Multiple pregnancy rate per woman randomized.</p> </li> <li> <p>OHSS rate per woman randomized, as defined in the included studies.</p> </li> <li> <p>Number of oocytes retrieved per woman randomized.</p> </li> <li> <p>Days of gonadotrophin treatment per woman randomized.</p> </li> <li> <p>Amount of gonadotrophins administered per woman randomized.</p> </li> <li> <p>Ovarian cyst formation rate per woman randomized ‐ defined as any intraovarian sonolucent structure with a mean diameter of 15 mm or more confirmed with ultrasound at least one week after start pituitary suppression (<a href="./references#CD006109-bbs2-0121" title="BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF , TanSL . Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin‐releasing hormone analogues and on subsequent implantation and pregnancy rates. Fertility and Sterility1998;70(6):1063‐9. ">Biljan 1998a</a>). </p> </li> </ul> </p> </section> </section> </section> <section id="CD006109-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <p>We obtained all studies that described (or might have described) RCTs of pretreatment with COCP, progestogen or oestrogen therapy prior to GnRHa (agonists or antagonists) and gonadotrophins or gonadotrophins alone in women undergoing IVF, using the following search strategies. </p> <section id="CD006109-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases:</p> <p> <ul id="CD006109-list-0004"> <li> <p>the Cochrane Gynaecology and Fertility Group (CGF) Specialised Register, searched on Procite platform from inception to 16 January 2017 (<a href="./appendices#CD006109-sec-0261">Appendix 2</a>); </p> </li> <li> <p>Cochrane Central Register of Studies Online (CENTRAL CRSO) searched 16 January 2017 on web platform (<a href="./appendices#CD006109-sec-0262">Appendix 3</a>); </p> </li> <li> <p>MEDLINE; searched on Ovid platform 1946 to 16 January 2017 (<a href="./appendices#CD006109-sec-0263">Appendix 4</a>). We combined this search with the Cochrane highly sensitive search strategy for identifying randomized trials (<a href="./references#CD006109-bbs2-0133" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>); </p> </li> <li> <p>Embase; searched on Ovid platform 1980 to 16 January 2017 (<a href="./appendices#CD006109-sec-0264">Appendix 5</a>). We combined this search with trial filters developed by the Scottish Intercollegiate Guidelines Network (<a href="./references#CD006109-bbs2-0142" title="Scottish Intercollegiate Guidelines Network. Search filters. www.sign.ac.uk/methodology/filters.html#random (accessed 18 November 2008). ">SIGN</a>); </p> </li> <li> <p>PsycINFO; searched on the Ovid platform from 1806 to 16 January 2017 (<a href="./appendices#CD006109-sec-0265">Appendix 6</a>); </p> </li> <li> <p>Cumulative Index to Nursing and Allied Health Literature (CINAHL Plus); searched on the Ebsco platform from 1982 to 16 January 2017 (<a href="./appendices#CD006109-sec-0266">Appendix 7</a>). We combined this search with trial filters developed by the Scottish Intercollegiate Guidelines Network (<a href="./references#CD006109-bbs2-0142" title="Scottish Intercollegiate Guidelines Network. Search filters. www.sign.ac.uk/methodology/filters.html#random (accessed 18 November 2008). ">SIGN</a>). </p> </li> </ul> </p> <p>We place no restrictions by language. We managed output of these searches with the reference manager, Endnote (<a href="./references#CD006109-bbs2-0125" title="Thomson Reuters. EndNote. Version X1. New York: Thomson Reuters, 2008. ">EndNote</a>). Through this program, duplicates can be found and removed. </p> </section> <section id="CD006109-sec-0046"> <h4 class="title">Searching other resources</h4> <p>In addition, we searched some other resources than the electronic databases mentioned above to obtain more relevant trials. We accessed all the websites on 13 January 2017, except for OpenSIGLE. </p> <p> <ul id="CD006109-list-0005"> <li> <p>Trial registers for ongoing and registered trials: Current Controlled Trials (<a href="http://www.controlled-trials.com" target="_blank">www.controlled‐trials.com</a>), ClinicalTrials.gov (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>), and the World Health Organization (WHO) International Trials Registry Platform Search Portal (<a href="http://www.who.int/trialsearch" target="_blank">www.who.int/trialsearch</a>) (<a href="./appendices#CD006109-sec-0267">Appendix 8</a>). </p> </li> <li> <p>The Virtual Health Library.</p> </li> <li> <p>Citation indexes (<a href="http://scientific.thomson.com/products/sci" target="_blank">scientific.thomson.com/products/sci</a>). </p> </li> <li> <p>PubMed (<a href="http://www.ncbi.nlm.nih.gov/pubmed" target="_blank">www.ncbi.nlm.nih.gov/pubmed</a>); we combined this search with random control filters for PubMed (<a href="./references#CD006109-bbs2-0133" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> </li> <li> <p>Conference abstracts on the ISI Web of Knowledge (<a href="http://isiwebofknowledge.com" target="_blank">isiwebofknowledge.com</a>). </p> </li> <li> <p>Open System for Information on Grey Literature (<a href="http://opensigle.inist.fr" target="_blank">opensigle.inist.fr</a>, accessed on 16 January 2017). </p> </li> <li> <p>Reference lists of appropriate studies.</p> </li> <li> <p>Handsearching of the abstracts of the 32nd annual meeting of the European Society of Human Reproduction and Embryology in Helsinki (Finland), 3 to 6 July 2016 (<a href="./references#CD006109-bbs2-0127" title="European Society of Human Reproduction and Embryology. 32nd annual meeting of the European Society of Human Reproduction and Embryology. Helsinki, Finland 2016. Human Reproduction2016;31 Suppl 1:Abstract book. ">ESHRE 2016</a>). </p> </li> </ul> </p> </section> </section> <section id="CD006109-sec-0047"> <h3 class="title" id="CD006109-sec-0047">Data collection and analysis</h3> <section id="CD006109-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two review authors (ROA, AL) independently scanned the titles and abstracts of all the studies found with the search to exclude those that did not meet the inclusion criteria. We discussed any disagreement or doubt, whether a study was eligible for inclusion or not, with a third review author (CF) to achieve consensus. We obtained the full text of those RCTs deemed eligible for inclusion where possible, and subjected them to critical appraisal of their risk of bias. Where appropriate, we included them in this systematic review. </p> <p>Subsequently, we constructed a <a href="./references#CD006109-sec-0284" title="">Characteristics of included studies</a> table for those trials considered suitable for inclusion. We produced a <a href="./references#CD006109-sec-0285" title="">Characteristics of excluded studies</a> table for those that did not satisfy the inclusion criteria. In this table, we listed the reasons for exclusion. </p> </section> <section id="CD006109-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (ROA, AL) independently extracted the data using data extraction forms, which we designed for this particular review (<a href="./appendices#CD006109-sec-0268">Appendix 9</a>; <a href="./appendices#CD006109-sec-0269">Appendix 10</a>). We resolved any discrepancies by discussion and the help of a third review author (CF). </p> <p>The data extraction forms included risk of bias criteria and methodological details. The information about the studies is included in the review and presented in the <a href="./references#CD006109-sec-0284" title="">Characteristics of included studies</a> table. We managed the data using Review Manager 5 software (<a href="./references#CD006109-bbs2-0141" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> </section> <section id="CD006109-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed and reported on the risk of bias of included studies in accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006109-bbs2-0133" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), which recommends the explicit reporting of the following domains. </p> <p> <ul id="CD006109-list-0006"> <li> <p>Sequence generation</p> </li> </ul> </p> <p>Was sequence generation adequate (e.g. use of a random number table, a computer random number generator or coin tossing) or unclear (insufficient information about the process of sequence generation)? </p> <p> <ul id="CD006109-list-0007"> <li> <p>Allocation concealment</p> </li> </ul> </p> <p>Was allocation concealment adequate (e.g. use of central allocation or opaque sealed envelopes), inadequate (e.g. use of an open random allocation schedule, date of birth or case record number) or unclear (insufficient information about the process of allocation concealment)? </p> <p> <ul id="CD006109-list-0008"> <li> <p>Blinding of participants, providers and outcome assessors</p> </li> </ul> </p> <p>Was blinding adequate (e.g. participants and researchers were all blinded and it was unlikely that blinding could have been broken, either participants or some researchers were not blinded but outcome assessment was blinded or no blinding was used but this was not likely to influence outcomes), inadequate (e.g. no blinding or incomplete blinding and outcomes were likely to be influenced by this) or unclear (insufficient information about the process of blinding)? </p> <p> <ul id="CD006109-list-0009"> <li> <p>Incomplete outcome data</p> </li> </ul> </p> <p>Were outcome data addressed adequately (e.g. there were no missing outcome data, reasons for missing outcome data were unlikely to be related to true outcome or missing outcome data were balanced in numbers across intervention groups), inadequate (e.g. reasons for missing outcome data were likely to be related to true outcome) or unclear (insufficient information about the process of addressing outcome data)? </p> <p> <ul id="CD006109-list-0010"> <li> <p>Selective outcome reporting</p> </li> </ul> </p> <p>Was the study free of selective reporting? Adequate (e.g. the study protocol was available and all prespecified outcomes were reported or the study protocol was not available but it was clear that all prespecified outcomes were reported), inadequate (e.g. not all prespecified primary outcomes were reported) or unclear (insufficient information about the process of outcome reporting). </p> <p> <ul id="CD006109-list-0011"> <li> <p>Other sources of bias for RCTs</p> </li> </ul> </p> <p>Was the study free of other bias? Adequate (the study seemed to be free of other bias, e.g. comparable demographic characteristics between treatment groups), inadequate (e.g. extreme baseline imbalance, a potential source of bias related to the specific study design used or early stopping) or unclear (insufficient information about other sources of bias). </p> <p>By using a simple form (<a href="./appendices#CD006109-sec-0268">Appendix 9</a>; <a href="./appendices#CD006109-sec-0269">Appendix 10</a>), two review authors separately assessed these domains as 'low' (indicating a low risk of bias), 'unclear' (indicating an uncertain risk of bias) or 'high' (indicating a high risk of bias). </p> <p>The assessments of the two review authors (ROA, AL) were compared and we resolved any discrepancies in the interpretation of the risk of bias of a study by discussion with a third review author (CF). We did not exclude any study as a result of a rating of 'Unclear' or 'High'. Where it was unclear, we contacted authors of studies about the methods used and also sought any missing data. </p> <p>We presented the results of the risk of bias assessment in the <a href="./references#CD006109-sec-0284" title="">Characteristics of included studies</a> table, including commentary about each of the domains. This led to a methodological quality summary (<a href="#CD006109-fig-0001">Figure 1</a>; <a href="#CD006109-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD006109-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD006109-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD006109-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD006109-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> </section> <section id="CD006109-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data, we expressed results for each study as odds ratios (OR) with 95% confidence intervals (CI). For continuous variables, we reported the data as mean differences (MD) with 95% CIs. </p> </section> <section id="CD006109-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>To avoid analysis errors, we only pooled data that reported outcomes per woman randomized. Studies that reported 'per cycle' data were eligible for inclusion but were not included in the analyses; however, additional information was provided on such studies narratively. </p> </section> <section id="CD006109-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>In case of missing data in the included studies, we contacted the original investigators by e‐mail or post to request relevant missing information. If we did not receive a reply, we sent a reminder to the authors two weeks later. Furthermore, we contacted the members of the CGF group to ask if they know any of the authors personally or have contact details. </p> <p>We reported the data according to intention‐to‐treat (ITT) where possible. We reported live birth and ongoing pregnancy as a single outcome (i.e. live birth or ongoing pregnancy due to non‐reporting of live birth data by some studies who reported data on ongoing pregnancy). However, where a study reported data on both outcomes, we only included data for live birth in the analysis. </p> </section> <section id="CD006109-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>Before any meta‐analysis was done, we judged whether there was sufficient similarity between the eligible studies in their design and clinical characteristics to ensure that pooling was valid. We assessed statistical heterogeneity in the results of trials using the Chi<sup>2</sup> test. A low P value (or a large Chi<sup>2</sup> statistic relative to its degree of freedom) potentially provides evidence of heterogeneity of intervention effects and shows that results are not influenced by chance alone (<a href="./references#CD006109-bbs2-0133" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>).<br/> We used the I<sup>2</sup> statistic to assess the impact of the heterogeneity on the meta‐analysis. We interpreted the result of the I<sup>2</sup> statistic as follows: </p> <p> <ul id="CD006109-list-0012"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity; and</p> </li> <li> <p>75% to 100%: considerable heterogeneity (<a href="./references#CD006109-bbs2-0133" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> </li> </ul> </p> <p>If we found marked clinical or statistical heterogeneity (I<sup>2</sup> more than 50%), we explored reasons for this heterogeneity using a sensitivity analysis. </p> </section> <section id="CD006109-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>In view of the difficulty of detecting and correcting for publication bias and other reporting biases, we aimed to minimise their potential impact by ensuring a comprehensive search for eligible studies and by being alert for duplication of data. If there were 10 or more studies in an analysis, we intended to use a funnel plot to explore the possibility of small‐study effects (a tendency for estimates of the intervention effect to be more beneficial in smaller studies), but, due to the small number of studies per analysis, this was not possible. </p> </section> <section id="CD006109-sec-0056"> <h4 class="title">Data synthesis</h4> <p>We carried out statistical analysis using Review Manager 5 (<a href="./references#CD006109-bbs2-0141" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We used fixed‐effect meta‐analysis for combining data where studies were sufficiently similar. </p> <p>Comparisons were grouped separately by type of pretreatment (COCP, progesterone, oestrogen) and type of comparator (no pretreatment or alternative pretreatment) and the primary analysis was subgrouped by type of downregulation (antagonist or agonist). </p> </section> <section id="CD006109-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where data were available, we subgrouped the data to determine the separate evidence within the following subgroups. </p> <p> <ul id="CD006109-list-0013"> <li> <p>Types of downregulating agents:</p> <ul id="CD006109-list-0014"> <li> <p>GnRH agonist in study group versus GnRH agonist in control group;</p> </li> <li> <p>GnRH antagonist in study group versus GnRH antagonist in control group;</p> </li> <li> <p>GnRH antagonist in study group versus GnRH agonist in control group;</p> </li> <li> <p>GnRH agonist in study group versus GnRH antagonist in control group.</p> </li> </ul> </li> <li> <p>Women who were low responders (i.e. who responded poorly to controlled ovarian hyperstimulation).</p> </li> </ul> </p> <p>Where we detected substantial heterogeneity (I<sup>2</sup> greater than 50%), we explored possible explanations in sensitivity analyses. We took any statistical heterogeneity into consideration when interpreting the results especially if there were any variations in the direction of effect estimates. </p> </section> <section id="CD006109-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>We intended to conduct sensitivity analysis for the primary outcomes (live births or ongoing pregnancies and pregnancy losses) to determine whether the conclusions were robust to the choice of statistical model (fixed versus random) or summary effect measure (OR or risk ratio). </p> <section id="CD006109-sec-0059"> <h5 class="title">Overall quality of the body of evidence: 'Summary of findings' table</h5> <p>We prepared 'Summary of findings' tables using GRADEpro (<a href="./references#CD006109-bbs2-0129" title="GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed prior to 28 October 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro GDT 2014</a>) and Cochrane methods. These tables evaluated the overall quality of the body of evidence for the main review outcomes: </p> <p> <ul id="CD006109-list-0015"> <li> <p>live birth or ongoing pregnancy;</p> </li> <li> <p>pregnancy loss;</p> </li> <li> <p>multiple pregnancy;</p> </li> <li> <p>OHSS.</p> </li> </ul> </p> <p>The tables evaluated the main review comparisons:</p> <p> <ul id="CD006109-list-0016"> <li> <p>COCP compared to no pretreatment;</p> </li> <li> <p>progestogen compared to no pretreatment;</p> </li> <li> <p>oestrogen compared to no pretreatment.</p> </li> </ul> </p> <p>We assessed the quality of the evidence using GRADE criteria: risk of bias, consistency of effect, imprecision, indirectness and publication bias). Two review authors (ROA, AL) independently made judgements about evidence quality (high, moderate, low or very low) and resolved disagreements by discussion. Judgements were justified, documented and incorporated into reporting of results for each outcome. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006109-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006109-sec-0060"></div> <section id="CD006109-sec-0061"> <h3 class="title">Description of studies</h3> <section id="CD006109-sec-0062"> <h4 class="title">Results of the search</h4> <p>After searching the electronic databases, we found 1792 studies: 609 studies in the GF specialized register of controlled trials, 166 studies in CENTRAL, 511 studies in MEDLINE, 463 studies in Embase, 19 studies in CINAHL and 24 studies in PsycINFO. After removing the duplicates and searching other resources, there were 1528 studies left. We retrieved 137 full‐text articles of which 29 studies (42 references) were included and 87 studies (95 references) were excluded. For further details on included/excluded studies, see <a href="./references#CD006109-sec-0284" title="">Characteristics of included studies</a> and <a href="./references#CD006109-sec-0285" title="">Characteristics of excluded studies</a> tables. The process involved in the screening and selection of eligible studies for inclusion is shown in the PRISMA flow chart (<a href="./references#CD006109-bbs2-0138" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA Statement. BMJ2009;339:2535. ">Moher 2009</a>) (<a href="#CD006109-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD006109-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Study PRISMA flow chart" data-id="CD006109-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study PRISMA flow chart</p> </div> </div> </div> </section> <section id="CD006109-sec-0063"> <h4 class="title">Included studies</h4> <p>Nine of the included studies were identified from the searches carried out in 2015 and 2016 (<a href="./references#CD006109-bbs2-0003" title="BlockeelC , EngelsS , deVosM , HaentjensP , PolyzosNP , StoopD , et al. Oestradiol valerate pretreatment in GnRH antagonist cycles: a randomised controlled trial. Reproductive Biomedicine Online2012;24:272‐80. ">Blockeel 2012</a>; <a href="./references#CD006109-bbs2-0005" title="Cédrin‐DurnerinI , Guivarc'h‐LevequeA , HuguesJ‐N . Pretreatment with estrogen does not affect IVF‐ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomised trial. Fertility and Sterility2012;97(6):1359‐64. ">Cédrin‐Durnerin 2012</a>; <a href="./references#CD006109-bbs2-0011" title="Garcia‐VelascoJA , BermejoA , RuizF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility2011;96(3):590‐3. Garcia‐VelascoJA , BermejoA , Ruiz‐FloresF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial. Fertility and Sterility2010;94 Suppl 1(4):S28 Abstract no. O‐93. ">Garcia‐Velasco 2011</a>; <a href="./references#CD006109-bbs2-0012" title="HauzmanEE , ZapataA , BermejoA , IglesiasC , PellicerA , Garcia‐VelascoJ . Cycle scheduling for in vitro fertilisation with oral contraceptive pills versus oral estradiol valerate: a randomised controlled trial. Reproductive Biology and Endocrinology2013;11:96. ">Hauzman 2013</a>; <a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD006109-bbs2-0019" title="LukaszukK , LissJ , KunickiM , KuczynskiW , PastuszekE , JakielG , et al. Estradiol valerate pretreatment in short protocol GNRH‐agonist cycles versus combined pretreatment with oral contraceptive pills in long protocol GNRH‐agonist cycles: a randomised controlled trial. BioMed Research International2015;2015:1‐6. ">Lukaszuk 2015</a>; <a href="./references#CD006109-bbs2-0020" title="BroekmansJF , VerweijPJM , EijkemansMJC , MannaertsNMJL , WitjesH . Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(8):1688‐97. Nyboe AndersenA , WitjesH , GordonK , MannaertsB . Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pretreatment. Human Reproduction2011;26(12):3413‐23. TavmergenE , vonMauw , WitjesH , MannaertsB . Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling. 25th Annual Meeting of ESHRE; 2009 28 Jun‐1 Jul; Amsterdam, the Netherlands. 2009. ">Nyboe Andersen 2011</a>; <a href="./references#CD006109-bbs2-0022" title="PorratiL , VilelaM , ViglierchioMI , ValcarcelA , LombardiE , MarconiG . Oral contraceptive pretreatment achieves better pregnancy rates in IVF antagonists GnRH flexible protocols: a prospective randomized study. Human Reproduction2010;25 Suppl 1(6):i102 Abstract no. O‐259. ">Porrati 2010</a>; <a href="./references#CD006109-bbs2-0028" title="VilelaM , MarconiM , ZappacostaMP , PorratiL , ValcarcelA , MarconiG . Oral contraceptive (OcP) pretreatment achieves better pregnancy rates in in vitro fertilisation (IVF) antagonists GnRH flexible protocols: a prospective randomised study. Fertility and Sterility2011; Vol. 96, issue 3 (supplement):S252, P‐492. ">Vilela 2011</a>). The remaining 20 studies were identified from the previous updates of the review. </p> <p>The following is a summary of the methods, participants, interventions and outcomes of the included studies. Full details of these domains (for each study separately) are in the <a href="./references#CD006109-sec-0284" title="">Characteristics of included studies</a> table. </p> <section id="CD006109-sec-0064"> <h5 class="title">Methods</h5> <p>We included 29 trials, with 4702 women randomized to treatment (<a href="./references#CD006109-bbs2-0001" title="AstonK , ArthurI , MassonGM , JenkinsJM . Progestogen therapy and prevention of functional ovarian cysts during pituitary desensitisation with GnRH agonists. British Journal of Obstetrics and Gynaecology1995;102:835‐7. ">Aston 1995</a>; <a href="./references#CD006109-bbs2-0002" title="BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF . Prospective randomized trial on effect of pre‐treatment with an oral contraceptive (OC) on the length of time required for pituitary suppression by gonadotropin releasing hormone agonist (GnRH‐a) and subsequent implantation and pregnancy rates. Fertility and Sterility1998; Vol. Suppl 1, 70, issue 3:S133. BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF , TanSL . Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin‐releasing hormone analogues and on subsequent implantation and pregnancy rates. Fertility and Sterility1998;70(6):1063‐9. ">Biljan 1998b</a>; <a href="./references#CD006109-bbs2-0003" title="BlockeelC , EngelsS , deVosM , HaentjensP , PolyzosNP , StoopD , et al. Oestradiol valerate pretreatment in GnRH antagonist cycles: a randomised controlled trial. Reproductive Biomedicine Online2012;24:272‐80. ">Blockeel 2012</a>; <a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0005" title="Cédrin‐DurnerinI , Guivarc'h‐LevequeA , HuguesJ‐N . Pretreatment with estrogen does not affect IVF‐ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomised trial. Fertility and Sterility2012;97(6):1359‐64. ">Cédrin‐Durnerin 2012</a>; <a href="./references#CD006109-bbs2-0006" title="DalyDC , DalyCL , MayoD , JacobsA . Oocyte recruitment in IVF patients with limited ovarian reserve (LOR), maximizing quality of oocytes and embryos. Fertility and Sterility2002; Vol. Suppl 1, 78, issue 3:S148‐9. ">Daly 2002</a>; <a href="./references#CD006109-bbs2-0007" title="DitkoffEC , SauerMV . A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin‐releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Human Reproduction1996;11(5):1035‐7. ">Ditkoff 1996</a>; <a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>; <a href="./references#CD006109-bbs2-0009" title="FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol administration coordinates FSH‐induced follicular growth and improves the outcome of GnRH antagonist COH protocols. 19th Annual meeting of the ESHRE; 2003 Jun 29‐Jul 2; Madrid, Spain, 2003. 2003. FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol pre‐treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Human Reproduction2003;18(12):2698‐703. [DOI: 10.1093/humrep/deg516] ">Fanchin 2003</a>; <a href="./references#CD006109-bbs2-0010" title="FrancoJGJr , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH after 2nd phase protocols with GnRH analogs (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin) [Comparação da estimulação ovariana com FSH recombinante após protocolo de 2a fase com análogos do GnRH (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco Jr 2003</a>; <a href="./references#CD006109-bbs2-0011" title="Garcia‐VelascoJA , BermejoA , RuizF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility2011;96(3):590‐3. Garcia‐VelascoJA , BermejoA , Ruiz‐FloresF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial. Fertility and Sterility2010;94 Suppl 1(4):S28 Abstract no. O‐93. ">Garcia‐Velasco 2011</a>; <a href="./references#CD006109-bbs2-0012" title="HauzmanEE , ZapataA , BermejoA , IglesiasC , PellicerA , Garcia‐VelascoJ . Cycle scheduling for in vitro fertilisation with oral contraceptive pills versus oral estradiol valerate: a randomised controlled trial. Reproductive Biology and Endocrinology2013;11:96. ">Hauzman 2013</a>; <a href="./references#CD006109-bbs2-0013" title="HuguesJN , Cédrin‐DurnerinI , HervéF , Huet‐PecqueuxL , SantarelliJ . Incidence of preprogrammed norethisterone on the intensity of 'flare up' (flush) caused by GnRH agonist according to the IVF protocol [poster] [Incidence d'une préprogrammation par la noréthistérone sur la qualité du flare‐up induit par un agoniste du GnRH en protocole court de FIV]. Contraception, Fertilite, Sexualite1994; Vol. 22, issue 5:331. ">Hugues 1994</a>; <a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>; <a href="./references#CD006109-bbs2-0015" title="HuirneJA , HuguesJN , PirardC , FischlF , SageJC , PoulyJL , et al. Cetrorelix in an oral contraceptive‐pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r‐hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction2006;21(6):1408‐15. [DOI: 10.1093/humrep/de1030] ">Huirne 2006c</a>; <a href="./references#CD006109-bbs2-0016" title="HwangJL , SeowKM , LinYH , HuangLW , HsiehBC , TsaiYL , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. [DOI: 10.1093/humrep/deh375] ">Hwang 2004</a>; <a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a>; <a href="./references#CD006109-bbs2-0019" title="LukaszukK , LissJ , KunickiM , KuczynskiW , PastuszekE , JakielG , et al. Estradiol valerate pretreatment in short protocol GNRH‐agonist cycles versus combined pretreatment with oral contraceptive pills in long protocol GNRH‐agonist cycles: a randomised controlled trial. BioMed Research International2015;2015:1‐6. ">Lukaszuk 2015</a>; <a href="./references#CD006109-bbs2-0020" title="BroekmansJF , VerweijPJM , EijkemansMJC , MannaertsNMJL , WitjesH . Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(8):1688‐97. Nyboe AndersenA , WitjesH , GordonK , MannaertsB . Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pretreatment. Human Reproduction2011;26(12):3413‐23. TavmergenE , vonMauw , WitjesH , MannaertsB . Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling. 25th Annual Meeting of ESHRE; 2009 28 Jun‐1 Jul; Amsterdam, the Netherlands. 2009. ">Nyboe Andersen 2011</a>; <a href="./references#CD006109-bbs2-0021" title="ObrucaA , FischlF , HuberJ . Programming oocyte retrieval using oral contraceptive pretreatment before ovarian stimulation with a GnRH antagonist (Cetrotide) protocol. Human Reproduction. 2002; Vol. 17 Abstract Book 1:89. ">Obruca 2002</a>; <a href="./references#CD006109-bbs2-0022" title="PorratiL , VilelaM , ViglierchioMI , ValcarcelA , LombardiE , MarconiG . Oral contraceptive pretreatment achieves better pregnancy rates in IVF antagonists GnRH flexible protocols: a prospective randomized study. Human Reproduction2010;25 Suppl 1(6):i102 Abstract no. O‐259. ">Porrati 2010</a>; <a href="./references#CD006109-bbs2-0023" title="RaoofiZ , AflatoonianA . Ovarian cysts formation during depot formulation of GnRH‐a therapy and the effect of pretreatment with oral contraceptive pills on subsequent implantation and pregnancy rate in ART cycles. Iranian Journal of Pharmaceutical Research2008;7(2):109‐13. ">Raoofi 2008</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>; <a href="./references#CD006109-bbs2-0025" title="Salat‐BarouxJ , AntoineJM , AlvarezS , CornetD , TibiC , MandelbaumJ , et al. Programmed ovulation induction and oocyte retrieval for in vitro fertilization. Journal of In Vitro Fertilization and Embryo Transfer1988;5(3):153‐7. ">Salat‐Baroux 1988</a>; <a href="./references#CD006109-bbs2-0026" title="ShakerAG , PittrofR , ZaidiJ , BekirJ , Kyei‐MensahA , TanSL . Administration of progestogens to hasten pituitary desensitization after the use of gonadotropin‐releasing hormone agonist in in vitro fertilization ‐ a prospective randomized study. Fertility and Sterility1995;64(4):791‐5. ">Shaker 1995</a>; <a href="./references#CD006109-bbs2-0027" title="TanSL , BiljanM . Fixed scheduling of long protocol of GNRH agonists ‐ use of oral contraceptive (OC) or progestogen pre‐treatment. Gynecological Endocrinology. 2001; Vol. 15 Suppl 2:31. ">Tan 2001</a>; <a href="./references#CD006109-bbs2-0028" title="VilelaM , MarconiM , ZappacostaMP , PorratiL , ValcarcelA , MarconiG . Oral contraceptive (OcP) pretreatment achieves better pregnancy rates in in vitro fertilisation (IVF) antagonists GnRH flexible protocols: a prospective randomised study. Fertility and Sterility2011; Vol. 96, issue 3 (supplement):S252, P‐492. ">Vilela 2011</a>; <a href="./references#CD006109-bbs2-0029" title="YeH , HuangG‐N , ZengP‐H , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;26(2‐3):105‐11. ">Ye 2009</a>). Two of the included studies were three‐arm parallel RCTs (<a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>), one was a four‐arm RCT (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>), and the remaining 26 studies were two‐arm parallel RCTs. </p> <p>The largest trials were <a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a> (504 women), <a href="./references#CD006109-bbs2-0005" title="Cédrin‐DurnerinI , Guivarc'h‐LevequeA , HuguesJ‐N . Pretreatment with estrogen does not affect IVF‐ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomised trial. Fertility and Sterility2012;97(6):1359‐64. ">Cédrin‐Durnerin 2012</a> (472 women), <a href="./references#CD006109-bbs2-0020" title="BroekmansJF , VerweijPJM , EijkemansMJC , MannaertsNMJL , WitjesH . Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(8):1688‐97. Nyboe AndersenA , WitjesH , GordonK , MannaertsB . Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pretreatment. Human Reproduction2011;26(12):3413‐23. TavmergenE , vonMauw , WitjesH , MannaertsB . Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling. 25th Annual Meeting of ESHRE; 2009 28 Jun‐1 Jul; Amsterdam, the Netherlands. 2009. ">Nyboe Andersen 2011</a> (442 women), <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a> (351 women), <a href="./references#CD006109-bbs2-0019" title="LukaszukK , LissJ , KunickiM , KuczynskiW , PastuszekE , JakielG , et al. Estradiol valerate pretreatment in short protocol GNRH‐agonist cycles versus combined pretreatment with oral contraceptive pills in long protocol GNRH‐agonist cycles: a randomised controlled trial. BioMed Research International2015;2015:1‐6. ">Lukaszuk 2015</a> (298 women), <a href="./references#CD006109-bbs2-0011" title="Garcia‐VelascoJA , BermejoA , RuizF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility2011;96(3):590‐3. Garcia‐VelascoJA , BermejoA , Ruiz‐FloresF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial. Fertility and Sterility2010;94 Suppl 1(4):S28 Abstract no. O‐93. ">Garcia‐Velasco 2011</a> (228 women), <a href="./references#CD006109-bbs2-0029" title="YeH , HuangG‐N , ZengP‐H , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;26(2‐3):105‐11. ">Ye 2009</a> (220 women) and <a href="./references#CD006109-bbs2-0028" title="VilelaM , MarconiM , ZappacostaMP , PorratiL , ValcarcelA , MarconiG . Oral contraceptive (OcP) pretreatment achieves better pregnancy rates in in vitro fertilisation (IVF) antagonists GnRH flexible protocols: a prospective randomised study. Fertility and Sterility2011; Vol. 96, issue 3 (supplement):S252, P‐492. ">Vilela 2011</a> (210 women). The remainder included fewer than 200 women. Only one study used a cross‐over design and reported pre‐cross‐over data (<a href="./references#CD006109-bbs2-0006" title="DalyDC , DalyCL , MayoD , JacobsA . Oocyte recruitment in IVF patients with limited ovarian reserve (LOR), maximizing quality of oocytes and embryos. Fertility and Sterility2002; Vol. Suppl 1, 78, issue 3:S148‐9. ">Daly 2002</a>). The remaining 28 trials used a parallel design. Four studies were conducted in multiple centres (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>; <a href="./references#CD006109-bbs2-0015" title="HuirneJA , HuguesJN , PirardC , FischlF , SageJC , PoulyJL , et al. Cetrorelix in an oral contraceptive‐pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r‐hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction2006;21(6):1408‐15. [DOI: 10.1093/humrep/de1030] ">Huirne 2006c</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>). </p> <p>The trials took place in (or authors came from): Argentina (<a href="./references#CD006109-bbs2-0022" title="PorratiL , VilelaM , ViglierchioMI , ValcarcelA , LombardiE , MarconiG . Oral contraceptive pretreatment achieves better pregnancy rates in IVF antagonists GnRH flexible protocols: a prospective randomized study. Human Reproduction2010;25 Suppl 1(6):i102 Abstract no. O‐259. ">Porrati 2010</a>; <a href="./references#CD006109-bbs2-0028" title="VilelaM , MarconiM , ZappacostaMP , PorratiL , ValcarcelA , MarconiG . Oral contraceptive (OcP) pretreatment achieves better pregnancy rates in in vitro fertilisation (IVF) antagonists GnRH flexible protocols: a prospective randomised study. Fertility and Sterility2011; Vol. 96, issue 3 (supplement):S252, P‐492. ">Vilela 2011</a>); France (<a href="./references#CD006109-bbs2-0041" title="Cédrin‐DurnerinI , BulwaS , HervéF , Martin‐PontB , UzanM , HuguesJN . The hormonal flare‐up following gonadotrophin‐releasing hormone agonist administration is influenced by a progestogen pretreatment. Human Reproduction1996;11(9):1859‐63. Cédrin‐DurnerinI , BulwaS , HervéF , PecqueuxL , UzanM , HuguesJN . Influence of norethisterone pretreatment on the initial flare‐up induced by a gonadotrophin‐releasing hormone agonist in a short protocol for IVF. Human Reproduction1995;10 Abstract Book 2:116. ">Cédrin‐Durnerin 1996</a>; <a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0005" title="Cédrin‐DurnerinI , Guivarc'h‐LevequeA , HuguesJ‐N . Pretreatment with estrogen does not affect IVF‐ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomised trial. Fertility and Sterility2012;97(6):1359‐64. ">Cédrin‐Durnerin 2012</a>; <a href="./references#CD006109-bbs2-0009" title="FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol administration coordinates FSH‐induced follicular growth and improves the outcome of GnRH antagonist COH protocols. 19th Annual meeting of the ESHRE; 2003 Jun 29‐Jul 2; Madrid, Spain, 2003. 2003. FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol pre‐treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Human Reproduction2003;18(12):2698‐703. [DOI: 10.1093/humrep/deg516] ">Fanchin 2003</a>; <a href="./references#CD006109-bbs2-0013" title="HuguesJN , Cédrin‐DurnerinI , HervéF , Huet‐PecqueuxL , SantarelliJ . Incidence of preprogrammed norethisterone on the intensity of 'flare up' (flush) caused by GnRH agonist according to the IVF protocol [poster] [Incidence d'une préprogrammation par la noréthistérone sur la qualité du flare‐up induit par un agoniste du GnRH en protocole court de FIV]. Contraception, Fertilite, Sexualite1994; Vol. 22, issue 5:331. ">Hugues 1994</a>; <a href="./references#CD006109-bbs2-0025" title="Salat‐BarouxJ , AntoineJM , AlvarezS , CornetD , TibiC , MandelbaumJ , et al. Programmed ovulation induction and oocyte retrieval for in vitro fertilization. Journal of In Vitro Fertilization and Embryo Transfer1988;5(3):153‐7. ">Salat‐Baroux 1988</a>); UK (<a href="./references#CD006109-bbs2-0001" title="AstonK , ArthurI , MassonGM , JenkinsJM . Progestogen therapy and prevention of functional ovarian cysts during pituitary desensitisation with GnRH agonists. British Journal of Obstetrics and Gynaecology1995;102:835‐7. ">Aston 1995</a>; <a href="./references#CD006109-bbs2-0026" title="ShakerAG , PittrofR , ZaidiJ , BekirJ , Kyei‐MensahA , TanSL . Administration of progestogens to hasten pituitary desensitization after the use of gonadotropin‐releasing hormone agonist in in vitro fertilization ‐ a prospective randomized study. Fertility and Sterility1995;64(4):791‐5. ">Shaker 1995</a>); Canada (<a href="./references#CD006109-bbs2-0002" title="BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF . Prospective randomized trial on effect of pre‐treatment with an oral contraceptive (OC) on the length of time required for pituitary suppression by gonadotropin releasing hormone agonist (GnRH‐a) and subsequent implantation and pregnancy rates. Fertility and Sterility1998; Vol. Suppl 1, 70, issue 3:S133. BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF , TanSL . Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin‐releasing hormone analogues and on subsequent implantation and pregnancy rates. Fertility and Sterility1998;70(6):1063‐9. ">Biljan 1998b</a>; <a href="./references#CD006109-bbs2-0027" title="TanSL , BiljanM . Fixed scheduling of long protocol of GNRH agonists ‐ use of oral contraceptive (OC) or progestogen pre‐treatment. Gynecological Endocrinology. 2001; Vol. 15 Suppl 2:31. ">Tan 2001</a>); UK and Canada (<a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>); USA (<a href="./references#CD006109-bbs2-0006" title="DalyDC , DalyCL , MayoD , JacobsA . Oocyte recruitment in IVF patients with limited ovarian reserve (LOR), maximizing quality of oocytes and embryos. Fertility and Sterility2002; Vol. Suppl 1, 78, issue 3:S148‐9. ">Daly 2002</a>; <a href="./references#CD006109-bbs2-0007" title="DitkoffEC , SauerMV . A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin‐releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Human Reproduction1996;11(5):1035‐7. ">Ditkoff 1996</a>); USA and Europe (<a href="./references#CD006109-bbs2-0020" title="BroekmansJF , VerweijPJM , EijkemansMJC , MannaertsNMJL , WitjesH . Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(8):1688‐97. Nyboe AndersenA , WitjesH , GordonK , MannaertsB . Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pretreatment. Human Reproduction2011;26(12):3413‐23. TavmergenE , vonMauw , WitjesH , MannaertsB . Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling. 25th Annual Meeting of ESHRE; 2009 28 Jun‐1 Jul; Amsterdam, the Netherlands. 2009. ">Nyboe Andersen 2011</a>); Austria (<a href="./references#CD006109-bbs2-0021" title="ObrucaA , FischlF , HuberJ . Programming oocyte retrieval using oral contraceptive pretreatment before ovarian stimulation with a GnRH antagonist (Cetrotide) protocol. Human Reproduction. 2002; Vol. 17 Abstract Book 1:89. ">Obruca 2002</a>); Belgium (<a href="./references#CD006109-bbs2-0003" title="BlockeelC , EngelsS , deVosM , HaentjensP , PolyzosNP , StoopD , et al. Oestradiol valerate pretreatment in GnRH antagonist cycles: a randomised controlled trial. Reproductive Biomedicine Online2012;24:272‐80. ">Blockeel 2012</a>; <a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a>); Brazil (<a href="./references#CD006109-bbs2-0010" title="FrancoJGJr , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH after 2nd phase protocols with GnRH analogs (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin) [Comparação da estimulação ovariana com FSH recombinante após protocolo de 2a fase com análogos do GnRH (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco Jr 2003</a>); China (<a href="./references#CD006109-bbs2-0029" title="YeH , HuangG‐N , ZengP‐H , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;26(2‐3):105‐11. ">Ye 2009</a>); Iran (<a href="./references#CD006109-bbs2-0023" title="RaoofiZ , AflatoonianA . Ovarian cysts formation during depot formulation of GnRH‐a therapy and the effect of pretreatment with oral contraceptive pills on subsequent implantation and pregnancy rate in ART cycles. Iranian Journal of Pharmaceutical Research2008;7(2):109‐13. ">Raoofi 2008</a>); South Korea (<a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>); Taiwan (<a href="./references#CD006109-bbs2-0016" title="HwangJL , SeowKM , LinYH , HuangLW , HsiehBC , TsaiYL , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. [DOI: 10.1093/humrep/deh375] ">Hwang 2004</a>); Australia, Denmark, Jordan and Norway (<a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>); the Netherlands and Belgium (<a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>); Spain (<a href="./references#CD006109-bbs2-0011" title="Garcia‐VelascoJA , BermejoA , RuizF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility2011;96(3):590‐3. Garcia‐VelascoJA , BermejoA , Ruiz‐FloresF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial. Fertility and Sterility2010;94 Suppl 1(4):S28 Abstract no. O‐93. ">Garcia‐Velasco 2011</a>; <a href="./references#CD006109-bbs2-0012" title="HauzmanEE , ZapataA , BermejoA , IglesiasC , PellicerA , Garcia‐VelascoJ . Cycle scheduling for in vitro fertilisation with oral contraceptive pills versus oral estradiol valerate: a randomised controlled trial. Reproductive Biology and Endocrinology2013;11:96. ">Hauzman 2013</a>); Poland (<a href="./references#CD006109-bbs2-0019" title="LukaszukK , LissJ , KunickiM , KuczynskiW , PastuszekE , JakielG , et al. Estradiol valerate pretreatment in short protocol GNRH‐agonist cycles versus combined pretreatment with oral contraceptive pills in long protocol GNRH‐agonist cycles: a randomised controlled trial. BioMed Research International2015;2015:1‐6. ">Lukaszuk 2015</a>); Egypt, Iran, the Netherlands, Belgium, France and Austria (<a href="./references#CD006109-bbs2-0015" title="HuirneJA , HuguesJN , PirardC , FischlF , SageJC , PoulyJL , et al. Cetrorelix in an oral contraceptive‐pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r‐hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction2006;21(6):1408‐15. [DOI: 10.1093/humrep/de1030] ">Huirne 2006c</a>). </p> <p>Of the 29 included studies, 13 performed and adhered to a power calculation (<a href="./references#CD006109-bbs2-0001" title="AstonK , ArthurI , MassonGM , JenkinsJM . Progestogen therapy and prevention of functional ovarian cysts during pituitary desensitisation with GnRH agonists. British Journal of Obstetrics and Gynaecology1995;102:835‐7. ">Aston 1995</a>; <a href="./references#CD006109-bbs2-0002" title="BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF . Prospective randomized trial on effect of pre‐treatment with an oral contraceptive (OC) on the length of time required for pituitary suppression by gonadotropin releasing hormone agonist (GnRH‐a) and subsequent implantation and pregnancy rates. Fertility and Sterility1998; Vol. Suppl 1, 70, issue 3:S133. BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF , TanSL . Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin‐releasing hormone analogues and on subsequent implantation and pregnancy rates. Fertility and Sterility1998;70(6):1063‐9. ">Biljan 1998b</a>; <a href="./references#CD006109-bbs2-0005" title="Cédrin‐DurnerinI , Guivarc'h‐LevequeA , HuguesJ‐N . Pretreatment with estrogen does not affect IVF‐ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomised trial. Fertility and Sterility2012;97(6):1359‐64. ">Cédrin‐Durnerin 2012</a>; <a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>; <a href="./references#CD006109-bbs2-0009" title="FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol administration coordinates FSH‐induced follicular growth and improves the outcome of GnRH antagonist COH protocols. 19th Annual meeting of the ESHRE; 2003 Jun 29‐Jul 2; Madrid, Spain, 2003. 2003. FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol pre‐treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Human Reproduction2003;18(12):2698‐703. [DOI: 10.1093/humrep/deg516] ">Fanchin 2003</a>; <a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>; <a href="./references#CD006109-bbs2-0015" title="HuirneJA , HuguesJN , PirardC , FischlF , SageJC , PoulyJL , et al. Cetrorelix in an oral contraceptive‐pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r‐hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction2006;21(6):1408‐15. [DOI: 10.1093/humrep/de1030] ">Huirne 2006c</a>; <a href="./references#CD006109-bbs2-0016" title="HwangJL , SeowKM , LinYH , HuangLW , HsiehBC , TsaiYL , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. [DOI: 10.1093/humrep/deh375] ">Hwang 2004</a>; <a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a>; <a href="./references#CD006109-bbs2-0019" title="LukaszukK , LissJ , KunickiM , KuczynskiW , PastuszekE , JakielG , et al. Estradiol valerate pretreatment in short protocol GNRH‐agonist cycles versus combined pretreatment with oral contraceptive pills in long protocol GNRH‐agonist cycles: a randomised controlled trial. BioMed Research International2015;2015:1‐6. ">Lukaszuk 2015</a>; <a href="./references#CD006109-bbs2-0020" title="BroekmansJF , VerweijPJM , EijkemansMJC , MannaertsNMJL , WitjesH . Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(8):1688‐97. Nyboe AndersenA , WitjesH , GordonK , MannaertsB . Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pretreatment. Human Reproduction2011;26(12):3413‐23. TavmergenE , vonMauw , WitjesH , MannaertsB . Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling. 25th Annual Meeting of ESHRE; 2009 28 Jun‐1 Jul; Amsterdam, the Netherlands. 2009. ">Nyboe Andersen 2011</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>). Seven studies did not adhere to a power calculation (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0007" title="DitkoffEC , SauerMV . A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin‐releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Human Reproduction1996;11(5):1035‐7. ">Ditkoff 1996</a>; <a href="./references#CD006109-bbs2-0010" title="FrancoJGJr , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH after 2nd phase protocols with GnRH analogs (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin) [Comparação da estimulação ovariana com FSH recombinante após protocolo de 2a fase com análogos do GnRH (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco Jr 2003</a>; <a href="./references#CD006109-bbs2-0012" title="HauzmanEE , ZapataA , BermejoA , IglesiasC , PellicerA , Garcia‐VelascoJ . Cycle scheduling for in vitro fertilisation with oral contraceptive pills versus oral estradiol valerate: a randomised controlled trial. Reproductive Biology and Endocrinology2013;11:96. ">Hauzman 2013</a>; <a href="./references#CD006109-bbs2-0023" title="RaoofiZ , AflatoonianA . Ovarian cysts formation during depot formulation of GnRH‐a therapy and the effect of pretreatment with oral contraceptive pills on subsequent implantation and pregnancy rate in ART cycles. Iranian Journal of Pharmaceutical Research2008;7(2):109‐13. ">Raoofi 2008</a>; <a href="./references#CD006109-bbs2-0025" title="Salat‐BarouxJ , AntoineJM , AlvarezS , CornetD , TibiC , MandelbaumJ , et al. Programmed ovulation induction and oocyte retrieval for in vitro fertilization. Journal of In Vitro Fertilization and Embryo Transfer1988;5(3):153‐7. ">Salat‐Baroux 1988</a>; <a href="./references#CD006109-bbs2-0026" title="ShakerAG , PittrofR , ZaidiJ , BekirJ , Kyei‐MensahA , TanSL . Administration of progestogens to hasten pituitary desensitization after the use of gonadotropin‐releasing hormone agonist in in vitro fertilization ‐ a prospective randomized study. Fertility and Sterility1995;64(4):791‐5. ">Shaker 1995</a>), and in other studies this was unclear because there was only an abstract available or it was not reported. </p> </section> <section id="CD006109-sec-0065"> <h5 class="title">Participants</h5> <section id="CD006109-sec-0066"> <h6 class="title">Inclusion criteria</h6> <p>Of the 29 studies, 25 RCTs included women with a regular IVF/ICSI indication while four RCTs included women who had special indications for IVF: one trial included women who were low responders (i.e. women who respond poorly to controlled ovarian hyperstimulation (<a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>)); one included women with limited ovarian reserve (<a href="./references#CD006109-bbs2-0006" title="DalyDC , DalyCL , MayoD , JacobsA . Oocyte recruitment in IVF patients with limited ovarian reserve (LOR), maximizing quality of oocytes and embryos. Fertility and Sterility2002; Vol. Suppl 1, 78, issue 3:S148‐9. ">Daly 2002</a>); one included women with PCOS (<a href="./references#CD006109-bbs2-0016" title="HwangJL , SeowKM , LinYH , HuangLW , HsiehBC , TsaiYL , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. [DOI: 10.1093/humrep/deh375] ">Hwang 2004</a>); and another one included women with an ovarian cyst of over 5 mm in diameter or an endometrial thickness of over 5 mm and serum oestradiol concentration greater than 100 pmol/L after 14 days of GnRH agonist treatment (<a href="./references#CD006109-bbs2-0026" title="ShakerAG , PittrofR , ZaidiJ , BekirJ , Kyei‐MensahA , TanSL . Administration of progestogens to hasten pituitary desensitization after the use of gonadotropin‐releasing hormone agonist in in vitro fertilization ‐ a prospective randomized study. Fertility and Sterility1995;64(4):791‐5. ">Shaker 1995</a>). </p> <p>Twenty‐one studies mentioned an age limit as an inclusion criteria. Eight studies only included women aged 38 years or less (<a href="./references#CD006109-bbs2-0003" title="BlockeelC , EngelsS , deVosM , HaentjensP , PolyzosNP , StoopD , et al. Oestradiol valerate pretreatment in GnRH antagonist cycles: a randomised controlled trial. Reproductive Biomedicine Online2012;24:272‐80. ">Blockeel 2012</a>; <a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0005" title="Cédrin‐DurnerinI , Guivarc'h‐LevequeA , HuguesJ‐N . Pretreatment with estrogen does not affect IVF‐ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomised trial. Fertility and Sterility2012;97(6):1359‐64. ">Cédrin‐Durnerin 2012</a>; <a href="./references#CD006109-bbs2-0010" title="FrancoJGJr , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH after 2nd phase protocols with GnRH analogs (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin) [Comparação da estimulação ovariana com FSH recombinante após protocolo de 2a fase com análogos do GnRH (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco Jr 2003</a>; <a href="./references#CD006109-bbs2-0012" title="HauzmanEE , ZapataA , BermejoA , IglesiasC , PellicerA , Garcia‐VelascoJ . Cycle scheduling for in vitro fertilisation with oral contraceptive pills versus oral estradiol valerate: a randomised controlled trial. Reproductive Biology and Endocrinology2013;11:96. ">Hauzman 2013</a>; <a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>; <a href="./references#CD006109-bbs2-0025" title="Salat‐BarouxJ , AntoineJM , AlvarezS , CornetD , TibiC , MandelbaumJ , et al. Programmed ovulation induction and oocyte retrieval for in vitro fertilization. Journal of In Vitro Fertilization and Embryo Transfer1988;5(3):153‐7. ">Salat‐Baroux 1988</a>; <a href="./references#CD006109-bbs2-0029" title="YeH , HuangG‐N , ZengP‐H , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;26(2‐3):105‐11. ">Ye 2009</a>). Nine studies only included women aged 39 years or less (<a href="./references#CD006109-bbs2-0009" title="FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol administration coordinates FSH‐induced follicular growth and improves the outcome of GnRH antagonist COH protocols. 19th Annual meeting of the ESHRE; 2003 Jun 29‐Jul 2; Madrid, Spain, 2003. 2003. FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol pre‐treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Human Reproduction2003;18(12):2698‐703. [DOI: 10.1093/humrep/deg516] ">Fanchin 2003</a>; <a href="./references#CD006109-bbs2-0011" title="Garcia‐VelascoJA , BermejoA , RuizF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility2011;96(3):590‐3. Garcia‐VelascoJA , BermejoA , Ruiz‐FloresF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial. Fertility and Sterility2010;94 Suppl 1(4):S28 Abstract no. O‐93. ">Garcia‐Velasco 2011</a>; <a href="./references#CD006109-bbs2-0015" title="HuirneJA , HuguesJN , PirardC , FischlF , SageJC , PoulyJL , et al. Cetrorelix in an oral contraceptive‐pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r‐hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction2006;21(6):1408‐15. [DOI: 10.1093/humrep/de1030] ">Huirne 2006c</a>; <a href="./references#CD006109-bbs2-0016" title="HwangJL , SeowKM , LinYH , HuangLW , HsiehBC , TsaiYL , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. [DOI: 10.1093/humrep/deh375] ">Hwang 2004</a>; <a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a>; <a href="./references#CD006109-bbs2-0020" title="BroekmansJF , VerweijPJM , EijkemansMJC , MannaertsNMJL , WitjesH . Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(8):1688‐97. Nyboe AndersenA , WitjesH , GordonK , MannaertsB . Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pretreatment. Human Reproduction2011;26(12):3413‐23. TavmergenE , vonMauw , WitjesH , MannaertsB . Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling. 25th Annual Meeting of ESHRE; 2009 28 Jun‐1 Jul; Amsterdam, the Netherlands. 2009. ">Nyboe Andersen 2011</a>; <a href="./references#CD006109-bbs2-0022" title="PorratiL , VilelaM , ViglierchioMI , ValcarcelA , LombardiE , MarconiG . Oral contraceptive pretreatment achieves better pregnancy rates in IVF antagonists GnRH flexible protocols: a prospective randomized study. Human Reproduction2010;25 Suppl 1(6):i102 Abstract no. O‐259. ">Porrati 2010</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>; <a href="./references#CD006109-bbs2-0028" title="VilelaM , MarconiM , ZappacostaMP , PorratiL , ValcarcelA , MarconiG . Oral contraceptive (OcP) pretreatment achieves better pregnancy rates in in vitro fertilisation (IVF) antagonists GnRH flexible protocols: a prospective randomised study. Fertility and Sterility2011; Vol. 96, issue 3 (supplement):S252, P‐492. ">Vilela 2011</a>). One study included women less than 40 years (<a href="./references#CD006109-bbs2-0019" title="LukaszukK , LissJ , KunickiM , KuczynskiW , PastuszekE , JakielG , et al. Estradiol valerate pretreatment in short protocol GNRH‐agonist cycles versus combined pretreatment with oral contraceptive pills in long protocol GNRH‐agonist cycles: a randomised controlled trial. BioMed Research International2015;2015:1‐6. ">Lukaszuk 2015</a>). The other three studies used age limits above 40 years of age: one study used an upper limit of 41 years of age (<a href="./references#CD006109-bbs2-0006" title="DalyDC , DalyCL , MayoD , JacobsA . Oocyte recruitment in IVF patients with limited ovarian reserve (LOR), maximizing quality of oocytes and embryos. Fertility and Sterility2002; Vol. Suppl 1, 78, issue 3:S148‐9. ">Daly 2002</a>), one study an upper limit of 42 years of age (<a href="./references#CD006109-bbs2-0041" title="Cédrin‐DurnerinI , BulwaS , HervéF , Martin‐PontB , UzanM , HuguesJN . The hormonal flare‐up following gonadotrophin‐releasing hormone agonist administration is influenced by a progestogen pretreatment. Human Reproduction1996;11(9):1859‐63. Cédrin‐DurnerinI , BulwaS , HervéF , PecqueuxL , UzanM , HuguesJN . Influence of norethisterone pretreatment on the initial flare‐up induced by a gonadotrophin‐releasing hormone agonist in a short protocol for IVF. Human Reproduction1995;10 Abstract Book 2:116. ">Cédrin‐Durnerin 1996</a>), and one study used an upper limit of 44 years of age (<a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>). Six of these 21 studies defined lower limits of 18 years of age (<a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>; <a href="./references#CD006109-bbs2-0012" title="HauzmanEE , ZapataA , BermejoA , IglesiasC , PellicerA , Garcia‐VelascoJ . Cycle scheduling for in vitro fertilisation with oral contraceptive pills versus oral estradiol valerate: a randomised controlled trial. Reproductive Biology and Endocrinology2013;11:96. ">Hauzman 2013</a>; <a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>; <a href="./references#CD006109-bbs2-0015" title="HuirneJA , HuguesJN , PirardC , FischlF , SageJC , PoulyJL , et al. Cetrorelix in an oral contraceptive‐pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r‐hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction2006;21(6):1408‐15. [DOI: 10.1093/humrep/de1030] ">Huirne 2006c</a>; <a href="./references#CD006109-bbs2-0020" title="BroekmansJF , VerweijPJM , EijkemansMJC , MannaertsNMJL , WitjesH . Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(8):1688‐97. Nyboe AndersenA , WitjesH , GordonK , MannaertsB . Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pretreatment. Human Reproduction2011;26(12):3413‐23. TavmergenE , vonMauw , WitjesH , MannaertsB . Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling. 25th Annual Meeting of ESHRE; 2009 28 Jun‐1 Jul; Amsterdam, the Netherlands. 2009. ">Nyboe Andersen 2011</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>). </p> <p>Other common inclusion criteria were the presence of regular menstrual cycles (<a href="./references#CD006109-bbs2-0003" title="BlockeelC , EngelsS , deVosM , HaentjensP , PolyzosNP , StoopD , et al. Oestradiol valerate pretreatment in GnRH antagonist cycles: a randomised controlled trial. Reproductive Biomedicine Online2012;24:272‐80. ">Blockeel 2012</a>; <a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0005" title="Cédrin‐DurnerinI , Guivarc'h‐LevequeA , HuguesJ‐N . Pretreatment with estrogen does not affect IVF‐ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomised trial. Fertility and Sterility2012;97(6):1359‐64. ">Cédrin‐Durnerin 2012</a>; <a href="./references#CD006109-bbs2-0009" title="FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol administration coordinates FSH‐induced follicular growth and improves the outcome of GnRH antagonist COH protocols. 19th Annual meeting of the ESHRE; 2003 Jun 29‐Jul 2; Madrid, Spain, 2003. 2003. FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol pre‐treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Human Reproduction2003;18(12):2698‐703. [DOI: 10.1093/humrep/deg516] ">Fanchin 2003</a>; <a href="./references#CD006109-bbs2-0011" title="Garcia‐VelascoJA , BermejoA , RuizF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility2011;96(3):590‐3. Garcia‐VelascoJA , BermejoA , Ruiz‐FloresF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial. Fertility and Sterility2010;94 Suppl 1(4):S28 Abstract no. O‐93. ">Garcia‐Velasco 2011</a>; <a href="./references#CD006109-bbs2-0012" title="HauzmanEE , ZapataA , BermejoA , IglesiasC , PellicerA , Garcia‐VelascoJ . Cycle scheduling for in vitro fertilisation with oral contraceptive pills versus oral estradiol valerate: a randomised controlled trial. Reproductive Biology and Endocrinology2013;11:96. ">Hauzman 2013</a>; <a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>; <a href="./references#CD006109-bbs2-0020" title="BroekmansJF , VerweijPJM , EijkemansMJC , MannaertsNMJL , WitjesH . Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(8):1688‐97. Nyboe AndersenA , WitjesH , GordonK , MannaertsB . Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pretreatment. Human Reproduction2011;26(12):3413‐23. TavmergenE , vonMauw , WitjesH , MannaertsB . Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling. 25th Annual Meeting of ESHRE; 2009 28 Jun‐1 Jul; Amsterdam, the Netherlands. 2009. ">Nyboe Andersen 2011</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>; <a href="./references#CD006109-bbs2-0029" title="YeH , HuangG‐N , ZengP‐H , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;26(2‐3):105‐11. ">Ye 2009</a>), and a body mass index (BMI) between 18 kg/m<sup>2</sup> and 25 kg/m<sup>2</sup> (<a href="./references#CD006109-bbs2-0029" title="YeH , HuangG‐N , ZengP‐H , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;26(2‐3):105‐11. ">Ye 2009</a>), or less than 30 kg/m<sup>2</sup> (<a href="./references#CD006109-bbs2-0003" title="BlockeelC , EngelsS , deVosM , HaentjensP , PolyzosNP , StoopD , et al. Oestradiol valerate pretreatment in GnRH antagonist cycles: a randomised controlled trial. Reproductive Biomedicine Online2012;24:272‐80. ">Blockeel 2012</a>; <a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0005" title="Cédrin‐DurnerinI , Guivarc'h‐LevequeA , HuguesJ‐N . Pretreatment with estrogen does not affect IVF‐ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomised trial. Fertility and Sterility2012;97(6):1359‐64. ">Cédrin‐Durnerin 2012</a>; <a href="./references#CD006109-bbs2-0009" title="FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol administration coordinates FSH‐induced follicular growth and improves the outcome of GnRH antagonist COH protocols. 19th Annual meeting of the ESHRE; 2003 Jun 29‐Jul 2; Madrid, Spain, 2003. 2003. FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol pre‐treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Human Reproduction2003;18(12):2698‐703. [DOI: 10.1093/humrep/deg516] ">Fanchin 2003</a>; <a href="./references#CD006109-bbs2-0012" title="HauzmanEE , ZapataA , BermejoA , IglesiasC , PellicerA , Garcia‐VelascoJ . Cycle scheduling for in vitro fertilisation with oral contraceptive pills versus oral estradiol valerate: a randomised controlled trial. Reproductive Biology and Endocrinology2013;11:96. ">Hauzman 2013</a>; <a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>; <a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>). </p> </section> <section id="CD006109-sec-0067"> <h6 class="title">Exclusion criteria</h6> <p>Nine studies excluded women with an evidence of poor response. Two studies defined poor response as any previous ART cycles with less than three oocytes (<a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>; <a href="./references#CD006109-bbs2-0015" title="HuirneJA , HuguesJN , PirardC , FischlF , SageJC , PoulyJL , et al. Cetrorelix in an oral contraceptive‐pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r‐hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction2006;21(6):1408‐15. [DOI: 10.1093/humrep/de1030] ">Huirne 2006c</a>), <a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a> also excluded women if they had a history of three or more consecutive ART cycles without a clinical pregnancy. One study defined poor response as development of fewer than four follicles in previous IVF or ICSI cycles (<a href="./references#CD006109-bbs2-0003" title="BlockeelC , EngelsS , deVosM , HaentjensP , PolyzosNP , StoopD , et al. Oestradiol valerate pretreatment in GnRH antagonist cycles: a randomised controlled trial. Reproductive Biomedicine Online2012;24:272‐80. ">Blockeel 2012</a>). Three studies defined poor response as fewer than five oocytes in a previous IVF attempt or fewer than five follicles in a spontaneous cycle (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0005" title="Cédrin‐DurnerinI , Guivarc'h‐LevequeA , HuguesJ‐N . Pretreatment with estrogen does not affect IVF‐ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomised trial. Fertility and Sterility2012;97(6):1359‐64. ">Cédrin‐Durnerin 2012</a>; <a href="./references#CD006109-bbs2-0012" title="HauzmanEE , ZapataA , BermejoA , IglesiasC , PellicerA , Garcia‐VelascoJ . Cycle scheduling for in vitro fertilisation with oral contraceptive pills versus oral estradiol valerate: a randomised controlled trial. Reproductive Biology and Endocrinology2013;11:96. ">Hauzman 2013</a>), and one study defined poor response as more than three unsuccessful controlled ovarian stimulation cycles or a history of low or no ovarian response during FSH/hMG (<a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>). Two studies did not mention how they defined poor response to ovarian stimulation (<a href="./references#CD006109-bbs2-0011" title="Garcia‐VelascoJA , BermejoA , RuizF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility2011;96(3):590‐3. Garcia‐VelascoJA , BermejoA , Ruiz‐FloresF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial. Fertility and Sterility2010;94 Suppl 1(4):S28 Abstract no. O‐93. ">Garcia‐Velasco 2011</a>; <a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a>). </p> <p>Other common exclusion criteria were: a high baseline serum FSH level (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0005" title="Cédrin‐DurnerinI , Guivarc'h‐LevequeA , HuguesJ‐N . Pretreatment with estrogen does not affect IVF‐ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomised trial. Fertility and Sterility2012;97(6):1359‐64. ">Cédrin‐Durnerin 2012</a>; <a href="./references#CD006109-bbs2-0007" title="DitkoffEC , SauerMV . A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin‐releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Human Reproduction1996;11(5):1035‐7. ">Ditkoff 1996</a>; <a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>; <a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>; <a href="./references#CD006109-bbs2-0016" title="HwangJL , SeowKM , LinYH , HuangLW , HsiehBC , TsaiYL , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. [DOI: 10.1093/humrep/deh375] ">Hwang 2004</a>; <a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a>; <a href="./references#CD006109-bbs2-0020" title="BroekmansJF , VerweijPJM , EijkemansMJC , MannaertsNMJL , WitjesH . Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(8):1688‐97. Nyboe AndersenA , WitjesH , GordonK , MannaertsB . Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pretreatment. Human Reproduction2011;26(12):3413‐23. TavmergenE , vonMauw , WitjesH , MannaertsB . Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling. 25th Annual Meeting of ESHRE; 2009 28 Jun‐1 Jul; Amsterdam, the Netherlands. 2009. ">Nyboe Andersen 2011</a>), evidence of ovarian cysts or endometrioma (<a href="./references#CD006109-bbs2-0001" title="AstonK , ArthurI , MassonGM , JenkinsJM . Progestogen therapy and prevention of functional ovarian cysts during pituitary desensitisation with GnRH agonists. British Journal of Obstetrics and Gynaecology1995;102:835‐7. ">Aston 1995</a>; <a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>; <a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a>), and PCOS (<a href="./references#CD006109-bbs2-0003" title="BlockeelC , EngelsS , deVosM , HaentjensP , PolyzosNP , StoopD , et al. Oestradiol valerate pretreatment in GnRH antagonist cycles: a randomised controlled trial. Reproductive Biomedicine Online2012;24:272‐80. ">Blockeel 2012</a>; <a href="./references#CD006109-bbs2-0011" title="Garcia‐VelascoJA , BermejoA , RuizF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility2011;96(3):590‐3. Garcia‐VelascoJA , BermejoA , Ruiz‐FloresF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial. Fertility and Sterility2010;94 Suppl 1(4):S28 Abstract no. O‐93. ">Garcia‐Velasco 2011</a>; <a href="./references#CD006109-bbs2-0012" title="HauzmanEE , ZapataA , BermejoA , IglesiasC , PellicerA , Garcia‐VelascoJ . Cycle scheduling for in vitro fertilisation with oral contraceptive pills versus oral estradiol valerate: a randomised controlled trial. Reproductive Biology and Endocrinology2013;11:96. ">Hauzman 2013</a>; <a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>; <a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD006109-bbs2-0022" title="PorratiL , VilelaM , ViglierchioMI , ValcarcelA , LombardiE , MarconiG . Oral contraceptive pretreatment achieves better pregnancy rates in IVF antagonists GnRH flexible protocols: a prospective randomized study. Human Reproduction2010;25 Suppl 1(6):i102 Abstract no. O‐259. ">Porrati 2010</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>; <a href="./references#CD006109-bbs2-0028" title="VilelaM , MarconiM , ZappacostaMP , PorratiL , ValcarcelA , MarconiG . Oral contraceptive (OcP) pretreatment achieves better pregnancy rates in in vitro fertilisation (IVF) antagonists GnRH flexible protocols: a prospective randomised study. Fertility and Sterility2011; Vol. 96, issue 3 (supplement):S252, P‐492. ">Vilela 2011</a>). </p> </section> </section> <section id="CD006109-sec-0068"> <h5 class="title">Interventions</h5> <p>Three of the 29 studies had more than two study arms and were used in more than one comparison (four arms: <a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; three arms: <a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>). </p> <section id="CD006109-sec-0069"> <h6 class="title">Combined oral contraceptive pill versus placebo or no pretreatment</h6> <p>In 17 trials (with 19 comparisons), the study group received pretreatment with a COCP, while the control group received no pretreatment. None of these studies used a placebo in the control group. Ten trials used ethinyl oestradiol as the oestrogen component in a daily dose of 30 μg (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0011" title="Garcia‐VelascoJA , BermejoA , RuizF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility2011;96(3):590‐3. Garcia‐VelascoJA , BermejoA , Ruiz‐FloresF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial. Fertility and Sterility2010;94 Suppl 1(4):S28 Abstract no. O‐93. ">Garcia‐Velasco 2011</a>; <a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>; <a href="./references#CD006109-bbs2-0015" title="HuirneJA , HuguesJN , PirardC , FischlF , SageJC , PoulyJL , et al. Cetrorelix in an oral contraceptive‐pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r‐hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction2006;21(6):1408‐15. [DOI: 10.1093/humrep/de1030] ">Huirne 2006c</a>; <a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a>; <a href="./references#CD006109-bbs2-0020" title="BroekmansJF , VerweijPJM , EijkemansMJC , MannaertsNMJL , WitjesH . Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(8):1688‐97. Nyboe AndersenA , WitjesH , GordonK , MannaertsB . Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pretreatment. Human Reproduction2011;26(12):3413‐23. TavmergenE , vonMauw , WitjesH , MannaertsB . Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling. 25th Annual Meeting of ESHRE; 2009 28 Jun‐1 Jul; Amsterdam, the Netherlands. 2009. ">Nyboe Andersen 2011</a>; <a href="./references#CD006109-bbs2-0021" title="ObrucaA , FischlF , HuberJ . Programming oocyte retrieval using oral contraceptive pretreatment before ovarian stimulation with a GnRH antagonist (Cetrotide) protocol. Human Reproduction. 2002; Vol. 17 Abstract Book 1:89. ">Obruca 2002</a>; <a href="./references#CD006109-bbs2-0023" title="RaoofiZ , AflatoonianA . Ovarian cysts formation during depot formulation of GnRH‐a therapy and the effect of pretreatment with oral contraceptive pills on subsequent implantation and pregnancy rate in ART cycles. Iranian Journal of Pharmaceutical Research2008;7(2):109‐13. ">Raoofi 2008</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>); seven trials used desogestrel 150 μg daily (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0011" title="Garcia‐VelascoJA , BermejoA , RuizF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility2011;96(3):590‐3. Garcia‐VelascoJA , BermejoA , Ruiz‐FloresF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial. Fertility and Sterility2010;94 Suppl 1(4):S28 Abstract no. O‐93. ">Garcia‐Velasco 2011</a>; <a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a>; <a href="./references#CD006109-bbs2-0020" title="BroekmansJF , VerweijPJM , EijkemansMJC , MannaertsNMJL , WitjesH . Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(8):1688‐97. Nyboe AndersenA , WitjesH , GordonK , MannaertsB . Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pretreatment. Human Reproduction2011;26(12):3413‐23. TavmergenE , vonMauw , WitjesH , MannaertsB . Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling. 25th Annual Meeting of ESHRE; 2009 28 Jun‐1 Jul; Amsterdam, the Netherlands. 2009. ">Nyboe Andersen 2011</a>; <a href="./references#CD006109-bbs2-0021" title="ObrucaA , FischlF , HuberJ . Programming oocyte retrieval using oral contraceptive pretreatment before ovarian stimulation with a GnRH antagonist (Cetrotide) protocol. Human Reproduction. 2002; Vol. 17 Abstract Book 1:89. ">Obruca 2002</a>; <a href="./references#CD006109-bbs2-0023" title="RaoofiZ , AflatoonianA . Ovarian cysts formation during depot formulation of GnRH‐a therapy and the effect of pretreatment with oral contraceptive pills on subsequent implantation and pregnancy rate in ART cycles. Iranian Journal of Pharmaceutical Research2008;7(2):109‐13. ">Raoofi 2008</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>); three trials used levonorgestrel 150 μg daily as the progestogen component (<a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>; <a href="./references#CD006109-bbs2-0015" title="HuirneJA , HuguesJN , PirardC , FischlF , SageJC , PoulyJL , et al. Cetrorelix in an oral contraceptive‐pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r‐hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction2006;21(6):1408‐15. [DOI: 10.1093/humrep/de1030] ">Huirne 2006c</a>; <a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>); one trial used Diane‐35, which contained ethinyl oestradiol 35 μg and cyproterone acetate 2 mg (<a href="./references#CD006109-bbs2-0016" title="HwangJL , SeowKM , LinYH , HuangLW , HsiehBC , TsaiYL , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. [DOI: 10.1093/humrep/deh375] ">Hwang 2004</a>); and two trials used a combination of ethinyl oestradiol 20 μg and levonorgestrel 100 μg (<a href="./references#CD006109-bbs2-0022" title="PorratiL , VilelaM , ViglierchioMI , ValcarcelA , LombardiE , MarconiG . Oral contraceptive pretreatment achieves better pregnancy rates in IVF antagonists GnRH flexible protocols: a prospective randomized study. Human Reproduction2010;25 Suppl 1(6):i102 Abstract no. O‐259. ">Porrati 2010</a>; <a href="./references#CD006109-bbs2-0028" title="VilelaM , MarconiM , ZappacostaMP , PorratiL , ValcarcelA , MarconiG . Oral contraceptive (OcP) pretreatment achieves better pregnancy rates in in vitro fertilisation (IVF) antagonists GnRH flexible protocols: a prospective randomised study. Fertility and Sterility2011; Vol. 96, issue 3 (supplement):S252, P‐492. ">Vilela 2011</a>). For other studies, there were not enough data available on the type of COCP used. </p> <p>The starting days of pretreatment in 10 of the trials varied from cycle day one to five. Five studies started COCP pretreatment on cycle day one (<a href="./references#CD006109-bbs2-0002" title="BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF . Prospective randomized trial on effect of pre‐treatment with an oral contraceptive (OC) on the length of time required for pituitary suppression by gonadotropin releasing hormone agonist (GnRH‐a) and subsequent implantation and pregnancy rates. Fertility and Sterility1998; Vol. Suppl 1, 70, issue 3:S133. BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF , TanSL . Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin‐releasing hormone analogues and on subsequent implantation and pregnancy rates. Fertility and Sterility1998;70(6):1063‐9. ">Biljan 1998b</a>; <a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a>; <a href="./references#CD006109-bbs2-0021" title="ObrucaA , FischlF , HuberJ . Programming oocyte retrieval using oral contraceptive pretreatment before ovarian stimulation with a GnRH antagonist (Cetrotide) protocol. Human Reproduction. 2002; Vol. 17 Abstract Book 1:89. ">Obruca 2002</a>; <a href="./references#CD006109-bbs2-0023" title="RaoofiZ , AflatoonianA . Ovarian cysts formation during depot formulation of GnRH‐a therapy and the effect of pretreatment with oral contraceptive pills on subsequent implantation and pregnancy rate in ART cycles. Iranian Journal of Pharmaceutical Research2008;7(2):109‐13. ">Raoofi 2008</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>); two studies started the pretreatment on cycle day two or three (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>); one study started the pretreatment on a variable cycle day from one to five (<a href="./references#CD006109-bbs2-0015" title="HuirneJA , HuguesJN , PirardC , FischlF , SageJC , PoulyJL , et al. Cetrorelix in an oral contraceptive‐pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r‐hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction2006;21(6):1408‐15. [DOI: 10.1093/humrep/de1030] ">Huirne 2006c</a>); and one study started the pretreatment on cycle day five (<a href="./references#CD006109-bbs2-0016" title="HwangJL , SeowKM , LinYH , HuangLW , HsiehBC , TsaiYL , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. [DOI: 10.1093/humrep/deh375] ">Hwang 2004</a>). There were not enough data available from five trials on the start day of pretreatment (<a href="./references#CD006109-bbs2-0011" title="Garcia‐VelascoJA , BermejoA , RuizF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility2011;96(3):590‐3. Garcia‐VelascoJA , BermejoA , Ruiz‐FloresF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial. Fertility and Sterility2010;94 Suppl 1(4):S28 Abstract no. O‐93. ">Garcia‐Velasco 2011</a>; <a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD006109-bbs2-0020" title="BroekmansJF , VerweijPJM , EijkemansMJC , MannaertsNMJL , WitjesH . Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(8):1688‐97. Nyboe AndersenA , WitjesH , GordonK , MannaertsB . Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pretreatment. Human Reproduction2011;26(12):3413‐23. TavmergenE , vonMauw , WitjesH , MannaertsB . Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling. 25th Annual Meeting of ESHRE; 2009 28 Jun‐1 Jul; Amsterdam, the Netherlands. 2009. ">Nyboe Andersen 2011</a>; <a href="./references#CD006109-bbs2-0022" title="PorratiL , VilelaM , ViglierchioMI , ValcarcelA , LombardiE , MarconiG . Oral contraceptive pretreatment achieves better pregnancy rates in IVF antagonists GnRH flexible protocols: a prospective randomized study. Human Reproduction2010;25 Suppl 1(6):i102 Abstract no. O‐259. ">Porrati 2010</a>; <a href="./references#CD006109-bbs2-0028" title="VilelaM , MarconiM , ZappacostaMP , PorratiL , ValcarcelA , MarconiG . Oral contraceptive (OcP) pretreatment achieves better pregnancy rates in in vitro fertilisation (IVF) antagonists GnRH flexible protocols: a prospective randomised study. Fertility and Sterility2011; Vol. 96, issue 3 (supplement):S252, P‐492. ">Vilela 2011</a>). </p> <p>The duration of pretreatment in the 17 trials varied from 12 days to three consecutive cycles. Five studies used a fixed duration of 14 days of pretreatment (<a href="./references#CD006109-bbs2-0002" title="BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF . Prospective randomized trial on effect of pre‐treatment with an oral contraceptive (OC) on the length of time required for pituitary suppression by gonadotropin releasing hormone agonist (GnRH‐a) and subsequent implantation and pregnancy rates. Fertility and Sterility1998; Vol. Suppl 1, 70, issue 3:S133. BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF , TanSL . Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin‐releasing hormone analogues and on subsequent implantation and pregnancy rates. Fertility and Sterility1998;70(6):1063‐9. ">Biljan 1998b</a>; <a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a>; <a href="./references#CD006109-bbs2-0023" title="RaoofiZ , AflatoonianA . Ovarian cysts formation during depot formulation of GnRH‐a therapy and the effect of pretreatment with oral contraceptive pills on subsequent implantation and pregnancy rate in ART cycles. Iranian Journal of Pharmaceutical Research2008;7(2):109‐13. ">Raoofi 2008</a>), or 21 days of pretreatment (<a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD006109-bbs2-0022" title="PorratiL , VilelaM , ViglierchioMI , ValcarcelA , LombardiE , MarconiG . Oral contraceptive pretreatment achieves better pregnancy rates in IVF antagonists GnRH flexible protocols: a prospective randomized study. Human Reproduction2010;25 Suppl 1(6):i102 Abstract no. O‐259. ">Porrati 2010</a>); five studies used a variable duration of pretreatment of 12 to 16 days (<a href="./references#CD006109-bbs2-0011" title="Garcia‐VelascoJA , BermejoA , RuizF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility2011;96(3):590‐3. Garcia‐VelascoJA , BermejoA , Ruiz‐FloresF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial. Fertility and Sterility2010;94 Suppl 1(4):S28 Abstract no. O‐93. ">Garcia‐Velasco 2011</a>), 14 to 21 days (<a href="./references#CD006109-bbs2-0020" title="BroekmansJF , VerweijPJM , EijkemansMJC , MannaertsNMJL , WitjesH . Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(8):1688‐97. Nyboe AndersenA , WitjesH , GordonK , MannaertsB . Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pretreatment. Human Reproduction2011;26(12):3413‐23. TavmergenE , vonMauw , WitjesH , MannaertsB . Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling. 25th Annual Meeting of ESHRE; 2009 28 Jun‐1 Jul; Amsterdam, the Netherlands. 2009. ">Nyboe Andersen 2011</a>), 14 to 25 days (<a href="./references#CD006109-bbs2-0028" title="VilelaM , MarconiM , ZappacostaMP , PorratiL , ValcarcelA , MarconiG . Oral contraceptive (OcP) pretreatment achieves better pregnancy rates in in vitro fertilisation (IVF) antagonists GnRH flexible protocols: a prospective randomised study. Fertility and Sterility2011; Vol. 96, issue 3 (supplement):S252, P‐492. ">Vilela 2011</a>), and 14 to 28 days (<a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>). Three other studies used a variable duration of around two or three weeks minimum to around four weeks maximum (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>, 15 to 21 days; <a href="./references#CD006109-bbs2-0021" title="ObrucaA , FischlF , HuberJ . Programming oocyte retrieval using oral contraceptive pretreatment before ovarian stimulation with a GnRH antagonist (Cetrotide) protocol. Human Reproduction. 2002; Vol. 17 Abstract Book 1:89. ">Obruca 2002</a>, 18 to 28 days; <a href="./references#CD006109-bbs2-0015" title="HuirneJA , HuguesJN , PirardC , FischlF , SageJC , PoulyJL , et al. Cetrorelix in an oral contraceptive‐pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r‐hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction2006;21(6):1408‐15. [DOI: 10.1093/humrep/de1030] ">Huirne 2006c</a>, 21 to 28 days). <a href="./references#CD006109-bbs2-0016" title="HwangJL , SeowKM , LinYH , HuangLW , HsiehBC , TsaiYL , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. [DOI: 10.1093/humrep/deh375] ">Hwang 2004</a> used the longest pretreatment duration of three consecutive cycles. </p> <p>Two studies used agonists in both treatment groups. One study used buserelin acetate (long protocol) (<a href="./references#CD006109-bbs2-0002" title="BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF . Prospective randomized trial on effect of pre‐treatment with an oral contraceptive (OC) on the length of time required for pituitary suppression by gonadotropin releasing hormone agonist (GnRH‐a) and subsequent implantation and pregnancy rates. Fertility and Sterility1998; Vol. Suppl 1, 70, issue 3:S133. BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF , TanSL . Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin‐releasing hormone analogues and on subsequent implantation and pregnancy rates. Fertility and Sterility1998;70(6):1063‐9. ">Biljan 1998b</a>) and one used a depot of triptorelin acetate (<a href="./references#CD006109-bbs2-0023" title="RaoofiZ , AflatoonianA . Ovarian cysts formation during depot formulation of GnRH‐a therapy and the effect of pretreatment with oral contraceptive pills on subsequent implantation and pregnancy rate in ART cycles. Iranian Journal of Pharmaceutical Research2008;7(2):109‐13. ">Raoofi 2008</a>). </p> <p>Ten studies used antagonists in both treatment groups. Four studies used ganirelix acetate (<a href="./references#CD006109-bbs2-0003" title="BlockeelC , EngelsS , deVosM , HaentjensP , PolyzosNP , StoopD , et al. Oestradiol valerate pretreatment in GnRH antagonist cycles: a randomised controlled trial. Reproductive Biomedicine Online2012;24:272‐80. ">Blockeel 2012</a>; <a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>); three studies used cetrorelix acetate (<a href="./references#CD006109-bbs2-0021" title="ObrucaA , FischlF , HuberJ . Programming oocyte retrieval using oral contraceptive pretreatment before ovarian stimulation with a GnRH antagonist (Cetrotide) protocol. Human Reproduction. 2002; Vol. 17 Abstract Book 1:89. ">Obruca 2002</a>; <a href="./references#CD006109-bbs2-0022" title="PorratiL , VilelaM , ViglierchioMI , ValcarcelA , LombardiE , MarconiG . Oral contraceptive pretreatment achieves better pregnancy rates in IVF antagonists GnRH flexible protocols: a prospective randomized study. Human Reproduction2010;25 Suppl 1(6):i102 Abstract no. O‐259. ">Porrati 2010</a>; <a href="./references#CD006109-bbs2-0028" title="VilelaM , MarconiM , ZappacostaMP , PorratiL , ValcarcelA , MarconiG . Oral contraceptive (OcP) pretreatment achieves better pregnancy rates in in vitro fertilisation (IVF) antagonists GnRH flexible protocols: a prospective randomised study. Fertility and Sterility2011; Vol. 96, issue 3 (supplement):S252, P‐492. ">Vilela 2011</a>); one study used antide (<a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>); one study, a three‐arm parallel RCT, used cerotide in two of the treatment arms and a GnRH agonist in the second control arm (<a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>), and one study did not mention which GnRH antagonist was used (<a href="./references#CD006109-bbs2-0020" title="BroekmansJF , VerweijPJM , EijkemansMJC , MannaertsNMJL , WitjesH . Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(8):1688‐97. Nyboe AndersenA , WitjesH , GordonK , MannaertsB . Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pretreatment. Human Reproduction2011;26(12):3413‐23. TavmergenE , vonMauw , WitjesH , MannaertsB . Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling. 25th Annual Meeting of ESHRE; 2009 28 Jun‐1 Jul; Amsterdam, the Netherlands. 2009. ">Nyboe Andersen 2011</a>). </p> <p>Four trials used an antagonist in the study group and an agonist in the control group. Two trials used cetrorelix acetate as antagonist and buserelin acetate as agonist (<a href="./references#CD006109-bbs2-0015" title="HuirneJA , HuguesJN , PirardC , FischlF , SageJC , PoulyJL , et al. Cetrorelix in an oral contraceptive‐pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r‐hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction2006;21(6):1408‐15. [DOI: 10.1093/humrep/de1030] ">Huirne 2006c</a>; <a href="./references#CD006109-bbs2-0016" title="HwangJL , SeowKM , LinYH , HuangLW , HsiehBC , TsaiYL , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. [DOI: 10.1093/humrep/deh375] ">Hwang 2004</a>), and one used ganirelix acetate as antagonist and nafarelin acetate as agonist (<a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>). The other study did not mention which antagonists and agonists were used (<a href="./references#CD006109-bbs2-0011" title="Garcia‐VelascoJA , BermejoA , RuizF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility2011;96(3):590‐3. Garcia‐VelascoJA , BermejoA , Ruiz‐FloresF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial. Fertility and Sterility2010;94 Suppl 1(4):S28 Abstract no. O‐93. ">Garcia‐Velasco 2011</a>). </p> </section> <section id="CD006109-sec-0070"> <h6 class="title">Progestogen versus placebo or no pretreatment</h6> <p>In seven trials, the study group was given a pretreatment with a progestogen, while the control group received placebo (<a href="./references#CD006109-bbs2-0001" title="AstonK , ArthurI , MassonGM , JenkinsJM . Progestogen therapy and prevention of functional ovarian cysts during pituitary desensitisation with GnRH agonists. British Journal of Obstetrics and Gynaecology1995;102:835‐7. ">Aston 1995</a>), or no pretreatment (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0007" title="DitkoffEC , SauerMV . A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin‐releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Human Reproduction1996;11(5):1035‐7. ">Ditkoff 1996</a>; <a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>; <a href="./references#CD006109-bbs2-0013" title="HuguesJN , Cédrin‐DurnerinI , HervéF , Huet‐PecqueuxL , SantarelliJ . Incidence of preprogrammed norethisterone on the intensity of 'flare up' (flush) caused by GnRH agonist according to the IVF protocol [poster] [Incidence d'une préprogrammation par la noréthistérone sur la qualité du flare‐up induit par un agoniste du GnRH en protocole court de FIV]. Contraception, Fertilite, Sexualite1994; Vol. 22, issue 5:331. ">Hugues 1994</a>; <a href="./references#CD006109-bbs2-0025" title="Salat‐BarouxJ , AntoineJM , AlvarezS , CornetD , TibiC , MandelbaumJ , et al. Programmed ovulation induction and oocyte retrieval for in vitro fertilization. Journal of In Vitro Fertilization and Embryo Transfer1988;5(3):153‐7. ">Salat‐Baroux 1988</a>; <a href="./references#CD006109-bbs2-0026" title="ShakerAG , PittrofR , ZaidiJ , BekirJ , Kyei‐MensahA , TanSL . Administration of progestogens to hasten pituitary desensitization after the use of gonadotropin‐releasing hormone agonist in in vitro fertilization ‐ a prospective randomized study. Fertility and Sterility1995;64(4):791‐5. ">Shaker 1995</a>). Four studies used norethisterone 10 mg daily (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0007" title="DitkoffEC , SauerMV . A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin‐releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Human Reproduction1996;11(5):1035‐7. ">Ditkoff 1996</a>; <a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>; <a href="./references#CD006109-bbs2-0013" title="HuguesJN , Cédrin‐DurnerinI , HervéF , Huet‐PecqueuxL , SantarelliJ . Incidence of preprogrammed norethisterone on the intensity of 'flare up' (flush) caused by GnRH agonist according to the IVF protocol [poster] [Incidence d'une préprogrammation par la noréthistérone sur la qualité du flare‐up induit par un agoniste du GnRH en protocole court de FIV]. Contraception, Fertilite, Sexualite1994; Vol. 22, issue 5:331. ">Hugues 1994</a>), one study used medroxyprogesterone acetate 10 mg daily (<a href="./references#CD006109-bbs2-0001" title="AstonK , ArthurI , MassonGM , JenkinsJM . Progestogen therapy and prevention of functional ovarian cysts during pituitary desensitisation with GnRH agonists. British Journal of Obstetrics and Gynaecology1995;102:835‐7. ">Aston 1995</a>), and one study used ethynodiol acetate 4 mg daily (<a href="./references#CD006109-bbs2-0025" title="Salat‐BarouxJ , AntoineJM , AlvarezS , CornetD , TibiC , MandelbaumJ , et al. Programmed ovulation induction and oocyte retrieval for in vitro fertilization. Journal of In Vitro Fertilization and Embryo Transfer1988;5(3):153‐7. ">Salat‐Baroux 1988</a>). Another study used a single injection of 100 mg, but did not mention what type of progestogen they used (<a href="./references#CD006109-bbs2-0026" title="ShakerAG , PittrofR , ZaidiJ , BekirJ , Kyei‐MensahA , TanSL . Administration of progestogens to hasten pituitary desensitization after the use of gonadotropin‐releasing hormone agonist in in vitro fertilization ‐ a prospective randomized study. Fertility and Sterility1995;64(4):791‐5. ">Shaker 1995</a>). </p> <p>The starting days of pretreatment in all seven trials varied from cycle day one to 19. Two studies started the pretreatment with progestogen on cycle day one (<a href="./references#CD006109-bbs2-0007" title="DitkoffEC , SauerMV . A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin‐releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Human Reproduction1996;11(5):1035‐7. ">Ditkoff 1996</a>; <a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>), two studies on cycle day 15 (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0025" title="Salat‐BarouxJ , AntoineJM , AlvarezS , CornetD , TibiC , MandelbaumJ , et al. Programmed ovulation induction and oocyte retrieval for in vitro fertilization. Journal of In Vitro Fertilization and Embryo Transfer1988;5(3):153‐7. ">Salat‐Baroux 1988</a>), one study on cycle day 16 or 17 (<a href="./references#CD006109-bbs2-0026" title="ShakerAG , PittrofR , ZaidiJ , BekirJ , Kyei‐MensahA , TanSL . Administration of progestogens to hasten pituitary desensitization after the use of gonadotropin‐releasing hormone agonist in in vitro fertilization ‐ a prospective randomized study. Fertility and Sterility1995;64(4):791‐5. ">Shaker 1995</a>), and one study on cycle day 19 (<a href="./references#CD006109-bbs2-0001" title="AstonK , ArthurI , MassonGM , JenkinsJM . Progestogen therapy and prevention of functional ovarian cysts during pituitary desensitisation with GnRH agonists. British Journal of Obstetrics and Gynaecology1995;102:835‐7. ">Aston 1995</a>). There were not enough data available from one study on the start day of pretreatment (<a href="./references#CD006109-bbs2-0013" title="HuguesJN , Cédrin‐DurnerinI , HervéF , Huet‐PecqueuxL , SantarelliJ . Incidence of preprogrammed norethisterone on the intensity of 'flare up' (flush) caused by GnRH agonist according to the IVF protocol [poster] [Incidence d'une préprogrammation par la noréthistérone sur la qualité du flare‐up induit par un agoniste du GnRH en protocole court de FIV]. Contraception, Fertilite, Sexualite1994; Vol. 22, issue 5:331. ">Hugues 1994</a>). </p> <p>The duration of progestogen pretreatment varied from one to 21 days. In one study, the women received one single injection (<a href="./references#CD006109-bbs2-0026" title="ShakerAG , PittrofR , ZaidiJ , BekirJ , Kyei‐MensahA , TanSL . Administration of progestogens to hasten pituitary desensitization after the use of gonadotropin‐releasing hormone agonist in in vitro fertilization ‐ a prospective randomized study. Fertility and Sterility1995;64(4):791‐5. ">Shaker 1995</a>). One study used a duration of pretreatment of five days (<a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>), one study used seven days (<a href="./references#CD006109-bbs2-0001" title="AstonK , ArthurI , MassonGM , JenkinsJM . Progestogen therapy and prevention of functional ovarian cysts during pituitary desensitisation with GnRH agonists. British Journal of Obstetrics and Gynaecology1995;102:835‐7. ">Aston 1995</a>), and one study used eight days (<a href="./references#CD006109-bbs2-0007" title="DitkoffEC , SauerMV . A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin‐releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Human Reproduction1996;11(5):1035‐7. ">Ditkoff 1996</a>). Two trials used a variable duration of 10 to 15 days (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0013" title="HuguesJN , Cédrin‐DurnerinI , HervéF , Huet‐PecqueuxL , SantarelliJ . Incidence of preprogrammed norethisterone on the intensity of 'flare up' (flush) caused by GnRH agonist according to the IVF protocol [poster] [Incidence d'une préprogrammation par la noréthistérone sur la qualité du flare‐up induit par un agoniste du GnRH en protocole court de FIV]. Contraception, Fertilite, Sexualite1994; Vol. 22, issue 5:331. ">Hugues 1994</a>), and one trial used 11 to 17 days (<a href="./references#CD006109-bbs2-0025" title="Salat‐BarouxJ , AntoineJM , AlvarezS , CornetD , TibiC , MandelbaumJ , et al. Programmed ovulation induction and oocyte retrieval for in vitro fertilization. Journal of In Vitro Fertilization and Embryo Transfer1988;5(3):153‐7. ">Salat‐Baroux 1988</a>). </p> <p>Six trials used an agonist in both treatment groups. Three studies used buserelin acetate (<a href="./references#CD006109-bbs2-0001" title="AstonK , ArthurI , MassonGM , JenkinsJM . Progestogen therapy and prevention of functional ovarian cysts during pituitary desensitisation with GnRH agonists. British Journal of Obstetrics and Gynaecology1995;102:835‐7. ">Aston 1995</a>; <a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>; <a href="./references#CD006109-bbs2-0026" title="ShakerAG , PittrofR , ZaidiJ , BekirJ , Kyei‐MensahA , TanSL . Administration of progestogens to hasten pituitary desensitization after the use of gonadotropin‐releasing hormone agonist in in vitro fertilization ‐ a prospective randomized study. Fertility and Sterility1995;64(4):791‐5. ">Shaker 1995</a>), one study used triptorelin (<a href="./references#CD006109-bbs2-0041" title="Cédrin‐DurnerinI , BulwaS , HervéF , Martin‐PontB , UzanM , HuguesJN . The hormonal flare‐up following gonadotrophin‐releasing hormone agonist administration is influenced by a progestogen pretreatment. Human Reproduction1996;11(9):1859‐63. Cédrin‐DurnerinI , BulwaS , HervéF , PecqueuxL , UzanM , HuguesJN . Influence of norethisterone pretreatment on the initial flare‐up induced by a gonadotrophin‐releasing hormone agonist in a short protocol for IVF. Human Reproduction1995;10 Abstract Book 2:116. ">Cédrin‐Durnerin 1996</a>), one study used leuprolide acetate (<a href="./references#CD006109-bbs2-0007" title="DitkoffEC , SauerMV . A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin‐releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Human Reproduction1996;11(5):1035‐7. ">Ditkoff 1996</a>), and one study used dTRP6‐LHRH (<a href="./references#CD006109-bbs2-0013" title="HuguesJN , Cédrin‐DurnerinI , HervéF , Huet‐PecqueuxL , SantarelliJ . Incidence of preprogrammed norethisterone on the intensity of 'flare up' (flush) caused by GnRH agonist according to the IVF protocol [poster] [Incidence d'une préprogrammation par la noréthistérone sur la qualité du flare‐up induit par un agoniste du GnRH en protocole court de FIV]. Contraception, Fertilite, Sexualite1994; Vol. 22, issue 5:331. ">Hugues 1994</a>). </p> <p>One trial used an antagonist (ganirelix acetate) in both treatment groups (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>). </p> <p>One trial did not use GnRH analogues for pituitary desensitisation. Women that participated in this study only received pure FSH and hMG (<a href="./references#CD006109-bbs2-0025" title="Salat‐BarouxJ , AntoineJM , AlvarezS , CornetD , TibiC , MandelbaumJ , et al. Programmed ovulation induction and oocyte retrieval for in vitro fertilization. Journal of In Vitro Fertilization and Embryo Transfer1988;5(3):153‐7. ">Salat‐Baroux 1988</a>). </p> </section> <section id="CD006109-sec-0071"> <h6 class="title">Oestrogen versus placebo or no pretreatment</h6> <p>In five trials, the study group was given a pretreatment with oestrogen, while the control group received no pretreatment. Three studies used 17β‐oestradiol (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0005" title="Cédrin‐DurnerinI , Guivarc'h‐LevequeA , HuguesJ‐N . Pretreatment with estrogen does not affect IVF‐ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomised trial. Fertility and Sterility2012;97(6):1359‐64. ">Cédrin‐Durnerin 2012</a>; <a href="./references#CD006109-bbs2-0009" title="FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol administration coordinates FSH‐induced follicular growth and improves the outcome of GnRH antagonist COH protocols. 19th Annual meeting of the ESHRE; 2003 Jun 29‐Jul 2; Madrid, Spain, 2003. 2003. FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol pre‐treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Human Reproduction2003;18(12):2698‐703. [DOI: 10.1093/humrep/deg516] ">Fanchin 2003</a>), and two studies used oestradiol valerate (<a href="./references#CD006109-bbs2-0010" title="FrancoJGJr , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH after 2nd phase protocols with GnRH analogs (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin) [Comparação da estimulação ovariana com FSH recombinante após protocolo de 2a fase com análogos do GnRH (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco Jr 2003</a>; <a href="./references#CD006109-bbs2-0029" title="YeH , HuangG‐N , ZengP‐H , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;26(2‐3):105‐11. ">Ye 2009</a>). All these studies used 4 mg daily. </p> <p>The starting days of pretreatment varied from cycle day 15 to 21. One study started the pretreatment on cycle day 20 (<a href="./references#CD006109-bbs2-0009" title="FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol administration coordinates FSH‐induced follicular growth and improves the outcome of GnRH antagonist COH protocols. 19th Annual meeting of the ESHRE; 2003 Jun 29‐Jul 2; Madrid, Spain, 2003. 2003. FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol pre‐treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Human Reproduction2003;18(12):2698‐703. [DOI: 10.1093/humrep/deg516] ">Fanchin 2003</a>), and two on cycle day 21 (<a href="./references#CD006109-bbs2-0010" title="FrancoJGJr , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH after 2nd phase protocols with GnRH analogs (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin) [Comparação da estimulação ovariana com FSH recombinante após protocolo de 2a fase com análogos do GnRH (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco Jr 2003</a>; <a href="./references#CD006109-bbs2-0029" title="YeH , HuangG‐N , ZengP‐H , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;26(2‐3):105‐11. ">Ye 2009</a>). One study started pretreatment seven days before the presumed onset of menses and administered up to the next Thursday after the occurrence of menstrual bleeding (<a href="./references#CD006109-bbs2-0005" title="Cédrin‐DurnerinI , Guivarc'h‐LevequeA , HuguesJ‐N . Pretreatment with estrogen does not affect IVF‐ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomised trial. Fertility and Sterility2012;97(6):1359‐64. ">Cédrin‐Durnerin 2012</a>). One remaining study started the pretreatment 10 days before the presumed menses (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>). </p> <p>The duration of pretreatment varied from 10 to 17 days. In two studies the duration varied from 7 to 15 days (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0005" title="Cédrin‐DurnerinI , Guivarc'h‐LevequeA , HuguesJ‐N . Pretreatment with estrogen does not affect IVF‐ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomised trial. Fertility and Sterility2012;97(6):1359‐64. ">Cédrin‐Durnerin 2012</a>). Three studies used a fixed duration of pretreatment of 10 days (<a href="./references#CD006109-bbs2-0029" title="YeH , HuangG‐N , ZengP‐H , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;26(2‐3):105‐11. ">Ye 2009</a>), 11 days (<a href="./references#CD006109-bbs2-0009" title="FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol administration coordinates FSH‐induced follicular growth and improves the outcome of GnRH antagonist COH protocols. 19th Annual meeting of the ESHRE; 2003 Jun 29‐Jul 2; Madrid, Spain, 2003. 2003. FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol pre‐treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Human Reproduction2003;18(12):2698‐703. [DOI: 10.1093/humrep/deg516] ">Fanchin 2003</a>), and 14 days (<a href="./references#CD006109-bbs2-0010" title="FrancoJGJr , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH after 2nd phase protocols with GnRH analogs (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin) [Comparação da estimulação ovariana com FSH recombinante após protocolo de 2a fase com análogos do GnRH (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco Jr 2003</a>). </p> <p>Three trials used an antagonist in both treatment groups, one trial used ganirelix acetate (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>), one trial used cetrorelix acetate (<a href="./references#CD006109-bbs2-0009" title="FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol administration coordinates FSH‐induced follicular growth and improves the outcome of GnRH antagonist COH protocols. 19th Annual meeting of the ESHRE; 2003 Jun 29‐Jul 2; Madrid, Spain, 2003. 2003. FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol pre‐treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Human Reproduction2003;18(12):2698‐703. [DOI: 10.1093/humrep/deg516] ">Fanchin 2003</a>), and one trial did not report the name of the antagonist (<a href="./references#CD006109-bbs2-0005" title="Cédrin‐DurnerinI , Guivarc'h‐LevequeA , HuguesJ‐N . Pretreatment with estrogen does not affect IVF‐ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomised trial. Fertility and Sterility2012;97(6):1359‐64. ">Cédrin‐Durnerin 2012</a>). </p> <p>Two trials used an antagonist in the intervention group and an agonist in the control group, one trial used ganirelix acetate in the intervention group and nafarelin acetate in the control group (<a href="./references#CD006109-bbs2-0010" title="FrancoJGJr , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH after 2nd phase protocols with GnRH analogs (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin) [Comparação da estimulação ovariana com FSH recombinante após protocolo de 2a fase com análogos do GnRH (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco Jr 2003</a>), and one study used cetrotide in the intervention group and triptoreline in the control group (<a href="./references#CD006109-bbs2-0029" title="YeH , HuangG‐N , ZengP‐H , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;26(2‐3):105‐11. ">Ye 2009</a>). </p> </section> <section id="CD006109-sec-0072"> <h6 class="title">Combined oral contraceptive pill versus progestogen</h6> <p>There was only one study that compared COCP with progestogen (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>). The women in the COCP group received ethinyl oestradiol 30 μg plus desogestrel 150 μg daily and the women in the progestogen group received norethisterone 10 mg daily. This study started the COCP pretreatment on cycle day two or three with a duration of 15 to 21 days. The progestogen pretreatment was started on cycle day 15 with a duration of 10 to 15 days. Both groups received the GnRH antagonist, ganirelix acetate. </p> </section> <section id="CD006109-sec-0073"> <h6 class="title">Combined oral contraceptive pill versus oestrogen</h6> <p>Four trials compared a pretreatment of COCP with a pretreatment of oestrogen. One trial used ethinyl oestradiol 30 μg plus desogestrel 150 μg daily as a COCP and micronised 17β‐oestradiol 4 mg daily as oestrogen pretreatment (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>). The COCP pretreatment started on cycle day two or three with a duration of 15 to 21 days. The oestrogen pretreatment started 10 days before the presumed menses with a duration of 10 to 15 days and both groups received the GnRH antagonist, ganirelix acetate. Another study used ethinyl oestradiol 30 μg plus levonorgestrel 150 μg daily as a COCP and oestradiol valerate 4 mg daily as oestrogen pretreatment (<a href="./references#CD006109-bbs2-0012" title="HauzmanEE , ZapataA , BermejoA , IglesiasC , PellicerA , Garcia‐VelascoJ . Cycle scheduling for in vitro fertilisation with oral contraceptive pills versus oral estradiol valerate: a randomised controlled trial. Reproductive Biology and Endocrinology2013;11:96. ">Hauzman 2013</a>). The COCP pretreatment started on cycle day one or two and continued for 12 to 16 days. The oestrogen pretreatment started from day 20 of menstrual cycle for five to 12 days until the day before starting stimulation and both groups received the GnRH antagonist, ganirelix acetate. One study used ethinyl oestradiol plus desogestrel as COCP starting from day two to four of the cycle but their doses were not reported (<a href="./references#CD006109-bbs2-0019" title="LukaszukK , LissJ , KunickiM , KuczynskiW , PastuszekE , JakielG , et al. Estradiol valerate pretreatment in short protocol GNRH‐agonist cycles versus combined pretreatment with oral contraceptive pills in long protocol GNRH‐agonist cycles: a randomised controlled trial. BioMed Research International2015;2015:1‐6. ">Lukaszuk 2015</a>). In the control group, women were pretreated with oral oestradiol 2 mg twice daily from the day 20 of the natural cycle to day one to four of the new cycle. Both groups received the GnRH agonist, triptorelin. One study did not mention which COCP was used, but used ethinyl oestradiol 2 mg as an oestrogen pretreatment (<a href="./references#CD006109-bbs2-0006" title="DalyDC , DalyCL , MayoD , JacobsA . Oocyte recruitment in IVF patients with limited ovarian reserve (LOR), maximizing quality of oocytes and embryos. Fertility and Sterility2002; Vol. Suppl 1, 78, issue 3:S148‐9. ">Daly 2002</a>). This study only described that the oestrogen pretreatment was administered in the luteal phase of the preparation cycle, but did not report the exact starting days and durations of pretreatment. The COCP group received the GnRH agonist, leuprolide acetate, and the oestrogen group received the GnRH antagonist, ganirelix acetate. </p> </section> <section id="CD006109-sec-0074"> <h6 class="title">Progestogen versus oestrogen</h6> <p>There was only one study that compared progestogen with oestrogen (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>). The women in the progestogen group received norethisterone 10 mg daily and the women in the oestrogen group received micronised 17β‐oestradiol 4 mg daily. This study started the progestogen pretreatment on cycle day 15 with a duration of 10 to 15 days. The oestrogen pretreatment started 10 days before the presumed menses with also a duration of 10 to 15 days. Both groups received the GnRH antagonist, ganirelix acetate. </p> </section> </section> <section id="CD006109-sec-0075"> <h5 class="title">Outcomes</h5> <section id="CD006109-sec-0076"> <h6 class="title">Primary outcome</h6> <p>Fifteen studies reported the number of live births or ongoing pregnancies (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0005" title="Cédrin‐DurnerinI , Guivarc'h‐LevequeA , HuguesJ‐N . Pretreatment with estrogen does not affect IVF‐ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomised trial. Fertility and Sterility2012;97(6):1359‐64. ">Cédrin‐Durnerin 2012</a>; <a href="./references#CD006109-bbs2-0006" title="DalyDC , DalyCL , MayoD , JacobsA . Oocyte recruitment in IVF patients with limited ovarian reserve (LOR), maximizing quality of oocytes and embryos. Fertility and Sterility2002; Vol. Suppl 1, 78, issue 3:S148‐9. ">Daly 2002</a>; <a href="./references#CD006109-bbs2-0007" title="DitkoffEC , SauerMV . A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin‐releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Human Reproduction1996;11(5):1035‐7. ">Ditkoff 1996</a>; <a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>; <a href="./references#CD006109-bbs2-0010" title="FrancoJGJr , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH after 2nd phase protocols with GnRH analogs (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin) [Comparação da estimulação ovariana com FSH recombinante após protocolo de 2a fase com análogos do GnRH (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco Jr 2003</a>; <a href="./references#CD006109-bbs2-0011" title="Garcia‐VelascoJA , BermejoA , RuizF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility2011;96(3):590‐3. Garcia‐VelascoJA , BermejoA , Ruiz‐FloresF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial. Fertility and Sterility2010;94 Suppl 1(4):S28 Abstract no. O‐93. ">Garcia‐Velasco 2011</a>; <a href="./references#CD006109-bbs2-0012" title="HauzmanEE , ZapataA , BermejoA , IglesiasC , PellicerA , Garcia‐VelascoJ . Cycle scheduling for in vitro fertilisation with oral contraceptive pills versus oral estradiol valerate: a randomised controlled trial. Reproductive Biology and Endocrinology2013;11:96. ">Hauzman 2013</a>; <a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>; <a href="./references#CD006109-bbs2-0015" title="HuirneJA , HuguesJN , PirardC , FischlF , SageJC , PoulyJL , et al. Cetrorelix in an oral contraceptive‐pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r‐hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction2006;21(6):1408‐15. [DOI: 10.1093/humrep/de1030] ">Huirne 2006c</a>; <a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a>; <a href="./references#CD006109-bbs2-0020" title="BroekmansJF , VerweijPJM , EijkemansMJC , MannaertsNMJL , WitjesH . Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(8):1688‐97. Nyboe AndersenA , WitjesH , GordonK , MannaertsB . Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pretreatment. Human Reproduction2011;26(12):3413‐23. TavmergenE , vonMauw , WitjesH , MannaertsB . Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling. 25th Annual Meeting of ESHRE; 2009 28 Jun‐1 Jul; Amsterdam, the Netherlands. 2009. ">Nyboe Andersen 2011</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>; <a href="./references#CD006109-bbs2-0029" title="YeH , HuangG‐N , ZengP‐H , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;26(2‐3):105‐11. ">Ye 2009</a>). Three studies defined ongoing pregnancy as a positive heart activity at a gestational age of 12 weeks (<a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>; <a href="./references#CD006109-bbs2-0015" title="HuirneJA , HuguesJN , PirardC , FischlF , SageJC , PoulyJL , et al. Cetrorelix in an oral contraceptive‐pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r‐hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction2006;21(6):1408‐15. [DOI: 10.1093/humrep/de1030] ">Huirne 2006c</a>; <a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>). One study used the same definition but did not mention when they performed the ultrasound scan (<a href="./references#CD006109-bbs2-0007" title="DitkoffEC , SauerMV . A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin‐releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Human Reproduction1996;11(5):1035‐7. ">Ditkoff 1996</a>). Two studies defined ongoing pregnancy as a pregnancy developing beyond 12 weeks (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a>), and one study defined ongoing pregnancy as a pregnancy assessed by ultrasound at 12 to 16 weeks or later (<a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>). The remaining studies did not mention how they assessed ongoing pregnancy (<a href="./references#CD006109-bbs2-0005" title="Cédrin‐DurnerinI , Guivarc'h‐LevequeA , HuguesJ‐N . Pretreatment with estrogen does not affect IVF‐ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomised trial. Fertility and Sterility2012;97(6):1359‐64. ">Cédrin‐Durnerin 2012</a>; <a href="./references#CD006109-bbs2-0006" title="DalyDC , DalyCL , MayoD , JacobsA . Oocyte recruitment in IVF patients with limited ovarian reserve (LOR), maximizing quality of oocytes and embryos. Fertility and Sterility2002; Vol. Suppl 1, 78, issue 3:S148‐9. ">Daly 2002</a>; <a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>; <a href="./references#CD006109-bbs2-0010" title="FrancoJGJr , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH after 2nd phase protocols with GnRH analogs (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin) [Comparação da estimulação ovariana com FSH recombinante após protocolo de 2a fase com análogos do GnRH (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco Jr 2003</a>; <a href="./references#CD006109-bbs2-0011" title="Garcia‐VelascoJA , BermejoA , RuizF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility2011;96(3):590‐3. Garcia‐VelascoJA , BermejoA , Ruiz‐FloresF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial. Fertility and Sterility2010;94 Suppl 1(4):S28 Abstract no. O‐93. ">Garcia‐Velasco 2011</a>; <a href="./references#CD006109-bbs2-0012" title="HauzmanEE , ZapataA , BermejoA , IglesiasC , PellicerA , Garcia‐VelascoJ . Cycle scheduling for in vitro fertilisation with oral contraceptive pills versus oral estradiol valerate: a randomised controlled trial. Reproductive Biology and Endocrinology2013;11:96. ">Hauzman 2013</a>; <a href="./references#CD006109-bbs2-0020" title="BroekmansJF , VerweijPJM , EijkemansMJC , MannaertsNMJL , WitjesH . Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(8):1688‐97. Nyboe AndersenA , WitjesH , GordonK , MannaertsB . Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pretreatment. Human Reproduction2011;26(12):3413‐23. TavmergenE , vonMauw , WitjesH , MannaertsB . Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling. 25th Annual Meeting of ESHRE; 2009 28 Jun‐1 Jul; Amsterdam, the Netherlands. 2009. ">Nyboe Andersen 2011</a>; <a href="./references#CD006109-bbs2-0029" title="YeH , HuangG‐N , ZengP‐H , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;26(2‐3):105‐11. ">Ye 2009</a>). </p> <p>Ten studies reported the number of pregnancy losses. One study described this as the proportion of women with initially positive hCG in whom pregnancy failed to develop beyond 12 weeks of gestation (<a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a>). The other nine studies did not describe a definition (<a href="./references#CD006109-bbs2-0006" title="DalyDC , DalyCL , MayoD , JacobsA . Oocyte recruitment in IVF patients with limited ovarian reserve (LOR), maximizing quality of oocytes and embryos. Fertility and Sterility2002; Vol. Suppl 1, 78, issue 3:S148‐9. ">Daly 2002</a>; <a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>; <a href="./references#CD006109-bbs2-0010" title="FrancoJGJr , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH after 2nd phase protocols with GnRH analogs (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin) [Comparação da estimulação ovariana com FSH recombinante após protocolo de 2a fase com análogos do GnRH (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco Jr 2003</a>; <a href="./references#CD006109-bbs2-0011" title="Garcia‐VelascoJA , BermejoA , RuizF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility2011;96(3):590‐3. Garcia‐VelascoJA , BermejoA , Ruiz‐FloresF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial. Fertility and Sterility2010;94 Suppl 1(4):S28 Abstract no. O‐93. ">Garcia‐Velasco 2011</a>; <a href="./references#CD006109-bbs2-0016" title="HwangJL , SeowKM , LinYH , HuangLW , HsiehBC , TsaiYL , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. [DOI: 10.1093/humrep/deh375] ">Hwang 2004</a>; <a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>; <a href="./references#CD006109-bbs2-0025" title="Salat‐BarouxJ , AntoineJM , AlvarezS , CornetD , TibiC , MandelbaumJ , et al. Programmed ovulation induction and oocyte retrieval for in vitro fertilization. Journal of In Vitro Fertilization and Embryo Transfer1988;5(3):153‐7. ">Salat‐Baroux 1988</a>; <a href="./references#CD006109-bbs2-0029" title="YeH , HuangG‐N , ZengP‐H , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;26(2‐3):105‐11. ">Ye 2009</a>). </p> </section> <section id="CD006109-sec-0077"> <h6 class="title">Secondary outcomes</h6> <p>Twenty‐one studies reported the number of clinical pregnancies. Three studies defined clinical pregnancy as the presence of one or more foetal hearts confirmed with ultrasound, performed at least four weeks after embryo transfer (<a href="./references#CD006109-bbs2-0009" title="FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol administration coordinates FSH‐induced follicular growth and improves the outcome of GnRH antagonist COH protocols. 19th Annual meeting of the ESHRE; 2003 Jun 29‐Jul 2; Madrid, Spain, 2003. 2003. FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol pre‐treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Human Reproduction2003;18(12):2698‐703. [DOI: 10.1093/humrep/deg516] ">Fanchin 2003</a> or from six weeks after embryo transfer (<a href="./references#CD006109-bbs2-0010" title="FrancoJGJr , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH after 2nd phase protocols with GnRH analogs (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin) [Comparação da estimulação ovariana com FSH recombinante após protocolo de 2a fase com análogos do GnRH (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco Jr 2003</a>; <a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>). Two other studies used the same definition, but one of these also included the foetal sacs without heart activity (<a href="./references#CD006109-bbs2-0015" title="HuirneJA , HuguesJN , PirardC , FischlF , SageJC , PoulyJL , et al. Cetrorelix in an oral contraceptive‐pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r‐hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction2006;21(6):1408‐15. [DOI: 10.1093/humrep/de1030] ">Huirne 2006c</a>), and the other performed the ultrasound scan at seven weeks after embryo transfer (<a href="./references#CD006109-bbs2-0016" title="HwangJL , SeowKM , LinYH , HuangLW , HsiehBC , TsaiYL , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. [DOI: 10.1093/humrep/deh375] ">Hwang 2004</a>). One study defined clinical pregnancy as the presence of one or more intrauterine sacs confirmed with ultrasound, at a gestational age of six weeks (<a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>). In one study, we used a positive pregnancy test with evidence of a gestational sac to define clinical pregnancy, because no clinical or ongoing pregnancy rate was available (<a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>). One study defined clinical pregnancy as the evidence of a clinical gestational sac (<a href="./references#CD006109-bbs2-0007" title="DitkoffEC , SauerMV . A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin‐releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Human Reproduction1996;11(5):1035‐7. ">Ditkoff 1996</a>). In the other 12 studies, it was unclear how they defined this outcome (<a href="./references#CD006109-bbs2-0001" title="AstonK , ArthurI , MassonGM , JenkinsJM . Progestogen therapy and prevention of functional ovarian cysts during pituitary desensitisation with GnRH agonists. British Journal of Obstetrics and Gynaecology1995;102:835‐7. ">Aston 1995</a>; <a href="./references#CD006109-bbs2-0003" title="BlockeelC , EngelsS , deVosM , HaentjensP , PolyzosNP , StoopD , et al. Oestradiol valerate pretreatment in GnRH antagonist cycles: a randomised controlled trial. Reproductive Biomedicine Online2012;24:272‐80. ">Blockeel 2012</a>; <a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0005" title="Cédrin‐DurnerinI , Guivarc'h‐LevequeA , HuguesJ‐N . Pretreatment with estrogen does not affect IVF‐ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomised trial. Fertility and Sterility2012;97(6):1359‐64. ">Cédrin‐Durnerin 2012</a>; <a href="./references#CD006109-bbs2-0006" title="DalyDC , DalyCL , MayoD , JacobsA . Oocyte recruitment in IVF patients with limited ovarian reserve (LOR), maximizing quality of oocytes and embryos. Fertility and Sterility2002; Vol. Suppl 1, 78, issue 3:S148‐9. ">Daly 2002</a>; <a href="./references#CD006109-bbs2-0011" title="Garcia‐VelascoJA , BermejoA , RuizF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility2011;96(3):590‐3. Garcia‐VelascoJA , BermejoA , Ruiz‐FloresF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial. Fertility and Sterility2010;94 Suppl 1(4):S28 Abstract no. O‐93. ">Garcia‐Velasco 2011</a>; <a href="./references#CD006109-bbs2-0012" title="HauzmanEE , ZapataA , BermejoA , IglesiasC , PellicerA , Garcia‐VelascoJ . Cycle scheduling for in vitro fertilisation with oral contraceptive pills versus oral estradiol valerate: a randomised controlled trial. Reproductive Biology and Endocrinology2013;11:96. ">Hauzman 2013</a>; <a href="./references#CD006109-bbs2-0020" title="BroekmansJF , VerweijPJM , EijkemansMJC , MannaertsNMJL , WitjesH . Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(8):1688‐97. Nyboe AndersenA , WitjesH , GordonK , MannaertsB . Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pretreatment. Human Reproduction2011;26(12):3413‐23. TavmergenE , vonMauw , WitjesH , MannaertsB . Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling. 25th Annual Meeting of ESHRE; 2009 28 Jun‐1 Jul; Amsterdam, the Netherlands. 2009. ">Nyboe Andersen 2011</a>; <a href="./references#CD006109-bbs2-0021" title="ObrucaA , FischlF , HuberJ . Programming oocyte retrieval using oral contraceptive pretreatment before ovarian stimulation with a GnRH antagonist (Cetrotide) protocol. Human Reproduction. 2002; Vol. 17 Abstract Book 1:89. ">Obruca 2002</a>; <a href="./references#CD006109-bbs2-0022" title="PorratiL , VilelaM , ViglierchioMI , ValcarcelA , LombardiE , MarconiG . Oral contraceptive pretreatment achieves better pregnancy rates in IVF antagonists GnRH flexible protocols: a prospective randomized study. Human Reproduction2010;25 Suppl 1(6):i102 Abstract no. O‐259. ">Porrati 2010</a>; <a href="./references#CD006109-bbs2-0025" title="Salat‐BarouxJ , AntoineJM , AlvarezS , CornetD , TibiC , MandelbaumJ , et al. Programmed ovulation induction and oocyte retrieval for in vitro fertilization. Journal of In Vitro Fertilization and Embryo Transfer1988;5(3):153‐7. ">Salat‐Baroux 1988</a>; <a href="./references#CD006109-bbs2-0029" title="YeH , HuangG‐N , ZengP‐H , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;26(2‐3):105‐11. ">Ye 2009</a>). If no clinical pregnancy rates were reported, we used the ongoing pregnancy rates (if available) for our analysis. </p> <p>Ten studies reported the number of oocytes retrieved (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0007" title="DitkoffEC , SauerMV . A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin‐releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Human Reproduction1996;11(5):1035‐7. ">Ditkoff 1996</a>; <a href="./references#CD006109-bbs2-0010" title="FrancoJGJr , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH after 2nd phase protocols with GnRH analogs (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin) [Comparação da estimulação ovariana com FSH recombinante após protocolo de 2a fase com análogos do GnRH (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco Jr 2003</a>; <a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>; <a href="./references#CD006109-bbs2-0015" title="HuirneJA , HuguesJN , PirardC , FischlF , SageJC , PoulyJL , et al. Cetrorelix in an oral contraceptive‐pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r‐hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction2006;21(6):1408‐15. [DOI: 10.1093/humrep/de1030] ">Huirne 2006c</a>; <a href="./references#CD006109-bbs2-0016" title="HwangJL , SeowKM , LinYH , HuangLW , HsiehBC , TsaiYL , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. [DOI: 10.1093/humrep/deh375] ">Hwang 2004</a>; <a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD006109-bbs2-0021" title="ObrucaA , FischlF , HuberJ . Programming oocyte retrieval using oral contraceptive pretreatment before ovarian stimulation with a GnRH antagonist (Cetrotide) protocol. Human Reproduction. 2002; Vol. 17 Abstract Book 1:89. ">Obruca 2002</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>; <a href="./references#CD006109-bbs2-0025" title="Salat‐BarouxJ , AntoineJM , AlvarezS , CornetD , TibiC , MandelbaumJ , et al. Programmed ovulation induction and oocyte retrieval for in vitro fertilization. Journal of In Vitro Fertilization and Embryo Transfer1988;5(3):153‐7. ">Salat‐Baroux 1988</a>). One study only mentioned the number of cumulus‐oocyte complexes (<a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a>), and two studies mentioned the number of mature oocytes or follicles (<a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>; <a href="./references#CD006109-bbs2-0009" title="FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol administration coordinates FSH‐induced follicular growth and improves the outcome of GnRH antagonist COH protocols. 19th Annual meeting of the ESHRE; 2003 Jun 29‐Jul 2; Madrid, Spain, 2003. 2003. FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol pre‐treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Human Reproduction2003;18(12):2698‐703. [DOI: 10.1093/humrep/deg516] ">Fanchin 2003</a>), but we assumed that this meant the same as the number of oocytes retrieved and, therefore, we pooled the data of these studies. </p> <p>Thirteen studies reported the number of days of gonadotrophin treatment (<a href="./references#CD006109-bbs2-0003" title="BlockeelC , EngelsS , deVosM , HaentjensP , PolyzosNP , StoopD , et al. Oestradiol valerate pretreatment in GnRH antagonist cycles: a randomised controlled trial. Reproductive Biomedicine Online2012;24:272‐80. ">Blockeel 2012</a>; <a href="./references#CD006109-bbs2-0007" title="DitkoffEC , SauerMV . A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin‐releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Human Reproduction1996;11(5):1035‐7. ">Ditkoff 1996</a>; <a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>; <a href="./references#CD006109-bbs2-0010" title="FrancoJGJr , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH after 2nd phase protocols with GnRH analogs (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin) [Comparação da estimulação ovariana com FSH recombinante após protocolo de 2a fase com análogos do GnRH (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco Jr 2003</a>; <a href="./references#CD006109-bbs2-0012" title="HauzmanEE , ZapataA , BermejoA , IglesiasC , PellicerA , Garcia‐VelascoJ . Cycle scheduling for in vitro fertilisation with oral contraceptive pills versus oral estradiol valerate: a randomised controlled trial. Reproductive Biology and Endocrinology2013;11:96. ">Hauzman 2013</a>; <a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>; <a href="./references#CD006109-bbs2-0015" title="HuirneJA , HuguesJN , PirardC , FischlF , SageJC , PoulyJL , et al. Cetrorelix in an oral contraceptive‐pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r‐hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction2006;21(6):1408‐15. [DOI: 10.1093/humrep/de1030] ">Huirne 2006c</a>; <a href="./references#CD006109-bbs2-0016" title="HwangJL , SeowKM , LinYH , HuangLW , HsiehBC , TsaiYL , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. [DOI: 10.1093/humrep/deh375] ">Hwang 2004</a>; <a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a>; <a href="./references#CD006109-bbs2-0022" title="PorratiL , VilelaM , ViglierchioMI , ValcarcelA , LombardiE , MarconiG . Oral contraceptive pretreatment achieves better pregnancy rates in IVF antagonists GnRH flexible protocols: a prospective randomized study. Human Reproduction2010;25 Suppl 1(6):i102 Abstract no. O‐259. ">Porrati 2010</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>; <a href="./references#CD006109-bbs2-0028" title="VilelaM , MarconiM , ZappacostaMP , PorratiL , ValcarcelA , MarconiG . Oral contraceptive (OcP) pretreatment achieves better pregnancy rates in in vitro fertilisation (IVF) antagonists GnRH flexible protocols: a prospective randomised study. Fertility and Sterility2011; Vol. 96, issue 3 (supplement):S252, P‐492. ">Vilela 2011</a>). </p> <p>Thirteen studies reported the amount of gonadotrophins administered (<a href="./references#CD006109-bbs2-0003" title="BlockeelC , EngelsS , deVosM , HaentjensP , PolyzosNP , StoopD , et al. Oestradiol valerate pretreatment in GnRH antagonist cycles: a randomised controlled trial. Reproductive Biomedicine Online2012;24:272‐80. ">Blockeel 2012</a>; <a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0005" title="Cédrin‐DurnerinI , Guivarc'h‐LevequeA , HuguesJ‐N . Pretreatment with estrogen does not affect IVF‐ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomised trial. Fertility and Sterility2012;97(6):1359‐64. ">Cédrin‐Durnerin 2012</a>; <a href="./references#CD006109-bbs2-0009" title="FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol administration coordinates FSH‐induced follicular growth and improves the outcome of GnRH antagonist COH protocols. 19th Annual meeting of the ESHRE; 2003 Jun 29‐Jul 2; Madrid, Spain, 2003. 2003. FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol pre‐treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Human Reproduction2003;18(12):2698‐703. [DOI: 10.1093/humrep/deg516] ">Fanchin 2003</a>; <a href="./references#CD006109-bbs2-0010" title="FrancoJGJr , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH after 2nd phase protocols with GnRH analogs (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin) [Comparação da estimulação ovariana com FSH recombinante após protocolo de 2a fase com análogos do GnRH (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco Jr 2003</a>; <a href="./references#CD006109-bbs2-0012" title="HauzmanEE , ZapataA , BermejoA , IglesiasC , PellicerA , Garcia‐VelascoJ . Cycle scheduling for in vitro fertilisation with oral contraceptive pills versus oral estradiol valerate: a randomised controlled trial. Reproductive Biology and Endocrinology2013;11:96. ">Hauzman 2013</a>; <a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>; <a href="./references#CD006109-bbs2-0015" title="HuirneJA , HuguesJN , PirardC , FischlF , SageJC , PoulyJL , et al. Cetrorelix in an oral contraceptive‐pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r‐hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction2006;21(6):1408‐15. [DOI: 10.1093/humrep/de1030] ">Huirne 2006c</a>; <a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a>; <a href="./references#CD006109-bbs2-0022" title="PorratiL , VilelaM , ViglierchioMI , ValcarcelA , LombardiE , MarconiG . Oral contraceptive pretreatment achieves better pregnancy rates in IVF antagonists GnRH flexible protocols: a prospective randomized study. Human Reproduction2010;25 Suppl 1(6):i102 Abstract no. O‐259. ">Porrati 2010</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>; <a href="./references#CD006109-bbs2-0028" title="VilelaM , MarconiM , ZappacostaMP , PorratiL , ValcarcelA , MarconiG . Oral contraceptive (OcP) pretreatment achieves better pregnancy rates in in vitro fertilisation (IVF) antagonists GnRH flexible protocols: a prospective randomised study. Fertility and Sterility2011; Vol. 96, issue 3 (supplement):S252, P‐492. ">Vilela 2011</a>). Two studies reported the amount of gonadotrophins administered in the number of ampoules used, but we could not use these data in our analysis (<a href="./references#CD006109-bbs2-0007" title="DitkoffEC , SauerMV . A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin‐releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Human Reproduction1996;11(5):1035‐7. ">Ditkoff 1996</a>; <a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>). </p> </section> <section id="CD006109-sec-0078"> <h6 class="title">Other adverse outcomes</h6> <p>Six studies reported the number of women with ovarian cysts. In one study, we used the number of functional ovarian cysts with a diameter of 10 mm or more, measured after one week of GnRH agonist treatment (<a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>). Three studies defined an ovarian cyst as an intraovarian sonolucent structure with a mean diameter of 14 mm or more, measured after seven days (<a href="./references#CD006109-bbs2-0001" title="AstonK , ArthurI , MassonGM , JenkinsJM . Progestogen therapy and prevention of functional ovarian cysts during pituitary desensitisation with GnRH agonists. British Journal of Obstetrics and Gynaecology1995;102:835‐7. ">Aston 1995</a>) or eight days (<a href="./references#CD006109-bbs2-0007" title="DitkoffEC , SauerMV . A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin‐releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Human Reproduction1996;11(5):1035‐7. ">Ditkoff 1996</a>) of pituitary suppression, or on a day not specified (<a href="./references#CD006109-bbs2-0010" title="FrancoJGJr , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH after 2nd phase protocols with GnRH analogs (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin) [Comparação da estimulação ovariana com FSH recombinante após protocolo de 2a fase com análogos do GnRH (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco Jr 2003</a>). One study did not mention how they defined ovarian cyst formation and when they measured this (<a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>). One study only reported cyst formation as a reason for cycle cancellation, but it was unclear if there were more cysts formed that did not lead to cycle cancellation (<a href="./references#CD006109-bbs2-0025" title="Salat‐BarouxJ , AntoineJM , AlvarezS , CornetD , TibiC , MandelbaumJ , et al. Programmed ovulation induction and oocyte retrieval for in vitro fertilization. Journal of In Vitro Fertilization and Embryo Transfer1988;5(3):153‐7. ">Salat‐Baroux 1988</a>). We did not use these data in our analysis. </p> <p>Six studies reported the number of multiple pregnancies. One study defined multiple pregnancies as multiple clinical pregnancies (<a href="./references#CD006109-bbs2-0015" title="HuirneJA , HuguesJN , PirardC , FischlF , SageJC , PoulyJL , et al. Cetrorelix in an oral contraceptive‐pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r‐hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction2006;21(6):1408‐15. [DOI: 10.1093/humrep/de1030] ">Huirne 2006c</a>). One study described the number of ongoing or live born twin pregnancies (<a href="./references#CD006109-bbs2-0016" title="HwangJL , SeowKM , LinYH , HuangLW , HsiehBC , TsaiYL , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. [DOI: 10.1093/humrep/deh375] ">Hwang 2004</a>). Four studies did not describe when the number of multiple pregnancies was measured (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0010" title="FrancoJGJr , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH after 2nd phase protocols with GnRH analogs (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin) [Comparação da estimulação ovariana com FSH recombinante após protocolo de 2a fase com análogos do GnRH (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco Jr 2003</a>; <a href="./references#CD006109-bbs2-0011" title="Garcia‐VelascoJA , BermejoA , RuizF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility2011;96(3):590‐3. Garcia‐VelascoJA , BermejoA , Ruiz‐FloresF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial. Fertility and Sterility2010;94 Suppl 1(4):S28 Abstract no. O‐93. ">Garcia‐Velasco 2011</a>; <a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>). </p> <p>Five studies reported the number of women with OHSS. Two study used the WHO classification criteria to diagnose OHSS and divided the women in categories of mild (grade I), moderate (grade II) or severe (grade III) (<a href="./references#CD006109-bbs2-0020" title="BroekmansJF , VerweijPJM , EijkemansMJC , MannaertsNMJL , WitjesH . Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(8):1688‐97. Nyboe AndersenA , WitjesH , GordonK , MannaertsB . Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pretreatment. Human Reproduction2011;26(12):3413‐23. TavmergenE , vonMauw , WitjesH , MannaertsB . Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling. 25th Annual Meeting of ESHRE; 2009 28 Jun‐1 Jul; Amsterdam, the Netherlands. 2009. ">Nyboe Andersen 2011</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>); the other three studies did not mention how they diagnosed OHSS (<a href="./references#CD006109-bbs2-0010" title="FrancoJGJr , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH after 2nd phase protocols with GnRH analogs (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin) [Comparação da estimulação ovariana com FSH recombinante após protocolo de 2a fase com análogos do GnRH (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco Jr 2003</a>; <a href="./references#CD006109-bbs2-0016" title="HwangJL , SeowKM , LinYH , HuangLW , HsiehBC , TsaiYL , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. [DOI: 10.1093/humrep/deh375] ">Hwang 2004</a>; <a href="./references#CD006109-bbs2-0029" title="YeH , HuangG‐N , ZengP‐H , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;26(2‐3):105‐11. ">Ye 2009</a>). </p> <p>Six studies did not contribute data to the analyses: two of these studies reported 'per cycle' data and the numbers of cycles were not equivalent to the numbers of participants (<a href="./references#CD006109-bbs2-0002" title="BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF . Prospective randomized trial on effect of pre‐treatment with an oral contraceptive (OC) on the length of time required for pituitary suppression by gonadotropin releasing hormone agonist (GnRH‐a) and subsequent implantation and pregnancy rates. Fertility and Sterility1998; Vol. Suppl 1, 70, issue 3:S133. BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF , TanSL . Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin‐releasing hormone analogues and on subsequent implantation and pregnancy rates. Fertility and Sterility1998;70(6):1063‐9. ">Biljan 1998b</a>; <a href="./references#CD006109-bbs2-0026" title="ShakerAG , PittrofR , ZaidiJ , BekirJ , Kyei‐MensahA , TanSL . Administration of progestogens to hasten pituitary desensitization after the use of gonadotropin‐releasing hormone agonist in in vitro fertilization ‐ a prospective randomized study. Fertility and Sterility1995;64(4):791‐5. ">Shaker 1995</a>); outcomes reported included clinical pregnancy rate, number of days of GnRH agonist and number of oocytes retrieved. One study reported outcome data in denominators other than 'per woman' such as 'per cycle', 'per embryo transfer' (<a href="./references#CD006109-bbs2-0019" title="LukaszukK , LissJ , KunickiM , KuczynskiW , PastuszekE , JakielG , et al. Estradiol valerate pretreatment in short protocol GNRH‐agonist cycles versus combined pretreatment with oral contraceptive pills in long protocol GNRH‐agonist cycles: a randomised controlled trial. BioMed Research International2015;2015:1‐6. ">Lukaszuk 2015</a>), outcomes reported included clinical pregnancy, number of oocyte retrieved, multiple pregnancy, duration of stimulation days. Three studies had no available outcome data relevant to the review (<a href="./references#CD006109-bbs2-0013" title="HuguesJN , Cédrin‐DurnerinI , HervéF , Huet‐PecqueuxL , SantarelliJ . Incidence of preprogrammed norethisterone on the intensity of 'flare up' (flush) caused by GnRH agonist according to the IVF protocol [poster] [Incidence d'une préprogrammation par la noréthistérone sur la qualité du flare‐up induit par un agoniste du GnRH en protocole court de FIV]. Contraception, Fertilite, Sexualite1994; Vol. 22, issue 5:331. ">Hugues 1994</a>; <a href="./references#CD006109-bbs2-0023" title="RaoofiZ , AflatoonianA . Ovarian cysts formation during depot formulation of GnRH‐a therapy and the effect of pretreatment with oral contraceptive pills on subsequent implantation and pregnancy rate in ART cycles. Iranian Journal of Pharmaceutical Research2008;7(2):109‐13. ">Raoofi 2008</a>; <a href="./references#CD006109-bbs2-0027" title="TanSL , BiljanM . Fixed scheduling of long protocol of GNRH agonists ‐ use of oral contraceptive (OC) or progestogen pre‐treatment. Gynecological Endocrinology. 2001; Vol. 15 Suppl 2:31. ">Tan 2001</a>). </p> </section> </section> </section> <section id="CD006109-sec-0079"> <h4 class="title">Excluded studies</h4> <p>A total of 86 studies that described pretreatments with COCPs, progestogens or oestrogens were not eligible for inclusion for various reasons. Some of these studies had multiple reasons for exclusion, but we reported the most important reason. Full details of reasons for exclusion can be found in the <a href="./references#CD006109-sec-0285" title="">Characteristics of excluded studies</a> table. </p> <p> <ul id="CD006109-list-0017"> <li> <p>Twenty studies did not randomise their participants using standardized randomization procedures such as a computer or a random number table (<a href="./references#CD006109-bbs2-0035" title="BenadivaCA , Ben‐RafaelZ , BlascoL , TureckR , MastroianniLJ , FlickingerGL . Ovarian response to human menopausal gonadotropin following suppression with oral contraceptives. Fertility and Sterility1988;50(3):516‐8. ">Benadiva 1988</a>; <a href="./references#CD006109-bbs2-0040" title="Cédrin‐DurnerinI , HervéF , Huet‐PecqueuxL , KottlerML , HuguesJN . Progestogen pretreatment in the short‐term protocol does not affect the prognostic value of the oestradiol flare‐up in response to a GnRH agonist. Human Reproduction1995;10(11):2904‐8. ">Cédrin‐rDurnerin 1995</a>; <a href="./references#CD006109-bbs2-0043" title="CohenJ , DebacheC , SolalP , SerkineAM , AchardB , BoujenahA , et al. Results of planned in‐vitro fertilization programming through the pre‐administration of the oestrogen‐progesterone combined pill. Human Reproduction1987;2(1):7‐9. ">Cohen 1987</a>; <a href="./references#CD006109-bbs2-0044" title="CoppermanAB , MukherjeeT , SandlerB , GrunfeldL , BerghPA , ScottRT . Pre‐treatment with oral contraceptive pill improves outcome in IVF cycles of poor‐responders using the GnRH antagonist. Fertility and Sterility2003; Vol. Suppl 3, 80:S108. ">Copperman 2003</a>; <a href="./references#CD006109-bbs2-0045" title="CouzinetB , YoungJ , BraillyS , ChansonP , SchaisonG . Even after priming with ovarian steroids or pulsatile gonadotropin‐releasing hormone administration, naltrexone is unable to induce ovulation in women with functional hypothalamic amenorrhoea. Journal of Clinical Endocrinology and Metabolism1995;80(7):2102‐7. ">Couzinet 1995</a>; <a href="./references#CD006109-bbs2-0051" title="DitkoffEC , ProsserR , ZimmermannRC , LindheimS , SauerMV . The addition of norethindrone acetate to leuprolide acetate for ovarian suppression has no adverse effect on ovarian stimulation. Journal of Assisted Reproduction and Genetics1997;14(2):92‐6. ">Ditkoff 1997</a>; <a href="./references#CD006109-bbs2-0059" title="FormanRG , DemouzonJ , FeinsteinMC , TestartJ , FrydmanR . Studies on the influence of gonadotrophin‐levels in the early follicular phase on the ovarian response to stimulation. Human Reproduction1991;6(1):113‐7. ">Forman 1991</a>; <a href="./references#CD006109-bbs2-0061" title="FrydmanR , FormanR , RainhornJD , Belaisch‐AllartJ , HazoutA , TestartJ . A new approach to follicular stimulation for in vitro fertilization: programmed oocyte retrieval. Fertility and Sterility1986;46(4):657‐62. ">Frydman 1986</a>; <a href="./references#CD006109-bbs2-0062" title="GaleraF , VerduV , VillafañexV , GarijoE , RaywardJ , BajoJM . Comparison of plasmatic steroid levels with and without previous oral contraceptive administration in GnRH antagonist IVF cycles. Fertility and Sterility2004; Vol. Suppl 2, 82:S32. ">Galera 2004</a>; <a href="./references#CD006109-bbs2-0065" title="GodinPA , GaspardO , JouanC , ThononF , HincourtN , RavetS , et al. Importance of estradiol priming in in‐vitro maturation cycles. Human Reproduction2003;18 Suppl 1:153. ">Godin 2003</a>; <a href="./references#CD006109-bbs2-0067" title="GonenY , JacobsonW , CasperRF . Gonadotropin suppression with oral contraceptives before in vitro fertilization. Fertility and Sterility1990;53(2):282‐7. ">Gonen 1990</a>; <a href="./references#CD006109-bbs2-0081" title="LindheimSR , BaradDH , WittB , DitkoffE , SauerMV . Short‐term gonadotropin suppression with oral contraceptives benefits poor responders prior to controlled ovarian hyperstimulation. Journal of Assisted Reproduction and Genetics1996;13(9):745‐7. ">Lindheim 1996</a>; <a href="./references#CD006109-bbs2-0092" title="NealGS , SultanKM , LiuHC , DavisOK , RosenwaksZ . A dual approach to ovarian suppression using oral contraceptive pills and leuprolide acetate in high responder patients undergoing IVF. Fertility and Sterility1993;60(5):S111. ">Neal 1993</a>; <a href="./references#CD006109-bbs2-0094" title="PalombaS , FalboA , OrioF , RussoT , TolinoA , ZulloF . Pretreatment with oral contraceptives in infertile anovulatory patients with polycystic ovary syndrome who receive gonadotropins for controlled ovarian stimulation. Fertility and Sterility2008;89(6):1838‐42. [DOI: 10.1016/j.fertnstert.2007.05.035] ">Palomba 2008</a>; <a href="./references#CD006109-bbs2-0100" title="SchoolcraftW , SchlenkerT , GeeM , StevensJ , WagleyL . Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle‐stimulating hormone flare, growth hormone protocol. Fertility and Sterility1997;67(1):93‐7. ">Schoolcraft 1997</a>; <a href="./references#CD006109-bbs2-0102" title="SurreyES , CedarsMI . The effect of gonadotropin suppression on the induction of ovulation in premature ovarian failure patients. Fertility and Sterility1989;52(1):36‐41. ">Surrey 1989</a>; <a href="./references#CD006109-bbs2-0106" title="TarlatzisBC , PazaitouK , BiliH , BontisJ , PapadimasJ , LagosS , et al. Growth hormone, oestradiol, progesterone and testosterone concentrations in follicular fluid after ovarian stimulation with various regimes for assisted reproduction. Human Reproduction1993;8(10):1612‐6. ">Tarlatzis 1993</a>; <a href="./references#CD006109-bbs2-0110" title="WangY , ChenQ , WangN , ChenH , LyuQ , KuangY . Controlled ovarian stimulation using medroxyprogesterone acetate and hMG in patients with polycystic ovary syndrome treated for IVF a double‐blind randomized crossover clinical trial. Medicine2016;95(9):1‐8. ">Wang 2016</a>; <a href="./references#CD006109-bbs2-0112" title="WeismanZ , DirnfeldM , LissakA , SorokinY , AbramoviciH . Oral contraceptive pills and follicular fluid hormones in an in vitro fertilization program. Fertility and Sterility1989;52(3):451‐3. ">Weisman 1989</a>; <a href="./references#CD006109-bbs2-0113" title="YokotaY , YokotaM , YokotaH , MakitaM , SatoS , ArakiY . A novel procedure for improving pregnancy rates in frequent repeated IVF failure: estrogen rebound combined with GnRH agonist flare. Human Reproduction2006;21 Suppl 1:i130‐1. ">Yokota 2006</a>). </p> </li> <li> <p>Twenty‐four studies used a retrospective design (<a href="./references#CD006109-bbs2-0031" title="al‐MizyenE , SabatiniL , LowerAM , WilsonCMY , al‐ShawafT , GrudzinskasJG . Does pretreatment with progestogen or oral contraceptive pills in low responders followed by the GnRHa flare protocol improve the outcome of IVF‐ET?. Journal of Assisted Reproduction and Genetics2000;17(3):140‐6. ">al‐Mizyen 2000</a>; <a href="./references#CD006109-bbs2-0034" title="BellverJ , AlbertC , LabartaE , PellicerA . Early pregnancy loss in women stimulated with gonadotropin‐releasing hormone antagonist protocols according to oral contraceptive pill pretreatment. Fertility and Sterility2007;87(5):1098‐101. [DOI: 10.1016/j.fertnstert.2006.08.098] ">Bellver 2007</a>; <a href="./references#CD006109-bbs2-0036" title="BendiksonK , MilkiAA , Speck‐ZulakA , WestphalLM . Comparison of GnRH antagonist cycles with and without oral contraceptive pretreatment in potential poor prognosis patients. Clinical and Experimental Obstetrics and Gynecology2006;33(3):145‐7. ">Bendikson 2006</a>; <a href="./references#CD006109-bbs2-0037" title="BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF , TanSL . Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin‐releasing hormone analogues. Journal of Assisted Reproduction and Genetics1998;15(10):599‐604. ">Biljan 1998c</a>; <a href="./references#CD006109-bbs2-0042" title="ChungMT , TsaiYC , ChenSH , LooTC , TangHH , LinLY . Influence of pituitary suppression with triphasic or monophasic oral contraceptives on the outcome of in vitro fertilization and embryo transfer. Journal of Assisted Reproduction and Genetics2006;23:343‐6. [DOI: 10.1007/s10815‐006‐9056‐y] ">Chung 2006</a>; <a href="./references#CD006109-bbs2-0046" title="DamarioMA , BarmatL , LiuHC , DavisOK , RosenwaksZ . Dual suppression with oral contraceptives and gonadotrophin releasing‐hormone agonists improves in‐vitro fertilization outcome in high responder patients. Human Reproduction1997;12(11):2359‐65. ">Damario 1997</a>; <a href="./references#CD006109-bbs2-0050" title="DickeyRP , SartorBM , TaylorSN , LuPY , RyePH , PyrzakR . Oral contraceptives, not GnRH suppression, may be responsible for very low endogenous LH during IVF cycles. Fertility and Sterility2001; Vol. Suppl 3, 76, issue 3:S237. ">Dickey 2001</a>; <a href="./references#CD006109-bbs2-0053" title="DuvanCI , BerkerB , TurhanNO , SatirogluH . Oral contraceptive pretreatment does not improve outcome in microdose gonadotrophin‐releasing hormone agonist protocol among poor responder intracytoplasmic sperm injection patients. Journal of Assisted Reproduction and Genetics2008;25:89‐93. [DOI: 10.1007/s10815‐008‐9203‐8] ">Duvan 2008</a>; <a href="./references#CD006109-bbs2-0060" title="FrederickJ , DaCostaV , WynterS , ReidM , FrederickC , McKenzieC . Effect of the oral contraceptive pill on patients undergoing controlled ovarian hyperstimulation. West Indian Medical Journal2004;53(1):39‐43. ">Frederick 2004</a>; <a href="./references#CD006109-bbs2-0068" title="GonzalezP , MaloulS , CiuffardiI , FrederickJL , BalmacedaJP , AschRH . The use of progestins for programming assisted reproductive cycles and gonadotropin‐releasing hormone agonist flare‐up protocols in older patients. Fertility and Sterility1995;63(2):249‐51. ">Gonzalez 1995</a>; <a href="./references#CD006109-bbs2-0075" title="KeltzMD , GeraPS , SkorupskiJ , SteinDE . Comparison of FSH flare with and without pretreatment with oral contraceptive pills in poor responders undergoing in vitro fertilization. Fertility and Sterility2007;88(2):350‐3. [DOI: 10.1016/j.fertnstert.2006.11.123] KeltzMD , SharmaP , SteinDE . Comparison of FSH flare in poor responders undergoing in vitro fertilization (IVF) with and without prior oral contraceptive suppression. Fertility and Sterility2003; Vol. 80:S107. ">Keltz 2007</a>; <a href="./references#CD006109-bbs2-0076" title="KovacsP , BargPE , WittBR . Hypothalamic‐pituitary suppression with oral contraceptive pills does not improve outcome in poor responder patients undergoing in vitro fertilization‐embryo transfer cycles. Journal of Assisted Reproduction and Genetics2001;18(7):391‐4. ">Kovacs 2001</a>; <a href="./references#CD006109-bbs2-0078" title="LeondiresMP , EscalpesM , SegarsJH , ScottRT , MillerBT . Microdose follicular phase gonadotropin‐releasing hormone agonist (GnRH‐a) compared with luteal phase GnRH‐a for ovarian stimulation at in vitro fertilization. Fertility and Sterility1999;72(6):1018‐23. ">Leondires 1999</a>; <a href="./references#CD006109-bbs2-0083" title="LoutradisD , StefanidisK , DrakakisP , KallianidisK , ElSheikhA , MilingosS , et al. Does pre‐treatment with micronized progesterone affect the ovarian response to a gonadotropin releasing hormone agonist flare‐up protocol?. Gynecological Endocrinology2003;17(2):101‐6. ">Loutradis 2003</a>; <a href="./references#CD006109-bbs2-0089" title="MinJK , ClamanP . Oral contraceptive (OC) pre‐treatment does not influence oocyte yield in poor responders undergoing gonadotropin releasing hormone (GnRH) antagonist cycles for in vitro fertilization (IVF). Fertility and Sterility2005; Vol. Suppl 1, 84:S45‐6. ">Min 2005</a>; <a href="./references#CD006109-bbs2-0090" title="MirkinS , StadtmauerLA , GibbonsWE , OehningerS . Clinical and endocrine impact of pretreatment with oral contraceptive pills in poor responders undergoing IVF with a combination of microdose flare leuprolide acetate and high dose gonadotropins. Fertility and Sterility2003; Vol. Suppl 3, 80:S190‐1. ">Mirkin 2003</a>; <a href="./references#CD006109-bbs2-0093" title="PadosG , TarlatzisBC , BontisJ , LagosS , PapadimasJ , SpanosE , et al. Evaluation of different ovarian stimulation protocols for in vitro fertilization. Gynecological Endocrinology1995;9:103‐12. [DOI: 10.3109/09513599509160198] ">Pados 1995</a>; <a href="./references#CD006109-bbs2-0095" title="PinkasH , SapirO , AvrechOM , Ben‐HaroushA , AshkenziJ , FischB , et al. The effect of oral contraceptive pill for cycle scheduling prior to GnRH‐antagonist protocol on IVF cycle parameters and pregnancy outcome. Journal of Assisted Reproduction and Genetics2008;25:29‐33. [DOI: 10.1007/s10815‐007‐9189‐7] ">Pinkas 2008</a>; <a href="./references#CD006109-bbs2-0096" title="RamsewakSS , DuffyS , TaylorJ , WoodwardB . The oral contraceptive pill effectively permits cycle batching for an intermittent in vitro fertilization programme in Trinidad and Tobago. West Indian Medical Journal2005;54(2):127‐9. ">Ramsewak 2005</a>; <a href="./references#CD006109-bbs2-0104" title="TalebianS , KreyLC , NoyesN . Use of oral contraceptives with GnRH antagonists and recombinant gonadotropins in IVF cycles have no deleterious effect on pregnancy outcome. Fertility and Sterility2004; Vol. Suppl 2, 82:S234. ">Talebian 2004</a>; <a href="./references#CD006109-bbs2-0105" title="TalebianS , KreyLC , RehA , GrangulyN , LiuM , NoyesN . Oral contraceptive (OC) pre‐treatment in GnRH antagonist (ANT) cycles is a reasonable option to control the timing of IVF cycles. Fertility and Sterility2007; Vol. Suppl 1, 88:S291. ">Talebian 2007</a>; <a href="./references#CD006109-bbs2-0111" title="WeiD , ShiY , LiJ , WangZ , ZhangL , SunY , et al. Effect of pretreatment with oral contraceptives and progestins on IVF outcomes in women with polycystic ovary syndrome. Human Reproduction2016;32(2):1‐8. [DOI: 10.1093/humrep/dew325] ">Wei 2016</a>; <a href="./references#CD006109-bbs2-0114" title="YoshidaA , KakinumaM , MatsubaT , SeidaK , SuzukiH , TanakaM . Effectiveness of using estradiol‐GnRH antagonist protocol with unsuccessful oral contraceptive pill‐GnRH antagonist protocol cases (full term pregnancies had not resulted) in in‐vitro fertilization (IVF) cycles. Fertility and Sterility2005; Vol. Suppl 1, 84:S45. ">Yoshida 2005</a>; <a href="./references#CD006109-bbs2-0116" title="ZhaoJZ , LinXH , HuangXF , LinJJ , LinWQ , YeBL . Effect of desogestrel and ethinyl estradiol pretreatment in superovulation cycles with short protocol. Chinese Journal of Obstetrics and Gynecology [Zhonghua Fu Chan Ke Za Zhi]2008;43(2):102‐5. ">Zhao 2008</a>). </p> </li> <li> <p>In five studies, participants served as their own controls in previous cycles (<a href="./references#CD006109-bbs2-0038" title="BraniganEF , EstesMA . Treatment of high responders with oral contraceptive pills (OC) before ovarian hyperstimulation for IVF. Fertility and Sterility1998; Vol. 69, issue 3:599. ">Branigan 1998</a>; <a href="./references#CD006109-bbs2-0056" title="FanchinR , Cunha FilhoJ , SchonauerL , KadochI , Cohen BacriP , FrydmanR . Co‐ordination of early antral follicles by luteal estradiol administration: basis for novel controlled ovarian hyperstimulation. Human Reproduction. 2002; Vol. 17 Abstract Book 1:88‐9. FanchinR , Cunha‐FilhoJS , SchonauerLM , KadochIJ , Cohen‐BacriP , FrydmanR . Coordination of early antral follicles by luteal estradiol administration provides a basis for alternative controlled ovarian hyperstimulation regimens. Fertility and Sterility2003;79(2):316‐21. ">Fanchin 2003b</a>; <a href="./references#CD006109-bbs2-0058" title="FischB , RoyburtM , PinkasH , AvrechOM , GoldmanGA , BarJ , et al. Augmentation of low ovarian response to superovulation before in vitro fertilization following priming with contraceptive pills. Israel Journal of Medical Sciences1996;32(12):1172‐6. ">Fisch 1996</a>; <a href="./references#CD006109-bbs2-0091" title="MulangiAS , Nelson‐WhiteTM , RacowskyC , GeletyTJ . Follicular phase endocrine response to oral contraceptives (OCs) followed by gonadotropin releasing hormone agonist (GnRHa) for down‐regulation prior to controlled ovarian hyperstimulation (COH) for the purpose of IVF. Fertility and Sterility1997; Vol. Suppl 1, 68:S6. ">Mulangi 1997</a>; <a href="./references#CD006109-bbs2-0103" title="SurreyES , BowerJ , HillDM , RamseyJ , SurreyMW . Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization. Fertility and Sterility1998; Vol. 69, issue 3:419‐24. ">Surrey 1998</a>). </p> </li> <li> <p>There was insufficient information in five studies to determine their true randomization status (<a href="./references#CD006109-bbs2-0030" title="AghahosseiniM , AleyassinA , KhodaverdiS , EsfahaniF , MohammadbeigiR , MovahediS , et al. Estradiol supplementation during the luteal phase in poor responder patients undergoing in vitro fertilization: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2011;28:785‐90. ">Aghahosseini 2011</a>; <a href="./references#CD006109-bbs2-0033" title="BakasP , HassiakosD , GrigoriadisC , VlahosNF , LiapisA , CreatsasG . Effect of a low dose combined oral contraceptive pill on the hormonal profile and cycle outcome following COS with a GnRH antagonist protocol in women over 35 years old. Gynecological Endocrinology2014;30(11):825‐9. ">Bakas 2014</a>; <a href="./references#CD006109-bbs2-0047" title="DavarR , RahseparM , RahmaniE . Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling. Iranian Journal of Reproductive Medicine2014;12 Suppl 1(6):71. ">Davar 2014</a>; <a href="./references#CD006109-bbs2-0054" title="EngelsS , BlockeelC , HaentjensP , DeVosM , CamusM , DevroeyP . How to avoid oocyte retrievals during weekend days using a GnRH antagonist protocol? A randomised controlled trial. Human Reproduction2011;26 Suppl 1:i308 Abstract no: P‐480. ">Engels 2011</a>; <a href="./references#CD006109-bbs2-0088" title="MervielP , Cabry‐GoubetR , LourdelE , DevauxA , Belhadri‐MansouriN , CopinH , et al. Comparative prospective study of 2 ovarian stimulation protocols in poor responders: effect on implantation rate and ongoing pregnancy. Reproductive Health2015;12:52. SchefflerF , MervielP , LourdelE , et al. Contraceptive pill and gonadotropin‐releasing hormone (GnRH) flare‐up agonist versus GnRH antagonist protocol in poor responders: lessons to a prospective study. Human Reproduction2015;30 Suppl:i295 Abstract no: p‐410. ">Merviel 2015</a>). </p> </li> <li> <p>Three studies used a cross‐over design and there were no available pre‐cross‐over data (<a href="./references#CD006109-bbs2-0041" title="Cédrin‐DurnerinI , BulwaS , HervéF , Martin‐PontB , UzanM , HuguesJN . The hormonal flare‐up following gonadotrophin‐releasing hormone agonist administration is influenced by a progestogen pretreatment. Human Reproduction1996;11(9):1859‐63. Cédrin‐DurnerinI , BulwaS , HervéF , PecqueuxL , UzanM , HuguesJN . Influence of norethisterone pretreatment on the initial flare‐up induced by a gonadotrophin‐releasing hormone agonist in a short protocol for IVF. Human Reproduction1995;10 Abstract Book 2:116. ">Cédrin‐Durnerin 1996</a>; <a href="./references#CD006109-bbs2-0055" title="FanchinR , SchonauerL , Cunha FilhoJ , KadochI , Cohen BacrieP , FrydmanR . Luteal E2 administration reduces size and improves homogeneity of selectable follicles on cycle‐day 3: bases for novel controlled ovarian hyperstimulation (COH) concepts. Fertility and Sterility2001; Vol. Suppl 1, 76, issue 3:S90. ">Fanchin 2001</a>; <a href="./references#CD006109-bbs2-0109" title="WangB , SunHX , HuYL , ChenH , ZhangNY . Application of GnRH‐antagonist to IVF‐ET for patients with poor ovarian response. National Journal of Andrology [Zhonghua Nan Ke Xue]2008;14(5):423‐6. ">Wang 2008</a>). </p> </li> <li> <p>Eight studies used a single‐arm design (<a href="./references#CD006109-bbs2-0039" title="BrodtJ , TaubertHD . Planned ovarian stimulation with preadministered contraceptives in an in‐vitro fertilization program [Programmierte ovarielle stimulation mittels ovulationshemmer‐vorbehandlung in einem in vitro fertilisations(IVF)‐programm]. Archives of Gynecology and Obstetrics1993;254(1‐4):246‐8. ">Brodt 1993</a>; <a href="./references#CD006109-bbs2-0049" title="DeZieglerD , BrioschiPA , BenchaaC , CampanaA , DitesheimPJ , FanchinR , et al. Programming ovulation in the menstrual cycle by a simple innovative approach: back to the future of assisted reproduction. Fertility and Sterility1999;72(1):77‐82. ">De Ziegler 1999</a>; <a href="./references#CD006109-bbs2-0063" title="GerliS , RemohiJ , PartrizioP , BorreroC , BalmacedaJP , SilberSJ , et al. Programming of ovarian stimulation with norethindrone acetate in IVF/GIFT cycles. Human Reproduction1989;4(7):746‐8. ">Gerli 1989</a>; <a href="./references#CD006109-bbs2-0072" title="HuguesJN , AttalahM , HervéF , Martin‐PontB , KottlerML , SantarelliJ . Effects of short‐term GnRH agonist ‐ human menopausal gonadotropin stimulation in patients pre‐treated with progestogen. Human Reproduction1992;7(8):1079‐84. ">Hugues 1992</a>; <a href="./references#CD006109-bbs2-0086" title="MeldrumD , ScottR , LevyMJ , AlperM , NoyesN . A pilot study to assess oral contraceptive (OC) pretreatment in women undergoing controlled ovarian hyperstimulation (COH) in ganirelix acetate cycles. Fertility and Sterility2002; Vol. Suppl 1, 78, issue 3:S176. ">Meldrum 2002</a>; <a href="./references#CD006109-bbs2-0087" title="MeldrumDR , CassidentiDL , RosenGF , YeeB , WisotAL . Oral contraceptive pretreatment and half dose of ganirelix does not excessively suppress LH and may be an excellent choice for scheduling IUI cycles. Journal of Assisted Reproduction and Genetics2008;25:417‐20. [DOI: 10.1007/s10815‐008‐9244‐z] ">Meldrum 2008</a>; <a href="./references#CD006109-bbs2-0099" title="SanghviA , NoyesN , KreyLC . An oral contraceptive (OCP) microdose flare leuprolide acetate (LA) stimulation protocol is useful for poor prognosis patients undergoing in vitro fertilization (IVF). Fertility and Sterility2002; Vol. Suppl 1, 78:S149. ">Sanghvi 2002</a>; <a href="./references#CD006109-bbs2-0108" title="TehraninejadES , NasiriR , RashidiB , HaghollahiF , AtaieM . Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients. Archives of Gynecology &amp; Obstetrics2010;282(3):319‐25. ">Tehraninejad 2010</a>). </p> </li> <li> <p>Nine studies compared two (or more) different dosages, timings or ways of administration of the same pretreatment (<a href="./references#CD006109-bbs2-0048" title="DavyC , GuibertJ , BlanchetV , NatafE , OlivennesF . The 'wash out' period do not create asynchrony of the follicle cohort when contraceptive pill is used to program GnRH antagonist IVF cycles. Human Reproduction. 2004; Vol. 19 Suppl 1:i5‐6. OlivennesFSr , DavyC , GuibertJ , NatafE , BlanchetV . Asynchrony of the follicle cohort is not induced by the “wash out” period when contraceptive pill is used to program GnRH antagonist IVF cycles. Fertility and Sterility2004; Vol. Suppl 2, 82:S234. ">Davy 2004</a>; <a href="./references#CD006109-bbs2-0066" title="GomezE , BallesterosA , LanderasJ , MunozM , MartinezMC . Preparation of endometrium with oral oestradiol valerate versus transdermal oestradiol for cryopreserved embryo transfer: a prospective randomized study. Human Reproduction2000;15:175‐6. ">Gomez 2000</a>; <a href="./references#CD006109-bbs2-0071" title="HaydardedeogluB , KilicdagEB , ParlakgummusAH , ZeynelogluHB . IVF/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist protocol in women with PCOS: a randomised trial. Archives of Gynecology and Obstetrics2012;286:763‐9. ">Haydardedeoglu 2012</a>; <a href="./references#CD006109-bbs2-0074" title="KarandeVC , LatashWDZ , BirkenkampT , CavanaughJ , MeloneK , HazlettD . Preliminary report of a prospective randomized controlled trial comparing the use of NuvaRing® to Desogen® in in vitro fertilization cycles with ganirelix acetate. Fertility and Sterility2004; Vol. Suppl 2, 82:S31‐2. ">Karande 2004</a>; <a href="./references#CD006109-bbs2-0077" title="KreinerD , diLandroR , MoschellaJ . Study of IVF success with pituitary suppression prior to follistim/HMG stimulation in ganirelix cycles using oral contraceptives and estrace. Fertility &amp; Sterility2007;Vol 88 Suppl 1:284, abstract no. 534. ">Kreiner 2007</a>; <a href="./references#CD006109-bbs2-0080" title="LewinA , FatumM , ShufaroY , SimonA , ReubinoffB , LauferN , et al. Artificial endometrial preparation for frozen‐thawed embryo transfer using oral oestradiol and a new low‐dose vaginal progesterone preparation: Endometrin tablets. Human Reproduction2001; Vol. Suppl 1, 16:152. LewinA , PisovG , TurgemanR , FatumM , ShufaroY , SimonA , et al. Simplified artificial endometrial preparation, using oral estradiol and novel vaginal progesterone tablets: a prospective randomized study. Gynecological Endocrinology2002;16(2):131‐6. ">Lewin 2002</a>; <a href="./references#CD006109-bbs2-0082" title="LiuKE , AlhajriM , GreenblattE . A randomized controlled trial of NuvaRing versus combined oral contraceptive pills for pretreatment in in vitro fertilization cycles. Fertility and Sterility2011;96(3):605‐8. ">Liu 2011</a>; <a href="./references#CD006109-bbs2-0085" title="MashiachS , DorJ , GoldenbergM , ShalevJ , BlanksteinJ , RudakeE , et al. Protocols for induction of ovulation ‐ the concept of programmed cycles. Annals of the New York Academy of Sciences1988;541:37‐45. MashiachS , DorJ , GoldenbergM , ShalevJ , LevranD , RudakE , et al. Programmed oocyte retrieval: clinical and biological effects of oral contraceptives administered before in vitro fertilization. Gynecological Endocrinology1989;3(2):107‐15. ">Mashiach 1989</a>; <a href="./references#CD006109-bbs2-0098" title="RussellJB , KnezevichKM , FabianKF , DicksonJA . Unstimulated immature oocyte retrieval: early versus mid follicular endometrial priming. Fertility and Sterility1997;67(4):616‐20. ">Russell 1997</a>). </p> </li> <li> <p>Two studies used interventions that were administered for luteal phase support and not for pretreatment (<a href="./references#CD006109-bbs2-0064" title="GhanemM , BediaryMH , HelalAS , et al. Is adding estradiole (E2) to progesterone (P) luteal support in high responder long GnRH agonist ICSI cycles detrimental to outcome? Randomised controlled trial (RCT). Fertility &amp; Sterility2015;104 Suppl(3):e224. ">Ghanem 2015</a>; <a href="./references#CD006109-bbs2-0097" title="RashidiB , NasiriR , RahmanpourH , Shahrokh TehraninejadE , DeldarM . Luteal phase estradiol versus luteal phase GnRH antagonist administration: their effects on antral follicular size coordination and basal hormonal levels. Iranian Journal of Reproductive Medicine2011;9(4):315‐8. ">Rashidi 2011</a>). </p> </li> <li> <p>In three studies, women only received ovarian stimulation, but no embryo transfer was performed as part of an ART cycle (<a href="./references#CD006109-bbs2-0032" title="AndersonRE , SteinAL , PaulsonRJ , StanczykFZ , VijodAG , LoboRA . Effects of norethindrone on gonadotropin and ovarian‐steroid secretion when used for cycle programming during in vitro fertilization. Fertility and Sterility1990;54(1):96‐101. ">Anderson 1990</a>; <a href="./references#CD006109-bbs2-0079" title="LetterieGS . Inhibition of gonadotropin surge by a brief mid‐cycle regimen of ethinyl estradiol and norethindrone: possible role in in vitro fertilization. Gynecological Endocrinology2000;14(1):1‐4. ">Letterie 2000</a>; <a href="./references#CD006109-bbs2-0101" title="SteinkampfMP , HammondKR , BlackwellRE . Effect of estrogen/progestin administration on the ovarian response to gonadotropins: a randomized, prospective study. Fertility and Sterility1991;55(3):642‐3. ">Steinkampf 1991</a>). </p> </li> <li> <p>In two studies, the women were oocyte donors (<a href="./references#CD006109-bbs2-0052" title="DoodyKJ , LangleyM , MarekD , DoodyK . Oral contraceptive pre‐treatment for IVF cycles employing recombinant FSH and a GnRH antagonist. Fertility and Sterility2001; Vol. Suppl 1, 76, issue 3:S236. ">Doody 2001</a>; <a href="./references#CD006109-bbs2-0084" title="MartínezF , BoadaM , CoroleuB , CluaE , PareraN , RodríguezI , et al. A prospective trial comparing oocyte donor ovarian response and recipient pregnancy rates between suppression with gonadotrophin‐releasing hormone agonist (GnRHa) alone and dual suppression with a contraceptive vaginal ring and GnRH. Human Reproduction2006;21(8):2121‐5. ">Martinez 2006</a>). </p> </li> <li> <p>In one study, the women had premature ovarian failure (<a href="./references#CD006109-bbs2-0107" title="TartagniM , CicinelliE , DePergolaG , DeSalviaMA , LavopaC , LoverroG . Effects of pretreatment with estrogens on ovarian stimulation with gonadotropins in women with premature ovarian failure: a randomized, placebo‐controlled trial. Fertility and Sterility2007;87(4):858‐61. [DOI: 10.1016/j.fertnstert.2006.08.086] ">Tartagni 2007</a>). </p> </li> <li> <p>In two studies, pretreatment was not stopped before oocyte retrieval, but continued to be used as luteal phase support (<a href="./references#CD006109-bbs2-0069" title="GrecoE , LitwickaK , ArriviC , VarricchioMT , CaragiaA , GrecoA , et al. The endometrial preparation for frozen‐thawed euploidblastocyst transfer: a prospective randomized trial comparing clinical results from natural modified cycle and exogenous hormone stimulation with GnRH agonist. Journal of Assisted Reproduction and Genetics2016;33:873‐84. [DOI: 10.1007/s10815‐016‐0736‐y] ">Greco 2016</a>; <a href="./references#CD006109-bbs2-0073" title="JungH , RohHK . The effects of E2 supplementation from the early proliferative phase to the late secretory phase of the endometrium in hMG‐stimulated IVF‐ET. Journal of Assisted Reproduction and Genetics2000;17(1):28‐33. ">Jung 2000</a>). </p> </li> <li> <p>In one study, the main comparison was mild versus standard stimulation (with pretreatment in one group) (<a href="./references#CD006109-bbs2-0115" title="YoussefM , vanWelyM , Al‐InanyH , MadaniT , JahangiriN , KhodabakhshiS , et al. A mild ovarian stimulation in women with poor ovarian reserve undergoing IVF: a multicenter randomized non‐inferiority trial. Human Reproduction2017;32(1):112‐8. YoussefM , vanWelyM , Al‐InanyH , MadaniT , JahangiriN , KhodabakhshiS , et al. Mild versus standard ovarian stimulation in poor responder women undergoing IVF and ICSI (prima) ‐ multicenter randomised controlled study. Human Reproduction2014;29:i50‐1. ">Youssef 2017</a>). </p> </li> </ul> </p> </section> </section> <section id="CD006109-sec-0080"> <h3 class="title">Risk of bias in included studies</h3> <p>A complete overview of classification of risk of bias domains can be found in the <a href="./references#CD006109-sec-0284" title="">Characteristics of included studies</a> table and in <a href="#CD006109-fig-0001">Figure 1</a> and <a href="#CD006109-fig-0002">Figure 2</a>. </p> <section id="CD006109-sec-0081"> <h4 class="title">Allocation</h4> <p>Eighteen studies were at low risk of random sequence generation: 13 of these studies used computer generated random numbers to randomise the women (<a href="./references#CD006109-bbs2-0002" title="BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF . Prospective randomized trial on effect of pre‐treatment with an oral contraceptive (OC) on the length of time required for pituitary suppression by gonadotropin releasing hormone agonist (GnRH‐a) and subsequent implantation and pregnancy rates. Fertility and Sterility1998; Vol. Suppl 1, 70, issue 3:S133. BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF , TanSL . Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin‐releasing hormone analogues and on subsequent implantation and pregnancy rates. Fertility and Sterility1998;70(6):1063‐9. ">Biljan 1998b</a>; <a href="./references#CD006109-bbs2-0003" title="BlockeelC , EngelsS , deVosM , HaentjensP , PolyzosNP , StoopD , et al. Oestradiol valerate pretreatment in GnRH antagonist cycles: a randomised controlled trial. Reproductive Biomedicine Online2012;24:272‐80. ">Blockeel 2012</a>; <a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>; <a href="./references#CD006109-bbs2-0009" title="FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol administration coordinates FSH‐induced follicular growth and improves the outcome of GnRH antagonist COH protocols. 19th Annual meeting of the ESHRE; 2003 Jun 29‐Jul 2; Madrid, Spain, 2003. 2003. FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol pre‐treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Human Reproduction2003;18(12):2698‐703. [DOI: 10.1093/humrep/deg516] ">Fanchin 2003</a>; <a href="./references#CD006109-bbs2-0011" title="Garcia‐VelascoJA , BermejoA , RuizF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility2011;96(3):590‐3. Garcia‐VelascoJA , BermejoA , Ruiz‐FloresF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial. Fertility and Sterility2010;94 Suppl 1(4):S28 Abstract no. O‐93. ">Garcia‐Velasco 2011</a>; <a href="./references#CD006109-bbs2-0012" title="HauzmanEE , ZapataA , BermejoA , IglesiasC , PellicerA , Garcia‐VelascoJ . Cycle scheduling for in vitro fertilisation with oral contraceptive pills versus oral estradiol valerate: a randomised controlled trial. Reproductive Biology and Endocrinology2013;11:96. ">Hauzman 2013</a>; <a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>; <a href="./references#CD006109-bbs2-0015" title="HuirneJA , HuguesJN , PirardC , FischlF , SageJC , PoulyJL , et al. Cetrorelix in an oral contraceptive‐pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r‐hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction2006;21(6):1408‐15. [DOI: 10.1093/humrep/de1030] ">Huirne 2006c</a>; <a href="./references#CD006109-bbs2-0016" title="HwangJL , SeowKM , LinYH , HuangLW , HsiehBC , TsaiYL , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. [DOI: 10.1093/humrep/deh375] ">Hwang 2004</a>; <a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a>; <a href="./references#CD006109-bbs2-0019" title="LukaszukK , LissJ , KunickiM , KuczynskiW , PastuszekE , JakielG , et al. Estradiol valerate pretreatment in short protocol GNRH‐agonist cycles versus combined pretreatment with oral contraceptive pills in long protocol GNRH‐agonist cycles: a randomised controlled trial. BioMed Research International2015;2015:1‐6. ">Lukaszuk 2015</a>; <a href="./references#CD006109-bbs2-0029" title="YeH , HuangG‐N , ZengP‐H , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;26(2‐3):105‐11. ">Ye 2009</a>), four studies used a table of random numbers (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0005" title="Cédrin‐DurnerinI , Guivarc'h‐LevequeA , HuguesJ‐N . Pretreatment with estrogen does not affect IVF‐ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomised trial. Fertility and Sterility2012;97(6):1359‐64. ">Cédrin‐Durnerin 2012</a>; <a href="./references#CD006109-bbs2-0010" title="FrancoJGJr , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH after 2nd phase protocols with GnRH analogs (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin) [Comparação da estimulação ovariana com FSH recombinante após protocolo de 2a fase com análogos do GnRH (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco Jr 2003</a>; <a href="./references#CD006109-bbs2-0026" title="ShakerAG , PittrofR , ZaidiJ , BekirJ , Kyei‐MensahA , TanSL . Administration of progestogens to hasten pituitary desensitization after the use of gonadotropin‐releasing hormone agonist in in vitro fertilization ‐ a prospective randomized study. Fertility and Sterility1995;64(4):791‐5. ">Shaker 1995</a>), and one study accomplished the randomization by tossing a coin (<a href="./references#CD006109-bbs2-0007" title="DitkoffEC , SauerMV . A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin‐releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Human Reproduction1996;11(5):1035‐7. ">Ditkoff 1996</a>). In the remaining 11 studies, there was insufficient information on the methods used in random sequence generation; they were thus rated at unclear risk of bias with respect to random sequence generation. </p> <p>If randomization is not done correctly, there might be a difference in baseline characteristics between the women in the treatment groups. This may influence the outcomes measured in the trial. Therefore, it is important that the method of randomization is reported. Due to the high number of included studies that did not report the method of randomization (15/33 studies), there might be a higher risk of bias. </p> <p>Fourteen studies were at low risk of allocation concealment: eight studies used sealed envelopes to conceal the allocation (<a href="./references#CD006109-bbs2-0002" title="BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF . Prospective randomized trial on effect of pre‐treatment with an oral contraceptive (OC) on the length of time required for pituitary suppression by gonadotropin releasing hormone agonist (GnRH‐a) and subsequent implantation and pregnancy rates. Fertility and Sterility1998; Vol. Suppl 1, 70, issue 3:S133. BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF , TanSL . Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin‐releasing hormone analogues and on subsequent implantation and pregnancy rates. Fertility and Sterility1998;70(6):1063‐9. ">Biljan 1998b</a>; <a href="./references#CD006109-bbs2-0003" title="BlockeelC , EngelsS , deVosM , HaentjensP , PolyzosNP , StoopD , et al. Oestradiol valerate pretreatment in GnRH antagonist cycles: a randomised controlled trial. Reproductive Biomedicine Online2012;24:272‐80. ">Blockeel 2012</a>; <a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0005" title="Cédrin‐DurnerinI , Guivarc'h‐LevequeA , HuguesJ‐N . Pretreatment with estrogen does not affect IVF‐ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomised trial. Fertility and Sterility2012;97(6):1359‐64. ">Cédrin‐Durnerin 2012</a>; <a href="./references#CD006109-bbs2-0011" title="Garcia‐VelascoJA , BermejoA , RuizF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility2011;96(3):590‐3. Garcia‐VelascoJA , BermejoA , Ruiz‐FloresF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial. Fertility and Sterility2010;94 Suppl 1(4):S28 Abstract no. O‐93. ">Garcia‐Velasco 2011</a>; <a href="./references#CD006109-bbs2-0012" title="HauzmanEE , ZapataA , BermejoA , IglesiasC , PellicerA , Garcia‐VelascoJ . Cycle scheduling for in vitro fertilisation with oral contraceptive pills versus oral estradiol valerate: a randomised controlled trial. Reproductive Biology and Endocrinology2013;11:96. ">Hauzman 2013</a>; <a href="./references#CD006109-bbs2-0016" title="HwangJL , SeowKM , LinYH , HuangLW , HsiehBC , TsaiYL , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. [DOI: 10.1093/humrep/deh375] ">Hwang 2004</a>; <a href="./references#CD006109-bbs2-0026" title="ShakerAG , PittrofR , ZaidiJ , BekirJ , Kyei‐MensahA , TanSL . Administration of progestogens to hasten pituitary desensitization after the use of gonadotropin‐releasing hormone agonist in in vitro fertilization ‐ a prospective randomized study. Fertility and Sterility1995;64(4):791‐5. ">Shaker 1995</a>); in five studies the allocation was done by a third party (<a href="./references#CD006109-bbs2-0001" title="AstonK , ArthurI , MassonGM , JenkinsJM . Progestogen therapy and prevention of functional ovarian cysts during pituitary desensitisation with GnRH agonists. British Journal of Obstetrics and Gynaecology1995;102:835‐7. ">Aston 1995</a>, hospital pharmacy and numbered bottles; <a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>, clinic nurses and sealed envelopes; <a href="./references#CD006109-bbs2-0009" title="FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol administration coordinates FSH‐induced follicular growth and improves the outcome of GnRH antagonist COH protocols. 19th Annual meeting of the ESHRE; 2003 Jun 29‐Jul 2; Madrid, Spain, 2003. 2003. FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol pre‐treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Human Reproduction2003;18(12):2698‐703. [DOI: 10.1093/humrep/deg516] ">Fanchin 2003</a>, independent person; <a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>, independent person from independent monitoring company; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>, central remote allocation); one study centralised the randomization process (<a href="./references#CD006109-bbs2-0007" title="DitkoffEC , SauerMV . A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin‐releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Human Reproduction1996;11(5):1035‐7. ">Ditkoff 1996</a>). </p> <p>Two studies were classified at high risk of allocation concealment, because they reported that the sequence of allocation was not concealed (<a href="./references#CD006109-bbs2-0010" title="FrancoJGJr , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH after 2nd phase protocols with GnRH analogs (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin) [Comparação da estimulação ovariana com FSH recombinante após protocolo de 2a fase com análogos do GnRH (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco Jr 2003</a>; <a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a>). In the remaining 14 studies, there was insufficient information to make a conclusive judgement with respect to allocation concealment and these were rated at unclear risk of bias in this domain. </p> <p>Most of the outcomes of this review were objectively assessed; thus a poorly designed allocation concealment method is not likely to have a big influence on these outcomes. For example, the number of live births is not likely to be influenced by the clinician if he or she knows which treatment the woman receives. However, some outcomes, such as OHSS, are diagnosed on clinical symptoms and so there might be a more important risk of bias when the clinician was aware of the treatment assigned to each woman. Nevertheless, outcomes that are objectively assessed may be influenced indirectly if allocation is not concealed. </p> </section> <section id="CD006109-sec-0082"> <h4 class="title">Blinding</h4> <p>One study was at low risk of blinding because it was described as double blind and placebo controlled (<a href="./references#CD006109-bbs2-0001" title="AstonK , ArthurI , MassonGM , JenkinsJM . Progestogen therapy and prevention of functional ovarian cysts during pituitary desensitisation with GnRH agonists. British Journal of Obstetrics and Gynaecology1995;102:835‐7. ">Aston 1995</a>). </p> <p>In 20 studies, there was insufficient information with respect to blinding of clinicians, participants and outcome assessors; these studies were assessed at unclear risk with regard to blinding (<a href="./references#CD006109-bbs2-0002" title="BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF . Prospective randomized trial on effect of pre‐treatment with an oral contraceptive (OC) on the length of time required for pituitary suppression by gonadotropin releasing hormone agonist (GnRH‐a) and subsequent implantation and pregnancy rates. Fertility and Sterility1998; Vol. Suppl 1, 70, issue 3:S133. BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF , TanSL . Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin‐releasing hormone analogues and on subsequent implantation and pregnancy rates. Fertility and Sterility1998;70(6):1063‐9. ">Biljan 1998b</a>; <a href="./references#CD006109-bbs2-0003" title="BlockeelC , EngelsS , deVosM , HaentjensP , PolyzosNP , StoopD , et al. Oestradiol valerate pretreatment in GnRH antagonist cycles: a randomised controlled trial. Reproductive Biomedicine Online2012;24:272‐80. ">Blockeel 2012</a>; <a href="./references#CD006109-bbs2-0005" title="Cédrin‐DurnerinI , Guivarc'h‐LevequeA , HuguesJ‐N . Pretreatment with estrogen does not affect IVF‐ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomised trial. Fertility and Sterility2012;97(6):1359‐64. ">Cédrin‐Durnerin 2012</a>; <a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>; <a href="./references#CD006109-bbs2-0009" title="FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol administration coordinates FSH‐induced follicular growth and improves the outcome of GnRH antagonist COH protocols. 19th Annual meeting of the ESHRE; 2003 Jun 29‐Jul 2; Madrid, Spain, 2003. 2003. FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol pre‐treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Human Reproduction2003;18(12):2698‐703. [DOI: 10.1093/humrep/deg516] ">Fanchin 2003</a>; <a href="./references#CD006109-bbs2-0010" title="FrancoJGJr , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH after 2nd phase protocols with GnRH analogs (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin) [Comparação da estimulação ovariana com FSH recombinante após protocolo de 2a fase com análogos do GnRH (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco Jr 2003</a>; <a href="./references#CD006109-bbs2-0011" title="Garcia‐VelascoJA , BermejoA , RuizF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility2011;96(3):590‐3. Garcia‐VelascoJA , BermejoA , Ruiz‐FloresF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial. Fertility and Sterility2010;94 Suppl 1(4):S28 Abstract no. O‐93. ">Garcia‐Velasco 2011</a>; <a href="./references#CD006109-bbs2-0012" title="HauzmanEE , ZapataA , BermejoA , IglesiasC , PellicerA , Garcia‐VelascoJ . Cycle scheduling for in vitro fertilisation with oral contraceptive pills versus oral estradiol valerate: a randomised controlled trial. Reproductive Biology and Endocrinology2013;11:96. ">Hauzman 2013</a>; <a href="./references#CD006109-bbs2-0013" title="HuguesJN , Cédrin‐DurnerinI , HervéF , Huet‐PecqueuxL , SantarelliJ . Incidence of preprogrammed norethisterone on the intensity of 'flare up' (flush) caused by GnRH agonist according to the IVF protocol [poster] [Incidence d'une préprogrammation par la noréthistérone sur la qualité du flare‐up induit par un agoniste du GnRH en protocole court de FIV]. Contraception, Fertilite, Sexualite1994; Vol. 22, issue 5:331. ">Hugues 1994</a>; <a href="./references#CD006109-bbs2-0015" title="HuirneJA , HuguesJN , PirardC , FischlF , SageJC , PoulyJL , et al. Cetrorelix in an oral contraceptive‐pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r‐hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction2006;21(6):1408‐15. [DOI: 10.1093/humrep/de1030] ">Huirne 2006c</a>; <a href="./references#CD006109-bbs2-0016" title="HwangJL , SeowKM , LinYH , HuangLW , HsiehBC , TsaiYL , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. [DOI: 10.1093/humrep/deh375] ">Hwang 2004</a>; <a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD006109-bbs2-0019" title="LukaszukK , LissJ , KunickiM , KuczynskiW , PastuszekE , JakielG , et al. Estradiol valerate pretreatment in short protocol GNRH‐agonist cycles versus combined pretreatment with oral contraceptive pills in long protocol GNRH‐agonist cycles: a randomised controlled trial. BioMed Research International2015;2015:1‐6. ">Lukaszuk 2015</a>; <a href="./references#CD006109-bbs2-0021" title="ObrucaA , FischlF , HuberJ . Programming oocyte retrieval using oral contraceptive pretreatment before ovarian stimulation with a GnRH antagonist (Cetrotide) protocol. Human Reproduction. 2002; Vol. 17 Abstract Book 1:89. ">Obruca 2002</a>; <a href="./references#CD006109-bbs2-0022" title="PorratiL , VilelaM , ViglierchioMI , ValcarcelA , LombardiE , MarconiG . Oral contraceptive pretreatment achieves better pregnancy rates in IVF antagonists GnRH flexible protocols: a prospective randomized study. Human Reproduction2010;25 Suppl 1(6):i102 Abstract no. O‐259. ">Porrati 2010</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>; <a href="./references#CD006109-bbs2-0025" title="Salat‐BarouxJ , AntoineJM , AlvarezS , CornetD , TibiC , MandelbaumJ , et al. Programmed ovulation induction and oocyte retrieval for in vitro fertilization. Journal of In Vitro Fertilization and Embryo Transfer1988;5(3):153‐7. ">Salat‐Baroux 1988</a>; <a href="./references#CD006109-bbs2-0026" title="ShakerAG , PittrofR , ZaidiJ , BekirJ , Kyei‐MensahA , TanSL . Administration of progestogens to hasten pituitary desensitization after the use of gonadotropin‐releasing hormone agonist in in vitro fertilization ‐ a prospective randomized study. Fertility and Sterility1995;64(4):791‐5. ">Shaker 1995</a>; <a href="./references#CD006109-bbs2-0027" title="TanSL , BiljanM . Fixed scheduling of long protocol of GNRH agonists ‐ use of oral contraceptive (OC) or progestogen pre‐treatment. Gynecological Endocrinology. 2001; Vol. 15 Suppl 2:31. ">Tan 2001</a>; <a href="./references#CD006109-bbs2-0028" title="VilelaM , MarconiM , ZappacostaMP , PorratiL , ValcarcelA , MarconiG . Oral contraceptive (OcP) pretreatment achieves better pregnancy rates in in vitro fertilisation (IVF) antagonists GnRH flexible protocols: a prospective randomised study. Fertility and Sterility2011; Vol. 96, issue 3 (supplement):S252, P‐492. ">Vilela 2011</a>). </p> <p>The remaining eight studies were at high risk of bias because they were described as either open label or not blinded with personnel and participants having knowledge of the treatment allocation. </p> <p>Poor blinding is less likely to influence the objective outcomes such as live birth, but it might have a bigger influence on the diagnosis of OHSS. </p> </section> <section id="CD006109-sec-0083"> <h4 class="title">Incomplete outcome data</h4> <p>Of the 29 studies, 13 were at low risk of attrition bias (<a href="./references#CD006109-bbs2-0003" title="BlockeelC , EngelsS , deVosM , HaentjensP , PolyzosNP , StoopD , et al. Oestradiol valerate pretreatment in GnRH antagonist cycles: a randomised controlled trial. Reproductive Biomedicine Online2012;24:272‐80. ">Blockeel 2012</a>; <a href="./references#CD006109-bbs2-0007" title="DitkoffEC , SauerMV . A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin‐releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Human Reproduction1996;11(5):1035‐7. ">Ditkoff 1996</a>; <a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>; <a href="./references#CD006109-bbs2-0012" title="HauzmanEE , ZapataA , BermejoA , IglesiasC , PellicerA , Garcia‐VelascoJ . Cycle scheduling for in vitro fertilisation with oral contraceptive pills versus oral estradiol valerate: a randomised controlled trial. Reproductive Biology and Endocrinology2013;11:96. ">Hauzman 2013</a>; <a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>; <a href="./references#CD006109-bbs2-0015" title="HuirneJA , HuguesJN , PirardC , FischlF , SageJC , PoulyJL , et al. Cetrorelix in an oral contraceptive‐pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r‐hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction2006;21(6):1408‐15. [DOI: 10.1093/humrep/de1030] ">Huirne 2006c</a>; <a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a>; <a href="./references#CD006109-bbs2-0020" title="BroekmansJF , VerweijPJM , EijkemansMJC , MannaertsNMJL , WitjesH . Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(8):1688‐97. Nyboe AndersenA , WitjesH , GordonK , MannaertsB . Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pretreatment. Human Reproduction2011;26(12):3413‐23. TavmergenE , vonMauw , WitjesH , MannaertsB . Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling. 25th Annual Meeting of ESHRE; 2009 28 Jun‐1 Jul; Amsterdam, the Netherlands. 2009. ">Nyboe Andersen 2011</a>; <a href="./references#CD006109-bbs2-0022" title="PorratiL , VilelaM , ViglierchioMI , ValcarcelA , LombardiE , MarconiG . Oral contraceptive pretreatment achieves better pregnancy rates in IVF antagonists GnRH flexible protocols: a prospective randomized study. Human Reproduction2010;25 Suppl 1(6):i102 Abstract no. O‐259. ">Porrati 2010</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>; <a href="./references#CD006109-bbs2-0028" title="VilelaM , MarconiM , ZappacostaMP , PorratiL , ValcarcelA , MarconiG . Oral contraceptive (OcP) pretreatment achieves better pregnancy rates in in vitro fertilisation (IVF) antagonists GnRH flexible protocols: a prospective randomised study. Fertility and Sterility2011; Vol. 96, issue 3 (supplement):S252, P‐492. ">Vilela 2011</a>; <a href="./references#CD006109-bbs2-0029" title="YeH , HuangG‐N , ZengP‐H , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;26(2‐3):105‐11. ">Ye 2009</a>). In these trials, the proportions of, and reasons for, withdrawals were balanced between the treatment groups or data were analyzed using an ITT basis where all women randomized at baseline were included in the analysis. </p> <p>In 10 studies, there were insufficient information with respect to the proportions of, and reasons for, withdrawals or losses to follow‐up and data were not analyzed on an ITT basis; these studies were rated at unclear risk of attrition bias (<a href="./references#CD006109-bbs2-0002" title="BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF . Prospective randomized trial on effect of pre‐treatment with an oral contraceptive (OC) on the length of time required for pituitary suppression by gonadotropin releasing hormone agonist (GnRH‐a) and subsequent implantation and pregnancy rates. Fertility and Sterility1998; Vol. Suppl 1, 70, issue 3:S133. BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF , TanSL . Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin‐releasing hormone analogues and on subsequent implantation and pregnancy rates. Fertility and Sterility1998;70(6):1063‐9. ">Biljan 1998b</a>; <a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0006" title="DalyDC , DalyCL , MayoD , JacobsA . Oocyte recruitment in IVF patients with limited ovarian reserve (LOR), maximizing quality of oocytes and embryos. Fertility and Sterility2002; Vol. Suppl 1, 78, issue 3:S148‐9. ">Daly 2002</a>; <a href="./references#CD006109-bbs2-0011" title="Garcia‐VelascoJA , BermejoA , RuizF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility2011;96(3):590‐3. Garcia‐VelascoJA , BermejoA , Ruiz‐FloresF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial. Fertility and Sterility2010;94 Suppl 1(4):S28 Abstract no. O‐93. ">Garcia‐Velasco 2011</a>; <a href="./references#CD006109-bbs2-0013" title="HuguesJN , Cédrin‐DurnerinI , HervéF , Huet‐PecqueuxL , SantarelliJ . Incidence of preprogrammed norethisterone on the intensity of 'flare up' (flush) caused by GnRH agonist according to the IVF protocol [poster] [Incidence d'une préprogrammation par la noréthistérone sur la qualité du flare‐up induit par un agoniste du GnRH en protocole court de FIV]. Contraception, Fertilite, Sexualite1994; Vol. 22, issue 5:331. ">Hugues 1994</a>; <a href="./references#CD006109-bbs2-0019" title="LukaszukK , LissJ , KunickiM , KuczynskiW , PastuszekE , JakielG , et al. Estradiol valerate pretreatment in short protocol GNRH‐agonist cycles versus combined pretreatment with oral contraceptive pills in long protocol GNRH‐agonist cycles: a randomised controlled trial. BioMed Research International2015;2015:1‐6. ">Lukaszuk 2015</a>; <a href="./references#CD006109-bbs2-0021" title="ObrucaA , FischlF , HuberJ . Programming oocyte retrieval using oral contraceptive pretreatment before ovarian stimulation with a GnRH antagonist (Cetrotide) protocol. Human Reproduction. 2002; Vol. 17 Abstract Book 1:89. ">Obruca 2002</a>; <a href="./references#CD006109-bbs2-0023" title="RaoofiZ , AflatoonianA . Ovarian cysts formation during depot formulation of GnRH‐a therapy and the effect of pretreatment with oral contraceptive pills on subsequent implantation and pregnancy rate in ART cycles. Iranian Journal of Pharmaceutical Research2008;7(2):109‐13. ">Raoofi 2008</a>; <a href="./references#CD006109-bbs2-0026" title="ShakerAG , PittrofR , ZaidiJ , BekirJ , Kyei‐MensahA , TanSL . Administration of progestogens to hasten pituitary desensitization after the use of gonadotropin‐releasing hormone agonist in in vitro fertilization ‐ a prospective randomized study. Fertility and Sterility1995;64(4):791‐5. ">Shaker 1995</a>; <a href="./references#CD006109-bbs2-0027" title="TanSL , BiljanM . Fixed scheduling of long protocol of GNRH agonists ‐ use of oral contraceptive (OC) or progestogen pre‐treatment. Gynecological Endocrinology. 2001; Vol. 15 Suppl 2:31. ">Tan 2001</a>). </p> <p>The remaining six studies were at high risk of attrition bias because the proportions of, and reasons for, withdrawals were not balanced between the treatment groups and data were not analyzed by ITT. </p> <p>Incomplete outcome data can bias the results of our review, especially with regard to adverse outcomes. For example, a study might have withdrawals due to OHSS that they do not report. Also imbalances in reasons for withdrawal can occur because of differences in interventions between the study group and control group. For example, when there are more withdrawals due to OHSS in the control group, this can be in favour of the intervention used in the study group. The risk of bias might increase if authors do not report this. </p> </section> <section id="CD006109-sec-0084"> <h4 class="title">Selective reporting</h4> <p>We were unable to retrieve the protocol of any of the included studies to examine whether all prespecified outcomes were reported. However, we examined the Methods sections of the studies to determine whether outcomes planed in the Methods section were eventually reported. In this regard, we classified 16 studies at low risk of selective reporting because these trials reported data on all the outcomes mentioned in the 'Methods' section of their publication (<a href="./references#CD006109-bbs2-0003" title="BlockeelC , EngelsS , deVosM , HaentjensP , PolyzosNP , StoopD , et al. Oestradiol valerate pretreatment in GnRH antagonist cycles: a randomised controlled trial. Reproductive Biomedicine Online2012;24:272‐80. ">Blockeel 2012</a>; <a href="./references#CD006109-bbs2-0005" title="Cédrin‐DurnerinI , Guivarc'h‐LevequeA , HuguesJ‐N . Pretreatment with estrogen does not affect IVF‐ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomised trial. Fertility and Sterility2012;97(6):1359‐64. ">Cédrin‐Durnerin 2012</a>; <a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>; <a href="./references#CD006109-bbs2-0011" title="Garcia‐VelascoJA , BermejoA , RuizF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility2011;96(3):590‐3. Garcia‐VelascoJA , BermejoA , Ruiz‐FloresF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial. Fertility and Sterility2010;94 Suppl 1(4):S28 Abstract no. O‐93. ">Garcia‐Velasco 2011</a>; <a href="./references#CD006109-bbs2-0012" title="HauzmanEE , ZapataA , BermejoA , IglesiasC , PellicerA , Garcia‐VelascoJ . Cycle scheduling for in vitro fertilisation with oral contraceptive pills versus oral estradiol valerate: a randomised controlled trial. Reproductive Biology and Endocrinology2013;11:96. ">Hauzman 2013</a>; <a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>; <a href="./references#CD006109-bbs2-0015" title="HuirneJA , HuguesJN , PirardC , FischlF , SageJC , PoulyJL , et al. Cetrorelix in an oral contraceptive‐pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r‐hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction2006;21(6):1408‐15. [DOI: 10.1093/humrep/de1030] ">Huirne 2006c</a>; <a href="./references#CD006109-bbs2-0016" title="HwangJL , SeowKM , LinYH , HuangLW , HsiehBC , TsaiYL , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. [DOI: 10.1093/humrep/deh375] ">Hwang 2004</a>; <a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a>; <a href="./references#CD006109-bbs2-0019" title="LukaszukK , LissJ , KunickiM , KuczynskiW , PastuszekE , JakielG , et al. Estradiol valerate pretreatment in short protocol GNRH‐agonist cycles versus combined pretreatment with oral contraceptive pills in long protocol GNRH‐agonist cycles: a randomised controlled trial. BioMed Research International2015;2015:1‐6. ">Lukaszuk 2015</a>; <a href="./references#CD006109-bbs2-0020" title="BroekmansJF , VerweijPJM , EijkemansMJC , MannaertsNMJL , WitjesH . Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(8):1688‐97. Nyboe AndersenA , WitjesH , GordonK , MannaertsB . Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pretreatment. Human Reproduction2011;26(12):3413‐23. TavmergenE , vonMauw , WitjesH , MannaertsB . Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling. 25th Annual Meeting of ESHRE; 2009 28 Jun‐1 Jul; Amsterdam, the Netherlands. 2009. ">Nyboe Andersen 2011</a>; <a href="./references#CD006109-bbs2-0022" title="PorratiL , VilelaM , ViglierchioMI , ValcarcelA , LombardiE , MarconiG . Oral contraceptive pretreatment achieves better pregnancy rates in IVF antagonists GnRH flexible protocols: a prospective randomized study. Human Reproduction2010;25 Suppl 1(6):i102 Abstract no. O‐259. ">Porrati 2010</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>; <a href="./references#CD006109-bbs2-0026" title="ShakerAG , PittrofR , ZaidiJ , BekirJ , Kyei‐MensahA , TanSL . Administration of progestogens to hasten pituitary desensitization after the use of gonadotropin‐releasing hormone agonist in in vitro fertilization ‐ a prospective randomized study. Fertility and Sterility1995;64(4):791‐5. ">Shaker 1995</a>; <a href="./references#CD006109-bbs2-0029" title="YeH , HuangG‐N , ZengP‐H , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;26(2‐3):105‐11. ">Ye 2009</a>). In two studies, there was insufficient information in the 'Methods' sections to make a conclusive judgement with respect to selective reporting of outcomes; therefore, they were rated at unclear risk of reporting bias (<a href="./references#CD006109-bbs2-0023" title="RaoofiZ , AflatoonianA . Ovarian cysts formation during depot formulation of GnRH‐a therapy and the effect of pretreatment with oral contraceptive pills on subsequent implantation and pregnancy rate in ART cycles. Iranian Journal of Pharmaceutical Research2008;7(2):109‐13. ">Raoofi 2008</a>; <a href="./references#CD006109-bbs2-0028" title="VilelaM , MarconiM , ZappacostaMP , PorratiL , ValcarcelA , MarconiG . Oral contraceptive (OcP) pretreatment achieves better pregnancy rates in in vitro fertilisation (IVF) antagonists GnRH flexible protocols: a prospective randomised study. Fertility and Sterility2011; Vol. 96, issue 3 (supplement):S252, P‐492. ">Vilela 2011</a>). In the remaining 11 studies, there was evidence of selective reporting as data were not reported on all the outcomes pre‐specified in the protocol or Methods section. </p> </section> <section id="CD006109-sec-0085"> <h4 class="title">Other potential sources of bias</h4> <p>For other potential sources of bias, we examined the baseline demographic characteristics of participants, such as age and BMI, to determine whether there was substantial imbalance in baseline demographic characteristics between the treatment groups. In this regard, 22 studies were at low risk of bias in this domain because of the absence of substantial imbalance between in baseline demographic characteristics between the treatment groups (<a href="./references#CD006109-bbs2-0001" title="AstonK , ArthurI , MassonGM , JenkinsJM . Progestogen therapy and prevention of functional ovarian cysts during pituitary desensitisation with GnRH agonists. British Journal of Obstetrics and Gynaecology1995;102:835‐7. ">Aston 1995</a>; <a href="./references#CD006109-bbs2-0002" title="BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF . Prospective randomized trial on effect of pre‐treatment with an oral contraceptive (OC) on the length of time required for pituitary suppression by gonadotropin releasing hormone agonist (GnRH‐a) and subsequent implantation and pregnancy rates. Fertility and Sterility1998; Vol. Suppl 1, 70, issue 3:S133. BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF , TanSL . Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin‐releasing hormone analogues and on subsequent implantation and pregnancy rates. Fertility and Sterility1998;70(6):1063‐9. ">Biljan 1998b</a>; <a href="./references#CD006109-bbs2-0003" title="BlockeelC , EngelsS , deVosM , HaentjensP , PolyzosNP , StoopD , et al. Oestradiol valerate pretreatment in GnRH antagonist cycles: a randomised controlled trial. Reproductive Biomedicine Online2012;24:272‐80. ">Blockeel 2012</a>; <a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0005" title="Cédrin‐DurnerinI , Guivarc'h‐LevequeA , HuguesJ‐N . Pretreatment with estrogen does not affect IVF‐ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomised trial. Fertility and Sterility2012;97(6):1359‐64. ">Cédrin‐Durnerin 2012</a>; <a href="./references#CD006109-bbs2-0007" title="DitkoffEC , SauerMV . A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin‐releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Human Reproduction1996;11(5):1035‐7. ">Ditkoff 1996</a>; <a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>; <a href="./references#CD006109-bbs2-0009" title="FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol administration coordinates FSH‐induced follicular growth and improves the outcome of GnRH antagonist COH protocols. 19th Annual meeting of the ESHRE; 2003 Jun 29‐Jul 2; Madrid, Spain, 2003. 2003. FanchinR , SalomonL , Castelo‐BrancoA , OlivennesF , FrydmanN , FrydmanR . Luteal estradiol pre‐treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Human Reproduction2003;18(12):2698‐703. [DOI: 10.1093/humrep/deg516] ">Fanchin 2003</a>; <a href="./references#CD006109-bbs2-0010" title="FrancoJGJr , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH after 2nd phase protocols with GnRH analogs (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin) [Comparação da estimulação ovariana com FSH recombinante após protocolo de 2a fase com análogos do GnRH (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco Jr 2003</a>; <a href="./references#CD006109-bbs2-0011" title="Garcia‐VelascoJA , BermejoA , RuizF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility2011;96(3):590‐3. Garcia‐VelascoJA , BermejoA , Ruiz‐FloresF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial. Fertility and Sterility2010;94 Suppl 1(4):S28 Abstract no. O‐93. ">Garcia‐Velasco 2011</a>; <a href="./references#CD006109-bbs2-0012" title="HauzmanEE , ZapataA , BermejoA , IglesiasC , PellicerA , Garcia‐VelascoJ . Cycle scheduling for in vitro fertilisation with oral contraceptive pills versus oral estradiol valerate: a randomised controlled trial. Reproductive Biology and Endocrinology2013;11:96. ">Hauzman 2013</a>; <a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>; <a href="./references#CD006109-bbs2-0015" title="HuirneJA , HuguesJN , PirardC , FischlF , SageJC , PoulyJL , et al. Cetrorelix in an oral contraceptive‐pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r‐hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction2006;21(6):1408‐15. [DOI: 10.1093/humrep/de1030] ">Huirne 2006c</a>; <a href="./references#CD006109-bbs2-0016" title="HwangJL , SeowKM , LinYH , HuangLW , HsiehBC , TsaiYL , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. [DOI: 10.1093/humrep/deh375] ">Hwang 2004</a>; <a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a>; <a href="./references#CD006109-bbs2-0019" title="LukaszukK , LissJ , KunickiM , KuczynskiW , PastuszekE , JakielG , et al. Estradiol valerate pretreatment in short protocol GNRH‐agonist cycles versus combined pretreatment with oral contraceptive pills in long protocol GNRH‐agonist cycles: a randomised controlled trial. BioMed Research International2015;2015:1‐6. ">Lukaszuk 2015</a>; <a href="./references#CD006109-bbs2-0020" title="BroekmansJF , VerweijPJM , EijkemansMJC , MannaertsNMJL , WitjesH . Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(8):1688‐97. Nyboe AndersenA , WitjesH , GordonK , MannaertsB . Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pretreatment. Human Reproduction2011;26(12):3413‐23. TavmergenE , vonMauw , WitjesH , MannaertsB . Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling. 25th Annual Meeting of ESHRE; 2009 28 Jun‐1 Jul; Amsterdam, the Netherlands. 2009. ">Nyboe Andersen 2011</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>; <a href="./references#CD006109-bbs2-0025" title="Salat‐BarouxJ , AntoineJM , AlvarezS , CornetD , TibiC , MandelbaumJ , et al. Programmed ovulation induction and oocyte retrieval for in vitro fertilization. Journal of In Vitro Fertilization and Embryo Transfer1988;5(3):153‐7. ">Salat‐Baroux 1988</a>; <a href="./references#CD006109-bbs2-0026" title="ShakerAG , PittrofR , ZaidiJ , BekirJ , Kyei‐MensahA , TanSL . Administration of progestogens to hasten pituitary desensitization after the use of gonadotropin‐releasing hormone agonist in in vitro fertilization ‐ a prospective randomized study. Fertility and Sterility1995;64(4):791‐5. ">Shaker 1995</a>; <a href="./references#CD006109-bbs2-0029" title="YeH , HuangG‐N , ZengP‐H , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;26(2‐3):105‐11. ">Ye 2009</a>). </p> <p>The remaining seven studies were rated as being at unclear risk due to insufficient information to make a conclusive judgement with respect to baseline demographic characteristics in the treatment groups. </p> </section> </section> <section id="CD006109-sec-0086"> <h3 class="title" id="CD006109-sec-0086">Effects of interventions</h3> <p>See: <a href="./full#CD006109-tbl-0001"><b>Summary of findings for the main comparison</b> Combined oral contraceptive pill compared to no pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</a>; <a href="./full#CD006109-tbl-0002"><b>Summary of findings 2</b> Progestogen compared to placebo or no pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</a>; <a href="./full#CD006109-tbl-0003"><b>Summary of findings 3</b> Oestrogen compared to no pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</a> </p> <section id="CD006109-sec-0087"> <h4 class="title">1. Combined oral contraceptive pill versus no pretreatment</h4> <p>Eight studies compared COCP versus no pretreatment (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0011" title="Garcia‐VelascoJA , BermejoA , RuizF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility2011;96(3):590‐3. Garcia‐VelascoJA , BermejoA , Ruiz‐FloresF , Martinez‐SalazarJ , RequenaA , PellicerA . Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial. Fertility and Sterility2010;94 Suppl 1(4):S28 Abstract no. O‐93. ">Garcia‐Velasco 2011</a>; <a href="./references#CD006109-bbs2-0015" title="HuirneJA , HuguesJN , PirardC , FischlF , SageJC , PoulyJL , et al. Cetrorelix in an oral contraceptive‐pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r‐hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction2006;21(6):1408‐15. [DOI: 10.1093/humrep/de1030] ">Huirne 2006c</a>; <a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>; <a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a>; <a href="./references#CD006109-bbs2-0020" title="BroekmansJF , VerweijPJM , EijkemansMJC , MannaertsNMJL , WitjesH . Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(8):1688‐97. Nyboe AndersenA , WitjesH , GordonK , MannaertsB . Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pretreatment. Human Reproduction2011;26(12):3413‐23. TavmergenE , vonMauw , WitjesH , MannaertsB . Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling. 25th Annual Meeting of ESHRE; 2009 28 Jun‐1 Jul; Amsterdam, the Netherlands. 2009. ">Nyboe Andersen 2011</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>). </p> <section id="CD006109-sec-0088"> <h5 class="title">Primary outcomes</h5> </section> <section id="CD006109-sec-0089"> <h5 class="title">1.1. Live birth or ongoing pregnancy</h5> <p>See <a href="#CD006109-fig-0004">Figure 4</a> and <a href="./references#CD006109-fig-0008" title="">Analysis 1.1</a>. </p> <div class="figure" id="CD006109-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Combined oral contraceptive pill (OCP) versus no pretreatment (Rx), outcome: 1.1 Live birth or ongoing pregnancy." data-id="CD006109-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Combined oral contraceptive pill (OCP) versus no pretreatment (Rx), outcome: 1.1 Live birth or ongoing pregnancy. </p> </div> </div> </div> <section id="CD006109-sec-0090"> <h6 class="title">1.1.1. Combined oral contraceptive pill plus antagonist versus antagonist</h6> <p>There was a lower rate of live birth or ongoing pregnancy in women pretreated with COCP compared with no pretreatment (OR 0.74, 95% CI 0.58 to 0.95; 6 RCTs; 1335 women; I<sup>2</sup> = 0%; moderate quality evidence). The evidence suggested that if the chance of a live birth or ongoing pregnancy following no pretreatment was assumed to be 27%, the chance following pretreatment with COCP would be between 18% and 26%. </p> </section> <section id="CD006109-sec-0091"> <h6 class="title">1.1.2. Combined oral contraceptive pill plus antagonist versus agonist</h6> <p>There was no clear evidence of a difference between the two treatment groups in live birth or ongoing pregnancy rates (OR 0.89, 95% CI 0.64 to 1.25; 4 RCTs; 724 women; I<sup>2</sup> = 0%; moderate quality evidence). The evidence suggested that if the chance of a live birth or ongoing pregnancy following no pretreatment was assumed to be 24%, the chance following pretreatment with COCP would be between 16% and 26%. </p> </section> <section id="CD006109-sec-0092"> <h6 class="title">1.1.3. Combined oral contraceptive pill plus antagonist versus antagonist, low response</h6> <p>Among women with low response, there was insufficient evidence to determine whether there was a difference between the groups in live birth or ongoing pregnancy rates (OR 1.71, 95% CI 0.61 to 4.79; 1 RCT; 80 women). </p> </section> <section id="CD006109-sec-0093"> <h6 class="title">1.1.4. Combined oral contraceptive pill plus antagonist versus agonist, low response</h6> <p>Among women with low response, there was insufficient evidence to determine whether there was a difference between the two treatment groups in live birth or ongoing pregnancy rates (OR 1.13, 95% CI 0.43 to 2.98; 1 RCT; 80 women). </p> </section> </section> <section id="CD006109-sec-0094"> <h5 class="title">1.2. Pregnancy loss</h5> <p>See <a href="#CD006109-fig-0005">Figure 5</a> and <a href="./references#CD006109-fig-0009" title="">Analysis 1.2</a>. </p> <div class="figure" id="CD006109-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Combined oral contraceptive pill (COCP) versus no pretreatment (Rx), outcome: 1.2 Pregnancy loss." data-id="CD006109-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Combined oral contraceptive pill (COCP) versus no pretreatment (Rx), outcome: 1.2 Pregnancy loss. </p> </div> </div> </div> <section id="CD006109-sec-0095"> <h6 class="title">1.2.1. Combined oral contraceptive pill plus antagonist versus antagonist</h6> <p>There was no clear evidence of a difference between the groups in rates of pregnancy loss (OR 1.36, 95% CI 0.82 to 2.26; 5 RCTs; 868 women; I<sup>2</sup> = 0%; moderate quality evidence). The evidence suggested that if the risk of a pregnancy loss following no pretreatment was assumed to be 6%, the risk following pretreatment with COCP would be between 5% and 13%. </p> </section> <section id="CD006109-sec-0096"> <h6 class="title">1.2.2. Combined oral contraceptive pill plus antagonist versus agonist</h6> <p>There were fewer pregnancy losses recorded in women who had COCP pretreatment than in those who had no pretreatment (OR 0.40, 95% CI 0.22 to 0.72; 5 RCTs; 780 women; I<sup>2</sup> = 18%; moderate quality evidence). The evidence suggested that if the risk of a pregnancy loss following no pretreatment was assumed to be 10%, the risk following pretreatment with COCP would be between 3% and 8%. </p> </section> <section id="CD006109-sec-0097"> <h6 class="title">1.2.3. Combined oral contraceptive pill plus antagonist versus antagonist, low response</h6> <p>Among women with low response, there was insufficient evidence to determine whether there was a difference between the groups in rates of pregnancy loss (OR 2.05, 95% CI 0.18 to 23.59; 1 RCT; 80 women). </p> </section> <section id="CD006109-sec-0098"> <h6 class="title">1.2.4. Combined oral contraceptive pill plus antagonist versus agonist, low response</h6> <p>Among women with low response, there was insufficient evidence to determine whether there was a difference between the groups in rates of pregnancy loss (OR 1.00, 95% CI 0.13 to 7.47; 1 RCT; 80 women). </p> </section> </section> <section id="CD006109-sec-0099"> <h5 class="title">Secondary outcomes</h5> </section> <section id="CD006109-sec-0100"> <h5 class="title">1.3. Clinical pregnancy rate</h5> <p>See <a href="./references#CD006109-fig-0010" title="">Analysis 1.3</a>. </p> <section id="CD006109-sec-0101"> <h6 class="title">1.3.1. Combined oral contraceptive pill plus antagonist versus antagonist</h6> <p>There was no clear evidence of a difference between the two treatment groups in clinical pregnancy rates (OR 0.85, 95% CI 0.63 to 1.15; 5 RCTs; 740 women; I<sup>2</sup> = 76%). The presence of substantial heterogeneity was explored in sensitivity analysis and there was no change in the evidence using a random‐effects model (OR 0.86, 95% CI 0.39 to 1.91) or risk ratio (RR) (RR 0.90, 95% CI 0.73 to 1.11). </p> </section> <section id="CD006109-sec-0102"> <h6 class="title">1.3.2. Combined oral contraceptive pill plus antagonist versus agonist</h6> <p>There was no clear evidence of a difference between the two treatment groups in clinical pregnancy rates (OR 0.84, 95% CI 0.59 to 1.20; 4 RCTs; 546 women; I<sup>2</sup> = 0%). </p> </section> <section id="CD006109-sec-0103"> <h6 class="title">1.3.3. Combined oral contraceptive pill plus antagonist versus antagonist, low response</h6> <p>Among women with low response, there was insufficient evidence to determine whether there was a difference between the groups in rates of clinical pregnancy (OR 1.85, 95% CI 0.69 to 4.97; 1 RCT; 80 women). </p> </section> <section id="CD006109-sec-0104"> <h6 class="title">1.3.4. Combined oral contraceptive pill plus antagonist versus agonist, low response</h6> <p>Among women with low response, there was insufficient evidence to determine whether there was a difference between the groups in rates of clinical pregnancy (OR 1.12, 95% CI 0.44 to 2.83); 1 RCT; 80 women). </p> </section> <section id="CD006109-sec-0105"> <h6 class="title">1.3.5. Combined oral contraceptive pill plus agonist versus agonist</h6> <p>Two studies reported this comparison, but neither reported data suitable for analysis. One (<a href="./references#CD006109-bbs2-0002" title="BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF . Prospective randomized trial on effect of pre‐treatment with an oral contraceptive (OC) on the length of time required for pituitary suppression by gonadotropin releasing hormone agonist (GnRH‐a) and subsequent implantation and pregnancy rates. Fertility and Sterility1998; Vol. Suppl 1, 70, issue 3:S133. BiljanMM , MahutteNG , DeanN , HemmingsR , BissonnetteF , TanSL . Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin‐releasing hormone analogues and on subsequent implantation and pregnancy rates. Fertility and Sterility1998;70(6):1063‐9. ">Biljan 1998b</a>) reported per‐cycle data and found no evidence of a difference between the groups. A second study reported a pregnancy rate of 9% in the study group and 11% in the control group, but did not report the number of women per group (<a href="https://archie.cochrane.org/sections/documents/view?version=z1310230121512767760158845370374%26format=REVMAN#STD-Raoofi-2008" target="_blank">Raoofi 2008</a>). </p> </section> </section> <section id="CD006109-sec-0106"> <h5 class="title">1.4. Multiple pregnancy rate</h5> <p>See <a href="./references#CD006109-fig-0011" title="">Analysis 1.4</a>. </p> <section id="CD006109-sec-0107"> <h6 class="title">1.4.1. Combined oral contraceptive pill plus antagonist versus antagonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in multiple pregnancy rates (OR 2.21, 95% CI 0.53 to 9.26; 2 RCTs; 125 women; I<sup>2</sup> = 0%; low quality evidence). The evidence suggested that if the risk of multiple pregnancy following no pretreatment was assumed to be 5%, the risk following pretreatment with COCP would be between 3% and 31%. </p> </section> <section id="CD006109-sec-0108"> <h6 class="title">1.4.2. Combined oral contraceptive pill plus antagonist versus agonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in multiple pregnancy rates (OR 1.36, 95% CI 0.85 to 2.19; 4 RCTs; 546 women; I<sup>2</sup> = 0%; moderate quality evidence). The evidence suggested that if the risk of multiple pregnancy following no pretreatment was assumed to be 5%, the risk following pretreatment with COCP would be between 4% and 10%. </p> </section> <section id="CD006109-sec-0109"> <h6 class="title">1.4.3. Combined oral contraceptive pill plus antagonist versus antagonist, low response</h6> <p>Among women with low response, there was insufficient evidence to determine whether there was a difference between the groups in multiple pregnancy rate (OR 2.11, 95% CI 0.36 to 12.24; 1 RCT; 80 women). </p> </section> <section id="CD006109-sec-0110"> <h6 class="title">1.4.4. Combined oral contraceptive pill plus antagonist versus agonist, low response</h6> <p>Among women with low response, there was insufficient evidence to determine whether there was a difference between the groups in the multiple pregnancy rate (OR 1.37, 95% CI 0.29 to 6.56; 1 RCT; 80 women). </p> </section> </section> <section id="CD006109-sec-0111"> <h5 class="title">1.5. Ovarian hyperstimulation syndrome rate</h5> <p>See <a href="./references#CD006109-fig-0012" title="">Analysis 1.5</a>. </p> <section id="CD006109-sec-0112"> <h6 class="title">1.5.1. Combined oral contraceptive pill plus antagonist versus antagonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in OHSS rates (OR 0.98, 95% CI 0.28 to 3.40; 2 RCTs; 642 women; I<sup>2</sup> = 0%, low quality evidence). </p> </section> <section id="CD006109-sec-0113"> <h6 class="title">1.5.2. Combined oral contraceptive pill plus antagonist versus agonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in OHSS rates (OR 0.63, 95% CI 0.20 to 1.96; 2 RCTs; 290 women; I<sup>2</sup> = 0%, low quality evidence). </p> </section> </section> <section id="CD006109-sec-0114"> <h5 class="title">1.6. Number of oocytes retrieved</h5> <p>See <a href="./references#CD006109-fig-0013" title="">Analysis 1.6</a>. </p> <section id="CD006109-sec-0115"> <h6 class="title">1.6.1. Combined oral contraceptive pill plus antagonist versus antagonist</h6> <p>There was no clear evidence of a difference between the groups in the mean number of oocytes retrieved (MD 0.44, 95% CI ‐0.11 to 0.99; 6 RCTs; 1077 women; I<sup>2</sup> = 59%). </p> </section> <section id="CD006109-sec-0116"> <h6 class="title">1.6.2. Combined oral contraceptive pill plus antagonist versus agonist</h6> <p>There was no clear evidence of a difference between the two treatment groups in the mean number of oocytes retrieved (MD 0.07, 95% CI ‐0.67 to 0.81; 4 RCTs; 552 women; I<sup>2</sup> = 0%). </p> </section> <section id="CD006109-sec-0117"> <h6 class="title">1.6.3. Combined oral contraceptive pill plus antagonist versus antagonist, low response</h6> <p>Among women with low response, there was no clear evidence of a difference between the groups in the mean number of oocytes retrieved (MD 0.70, 95% CI ‐0.11 to 1.51; 1 RCT; 80 women). </p> </section> <section id="CD006109-sec-0118"> <h6 class="title">1.6.4. Combined oral contraceptive pill plus antagonist versus agonist, low response</h6> <p>Among women with low response, there was no evidence of a difference between the groups in the number of oocytes retrieved (MD 0.10, 95% CI ‐0.75 to 0.95; 1 RCT; 80 women). </p> </section> <section id="CD006109-sec-0119"> <h6 class="title">1.6.5. Combined oral contraceptive pill plus agonist versus agonist</h6> <p>Two studies looked at the number of oocytes retrieved, but the data were unsuitable for analysis. The first study reported a median of 11 oocytes retrieved (range seven to 19) in the study group (51 cycles) and a median of 10 oocytes retrieved (range seven to 15) in the control group (51 cycles) (<a href="https://archie.cochrane.org/sections/documents/view?version=z1508111100480486471830377071876%26format=REVMAN#STD-Biljan-1998a" target="_blank">Biljan 1998a</a>). The second study reported a mean number of oocytes retrieved of approximately 5 (± 3) in the study group and 5 (± 6) in the control group, but did not report the number of women or cycles in each treatment group (<a href="https://archie.cochrane.org/sections/documents/view?version=z1508111100480486471830377071876%26format=REVMAN#STD-Raoofi-2008" target="_blank">Raoofi 2008)</a>. </p> </section> </section> <section id="CD006109-sec-0120"> <h5 class="title">1.7. Days of gonadotrophin treatment</h5> <p>See <a href="./references#CD006109-fig-0014" title="">Analysis 1.7</a>. </p> <section id="CD006109-sec-0121"> <h6 class="title">1.7.1. Combined oral contraceptive pill plus antagonist versus antagonist</h6> <p>Six RCTs reported days of gonadotrophin treatment but data were unsuitable for pooling due to extreme statistical heterogeneity (I<sup>2</sup> = 95%) with differing directions of effect. </p> </section> <section id="CD006109-sec-0122"> <h6 class="title">1.7.2. Combined oral contraceptive pill plus antagonist versus agonist</h6> <p>Four RCTs reported days of gonadotrophin treatment but data were unsuitable for pooling due to extreme statistical heterogeneity (I<sup>2</sup> = 95%) with differing directions of effect. </p> </section> <section id="CD006109-sec-0123"> <h6 class="title">1.7.3. Combined oral contraceptive pill plus antagonist versus antagonist, low response</h6> <p>Among women with low response, there was no evidence of a difference between the groups in the mean days of gonadotrophin treatment (MD 0.10 days, 95% CI ‐0.47 to 0.67; 1 RCT; 80 women). </p> </section> <section id="CD006109-sec-0124"> <h6 class="title">1.7.4. Combined oral contraceptive pill plus antagonist versus agonist, low response</h6> <p>Among women with low response, the mean number of days of gonadotrophin treatment was lower in women who had COCP treatment than in women who received no COCP pretreatment (MD ‐1.40 days, 95% CI ‐2.02 to ‐0.78; 1 RCT; n = 80). </p> </section> <section id="CD006109-sec-0125"> <h6 class="title">1.7.5. Combined oral contraceptive pill plus agonist versus agonist</h6> <p>Only one study reported on the number of days of gonadotrophin treatment (<a href="https://archie.cochrane.org/sections/documents/view?version=z1508111100480486471830377071876%26format=REVMAN#STD-Biljan-1998a" target="_blank">Biljan 1998a</a>). This study found a median of 10 days (range nine to 11) in the study group (51 cycles) and a median of 12 days (range 11 to 12) in the control group (51 cycles). The data were unsuitable for analysis. </p> </section> </section> <section id="CD006109-sec-0126"> <h5 class="title">1.8. Amount of gonadotrophins administered</h5> <p>See <a href="./references#CD006109-fig-0015" title="">Analysis 1.8</a>. </p> <section id="CD006109-sec-0127"> <h6 class="title">1.8.1. Combined oral contraceptive pill plus antagonist versus antagonist</h6> <p>More gonadotrophins were administered to the group who received pretreatment with a COCP than in the group who did not (MD 190.10 IU/L, 95% CI 134.91 to 245.28; 7 RCTs; 1275 women; I<sup>2</sup> = 88%). Sensitivity analysis using a random‐effects model did not change the statistical significance of this finding (MD 306.84 IU/L, 95% CI 112.13 to 501.56). </p> </section> <section id="CD006109-sec-0128"> <h6 class="title">1.8.2. Combined oral contraceptive pill plus antagonist versus agonist</h6> <p>Three RCTs reported the amount of gonadotrophins but data were unsuitable for pooling due to extreme statistical heterogeneity (I<sup>2</sup> = 94%) with differing directions of effect. </p> </section> <section id="CD006109-sec-0129"> <h6 class="title">1.8.3. Combined oral contraceptive pill plus antagonist versus antagonist, low response</h6> <p>Among women with low response, there was no clear evidence of a difference between the two treatment groups in the mean amount of gonadotrophin administered (MD 20.00 IU/L, 95% CI ‐165.39 to 205.39; 1 RCT; 80 women). </p> </section> <section id="CD006109-sec-0130"> <h6 class="title">1.8.4. Combined oral contraceptive pill plus antagonist versus agonist, low response</h6> <p>Among women with low response, the mean amount of gonadotrophin administered in the COCP group was lower than in the group who were not pretreated (MD ‐349.00, 95% CI ‐537.92 to ‐160.08; 1 RCT; 80 women). </p> </section> </section> <section id="CD006109-sec-0131"> <h5 class="title">1.9. Ovarian cyst formation rate</h5> <section id="CD006109-sec-0132"> <h6 class="title">1.9.1. Combined oral contraceptive pill plus antagonist versus antagonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in the number of women with ovarian cyst formation (OR 0.47, 95% CI 0.08 to 2.75; 1 RCT; 64 women). </p> </section> <section id="CD006109-sec-0133"> <h6 class="title">1.9.2. Combined oral contraceptive pill plus agonist versus agonist</h6> <p>Two studies reported on cyst formation, but the data were unsuitable for analysis. The first study found that there was no cyst formation in the intervention group (51 cycles) and cysts in 27 women in the control group (51 cycles) (<a href="https://archie.cochrane.org/sections/documents/view?version=z1508111100480486471830377071876%26format=REVMAN#STD-Biljan-1998a" target="_blank">Biljan 1998a</a>). This result was statistically significant according to the authors (OR 0.07, 95% CI 0.03 to 0.16; P &lt; 0.0001). <a href="https://archie.cochrane.org/sections/documents/view?version=z1508111100480486471830377071876%26format=REVMAN#STD-Raoofi-2008" target="_blank">Raoofi 2008</a> reported no women with cyst formation in either group. </p> </section> </section> </section> <section id="CD006109-sec-0134"> <h4 class="title">2. Progestogen versus placebo or no pretreatment</h4> <p>Four studies compared progestogen versus placebo or no treatment (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0007" title="DitkoffEC , SauerMV . A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin‐releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Human Reproduction1996;11(5):1035‐7. ">Ditkoff 1996</a>; <a href="./references#CD006109-bbs2-0008" title="EngmannL , MaconochieN , BekirJ , TanSL . A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility1999;72(3, Suppl 1):S10‐1. EngmannL , MaconochieN , BekirJ , TanSL . Progestogen therapy during pituitary desensitization with gonadotropin‐releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology1999;181(3):576‐82. EngmannL , MaconochieN , TanSL , BekirJ . Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation ‐ a prospective randomized study. Human Fertility. 1999; Vol. 2:190‐1. ">Engmann 1999</a>; <a href="./references#CD006109-bbs2-0025" title="Salat‐BarouxJ , AntoineJM , AlvarezS , CornetD , TibiC , MandelbaumJ , et al. Programmed ovulation induction and oocyte retrieval for in vitro fertilization. Journal of In Vitro Fertilization and Embryo Transfer1988;5(3):153‐7. ">Salat‐Baroux 1988</a>). </p> <section id="CD006109-sec-0135"> <h5 class="title">Primary outcomes</h5> </section> <section id="CD006109-sec-0136"> <h5 class="title">2.1. Live birth or ongoing pregnancy</h5> <section id="CD006109-sec-0137"> <h6 class="title">2.1.1. Progestogen plus agonist versus agonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in live birth or ongoing pregnancy rates (OR 1.35, 95% CI 0.69 to 2.65; 2 RCTs; 222 women; I<sup>2</sup> = 24%; low quality evidence). The evidence suggested that if the chance of a live birth or ongoing pregnancy following placebo or no pretreatment was assumed to be 17%, the chance following pretreatment with progestogen would be between 12% and 35%. </p> </section> <section id="CD006109-sec-0138"> <h6 class="title">2.1.2. Progestogen plus antagonist versus antagonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in live birth or ongoing pregnancy rates (OR 0.67, 95% CI 0.18 to 2.54; 1 RCT; 47 women; low quality evidence). The evidence suggested that if the chance of a live birth or ongoing pregnancy following placebo or no pretreatment was assumed to be 25%, the chance following pretreatment with progestogen would be between 3% and 76%. </p> </section> <section id="CD006109-sec-0139"> <h6 class="title">2.1.3. Progestogen plus gonadotrophins versus gonadotrophins</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in live birth or ongoing pregnancy rates (OR 0.63, 95% CI 0.09 to 4.23; 1 RCT; 42 women). </p> </section> </section> <section id="CD006109-sec-0140"> <h5 class="title">2.2. Pregnancy loss</h5> <section id="CD006109-sec-0141"> <h6 class="title">2.2.1. Progestogen plus agonist versus agonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in rates of pregnancy loss (OR 2.26, 95% CI 0.67 to 7.55; 2 RCTs; 222 women; I<sup>2</sup> = 0%; low quality evidence). The evidence suggested that if the risk of a pregnancy loss following placebo or no pretreatment was assumed to be 4%, the risk following pretreatment with progestogen would be between 2% and 22%. </p> </section> <section id="CD006109-sec-0142"> <h6 class="title">2.2.2. Progestogen plus antagonist versus antagonist</h6> <p>The only study in this subgroup did not report on the number of pregnancy losses (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>), but we calculated this number by subtracting the number of live births from the number of clinical pregnancies. There was no evidence of a difference in rates of pregnancy losses between the two treatment groups (OR 0.36, 95% CI 0.06 to 2.09; 1 RCT; 47 women; low quality evidence). The evidence suggested that if the risk of a pregnancy loss following placebo or no pretreatment was assumed to be 25%, the risk following pretreatment with progestogen would be between 1% and 67%. </p> </section> <section id="CD006109-sec-0143"> <h6 class="title">2.2.3. Progestogen plus gonadotrophins versus gonadotrophins</h6> <p>The only trial in this subgroup found one pregnancy loss in each treatment group. Thus, there was insufficient evidence to determine whether there was a difference between the groups in rates of pregnancy loss (OR 1.00, 95% CI 0.06 to 17.12; 1 RCT; 42 women). </p> </section> </section> <section id="CD006109-sec-0144"> <h5 class="title">Secondary outcomes</h5> </section> <section id="CD006109-sec-0145"> <h5 class="title">2.3. Clinical pregnancy rate</h5> <section id="CD006109-sec-0146"> <h6 class="title">2.3.1. Progestogen plus agonist versus agonist</h6> <p>We pooled results of three studies. In one of these studies, we used the number of positive pregnancy tests, because there were no data on clinical pregnancy rate. There was evidence of a difference in clinical pregnancy rates between the two treatment groups, with more clinical pregnancies obtained in the group pretreated with a progestogen (OR 1.99, 95% CI 1.20 to 3.28; 3 RCTs; 374 women; I<sup>2</sup> = 0%). </p> </section> <section id="CD006109-sec-0147"> <h6 class="title">2.3.2. Progestogen plus antagonist versus antagonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in clinical pregnancy rates (OR 0.52, 95% CI 0.16 to 1.71; 1 RCT; 47 women). </p> </section> <section id="CD006109-sec-0148"> <h6 class="title">2.3.3. Progestogen plus gonadotrophins versus gonadotrophins</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in clinical pregnancy rates (OR 0.71, 95% CI 0.14 to 3.64; 1 RCT; 42 women). </p> </section> </section> <section id="CD006109-sec-0149"> <h5 class="title">2.4. Multiple pregnancy</h5> <section id="CD006109-sec-0150"> <h6 class="title">2.4.1. Progestogen plus antagonist versus antagonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in multiple pregnancy rates (OR 1.05, 95% CI 0.06 to 17.76; 1 RCT; 47 women; low quality evidence). </p> </section> </section> <section id="CD006109-sec-0151"> <h5 class="title">2.5. Ovarian hyperstimulation syndrome rate</h5> <p>None of the studies reported on the number of women with OHSS.</p> </section> <section id="CD006109-sec-0152"> <h5 class="title">2.6. Number of oocytes retrieved</h5> <section id="CD006109-sec-0153"> <h6 class="title">2.6.1. Progestogen plus agonist versus agonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in the mean number of oocytes retrieved (MD ‐0.52, 95% CI ‐2.07 to 1.02; 2 RCTs; 222 women; I<sup>2</sup> = 15%). There was one other study that reported the mean number of oocytes retrieved, but because this was analyzed per cycle (instead of per woman randomized), we were unable to include the data (<a href="./references#CD006109-bbs2-0026" title="ShakerAG , PittrofR , ZaidiJ , BekirJ , Kyei‐MensahA , TanSL . Administration of progestogens to hasten pituitary desensitization after the use of gonadotropin‐releasing hormone agonist in in vitro fertilization ‐ a prospective randomized study. Fertility and Sterility1995;64(4):791‐5. ">Shaker 1995</a>). </p> </section> <section id="CD006109-sec-0154"> <h6 class="title">2.6.2. Progestogen plus antagonist versus antagonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in the mean number of oocytes retrieved (MD 2.70, 95% CI ‐0.98 to 6.38; 1 RCT; 47 women). </p> </section> <section id="CD006109-sec-0155"> <h6 class="title">2.6.3. Progestogen plus gonadotrophins versus gonadotrophins</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in the mean number of oocytes retrieved (MD 0.00, 95% CI ‐0.57 to 0.57; 1 RCT; 29 women). </p> </section> </section> <section id="CD006109-sec-0156"> <h5 class="title">2.7. Days of gonadotrophin treatment</h5> <section id="CD006109-sec-0157"> <h6 class="title">2.7.1. Progestogen plus agonist versus agonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in the mean days of gonadotrophin treatment (MD 0.11 days, 95% CI ‐0.30 to 0.52; 2 RCTs; 222 women; I<sup>2</sup> = 88%). The presence of substantial heterogeneity was explored in sensitivity analysis using a random‐effects model and there was no substantial change in the evidence (MD 0.10, 95% CI ‐1.07 to 1.28). </p> </section> </section> <section id="CD006109-sec-0158"> <h5 class="title">2.8. Amount of gonadotrophins administered</h5> <section id="CD006109-sec-0159"> <h6 class="title">2.8.1. Progestogen plus antagonist versus antagonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in the amount of gonadotrophin administered (MD 276.00 IU/L, 95% CI ‐75.53 to 627.53; 1 RCT; 47 women). </p> </section> </section> <section id="CD006109-sec-0160"> <h5 class="title">2.9. Ovarian cyst formation rate</h5> <section id="CD006109-sec-0161"> <h6 class="title">2.9.1. Progestogen plus agonist versus agonist</h6> <p>Fewer women had ovarian cyst formation in the group pretreated with a progestogen compared with those who had no progestogen pretreatment (OR 0.16, 95% CI 0.08 to 0.32; 3 RCTs; 374 women; I<sup>2</sup> = 1%). </p> </section> </section> </section> <section id="CD006109-sec-0162"> <h4 class="title">3. Oestrogen versus no pretreatment</h4> <p>Four studies compared oestrogen versus no pretreatment (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0005" title="Cédrin‐DurnerinI , Guivarc'h‐LevequeA , HuguesJ‐N . Pretreatment with estrogen does not affect IVF‐ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomised trial. Fertility and Sterility2012;97(6):1359‐64. ">Cédrin‐Durnerin 2012</a>; <a href="./references#CD006109-bbs2-0010" title="FrancoJGJr , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH after 2nd phase protocols with GnRH analogs (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin) [Comparação da estimulação ovariana com FSH recombinante após protocolo de 2a fase com análogos do GnRH (I ‐ estradiol + Ganirelix versus II ‐ Nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco Jr 2003</a>; <a href="./references#CD006109-bbs2-0029" title="YeH , HuangG‐N , ZengP‐H , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;26(2‐3):105‐11. ">Ye 2009</a>). </p> <section id="CD006109-sec-0163"> <h5 class="title">Primary outcomes</h5> </section> <section id="CD006109-sec-0164"> <h5 class="title">3.1. Live birth or ongoing pregnancy</h5> <p>See <a href="#CD006109-fig-0006">Figure 6</a> and <a href="./references#CD006109-fig-0025" title="">Analysis 3.1</a>. </p> <div class="figure" id="CD006109-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Oestrogen versus no pretreatment (Rx), outcome: 3.1 Live birth or ongoing pregnancy." data-id="CD006109-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Oestrogen versus no pretreatment (Rx), outcome: 3.1 Live birth or ongoing pregnancy. </p> </div> </div> </div> <section id="CD006109-sec-0165"> <h6 class="title">3.1.1. Oestrogen plus antagonist versus antagonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in live birth or ongoing pregnancy rates (OR 0.79, 95% CI 0.53 to 1.17; 2 RCTs; 502 women; I<sup>2</sup> = 29%; low quality evidence). The evidence suggested that if the chance of a live birth or ongoing pregnancy following no pretreatment was assumed to be 30%, the chance following pretreatment with oestrogen would be between 19% and 35%. </p> </section> <section id="CD006109-sec-0166"> <h6 class="title">3.1.2. Oestrogen plus antagonist versus agonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in live birth or ongoing pregnancy rates (OR 0.88, 95% CI 0.51 to 1.50; 2 RCTs; 242 women; I<sup>2</sup> = 0%; very low quality evidence). The evidence suggested that if the chance of a live birth or ongoing pregnancy following no pretreatment was assumed to be 35%, the chance following pretreatment with progestogen would be between 22% and 45%. </p> </section> </section> <section id="CD006109-sec-0167"> <h5 class="title">3.2. Pregnancy loss</h5> <p>See <a href="#CD006109-fig-0007">Figure 7</a> and <a href="./references#CD006109-fig-0026" title="">Analysis 3.2</a>. </p> <div class="figure" id="CD006109-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Oestrogen versus no pretreatment (Rx), outcome: 3.2 Pregnancy loss." data-id="CD006109-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Oestrogen versus no pretreatment (Rx), outcome: 3.2 Pregnancy loss. </p> </div> </div> </div> <section id="CD006109-sec-0168"> <h6 class="title">3.2.1. Oestrogen plus antagonist versus antagonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in rates of pregnancy loss (OR 0.16, 95% CI 0.02 to 1.47; 1 RCT; 49 women; very low quality evidence). The evidence suggested that if the risk of a pregnancy loss following no pretreatment was assumed to be 13%, the risk following pretreatment with oestrogen would be between 1% and 71%. </p> </section> <section id="CD006109-sec-0169"> <h6 class="title">3.2.2. Oestrogen plus antagonist versus agonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in rates of pregnancy losses (OR 1.59, 95% CI 0.62 to 4.06; 1 RCT; 220 women; very low quality evidence). The evidence suggested that if the risk of a pregnancy loss following no pretreatment was assumed to be 7%, the risk following pretreatment with oestrogen would be between 5% and 24%. </p> </section> </section> <section id="CD006109-sec-0170"> <h5 class="title">Secondary outcomes</h5> </section> <section id="CD006109-sec-0171"> <h5 class="title">3.3. Clinical pregnancy rate</h5> <section id="CD006109-sec-0172"> <h6 class="title">3.3.1. Oestrogen plus antagonist versus antagonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in clinical pregnancy rates (OR 0.91, 95% CI 0.66 to 1.24; 4 RCTs; 688 women; I<sup>2</sup> = 50%). </p> </section> <section id="CD006109-sec-0173"> <h6 class="title">3.3.2. Oestrogen plus antagonist versus agonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in clinical pregnancy rates (OR 0.76, 95% CI 0.45 to 1.27; 2 RCTs; 242 women; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD006109-sec-0174"> <h5 class="title">3.4. Multiple pregnancy rate</h5> <section id="CD006109-sec-0175"> <h6 class="title">3.4.1. Oestrogen plus antagonist versus agonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in multiple pregnancy rates (OR 2.24, 95% CI 0.09 to 53.59; 1 RCT; 22 women; very low quality evidence). </p> </section> </section> <section id="CD006109-sec-0176"> <h5 class="title">3.5. Ovarian hyperstimulation syndrome rate</h5> <section id="CD006109-sec-0177"> <h6 class="title">3.5.1. Oestrogen plus antagonist versus agonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in OHSS rates (OR 1.54, 95% CI 0.25 to 9.42; 1 RCT; 220 women). </p> </section> </section> <section id="CD006109-sec-0178"> <h5 class="title">3.6. Number of oocytes retrieved</h5> <section id="CD006109-sec-0179"> <h6 class="title">3.6.1. Oestrogen plus antagonist versus antagonist</h6> <p>More oocytes were retrieved in the group pretreated with oestrogen than in the no pretreatment group (MD 2.23, 95% CI 0.71 to 3.75; 2 RCTs; 139 women; I<sup>2</sup> = 0%). </p> </section> <section id="CD006109-sec-0180"> <h6 class="title">3.6.2. Oestrogen plus antagonist versus agonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in the number of oocytes retrieved (MD 0.40, 95% CI ‐4.47 to 5.27; 1 RCT; 22 women). </p> </section> </section> <section id="CD006109-sec-0181"> <h5 class="title">3.7. Days of gonadotrophin treatment</h5> <section id="CD006109-sec-0182"> <h6 class="title">3.7.1. Oestrogen plus antagonist versus antagonist</h6> <p>Women who were pretreated with oestrogen had more days of gonadotrophin treatment compared to those who did not receive pretreatment (MD 0.83 days, 95% CI 0.58 to 1.08; 2 RCTs; 529 women; I<sup>2</sup> = 0%). </p> </section> <section id="CD006109-sec-0183"> <h6 class="title">3.7.2. Oestrogen plus antagonist versus agonist</h6> <p>Women pretreated with oestrogen had fewer days of gonadotrophin treatment than those who did not receive oestrogen pretreatment (MD ‐2.50 days, 95% CI ‐4.07 to ‐0.93; 1 RCT; 22 women). </p> </section> </section> <section id="CD006109-sec-0184"> <h5 class="title">3.8. Amount of gonadotrophins administered</h5> <section id="CD006109-sec-0185"> <h6 class="title">3.8.1. Oestrogen plus antagonist versus antagonist</h6> <p>There was a higher total dose of gonadotrophin administered to women who were pretreated with oestrogen than to those who did not receive pretreatment (MD 168.38 IU/L, 95% CI ; 3 RCTs; 111.53 to 225.17, 668 women; I<sup>2</sup> = 0%). </p> </section> <section id="CD006109-sec-0186"> <h6 class="title">3.8.2. Oestrogen plus antagonist versus agonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in the amount of gonadotrophin administered (MD ‐16.00 IU/L, 95% CI ‐470.12 to 438.12; 1 RCT; 22 women). </p> </section> </section> <section id="CD006109-sec-0187"> <h5 class="title">3.9. Ovarian cyst formation rate</h5> <p>None of the studies reported ovarian cyst formation.</p> </section> </section> <section id="CD006109-sec-0188"> <h4 class="title">4. Combined oral contraceptive pill versus progestogen</h4> <p>One trial compared COCP versus progestogen (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>). This trial used a GnRH antagonist in both treatment groups. </p> <section id="CD006109-sec-0189"> <h5 class="title">Primary outcomes</h5> </section> <section id="CD006109-sec-0190"> <h5 class="title">4.1. Live birth or ongoing pregnancy</h5> <section id="CD006109-sec-0191"> <h6 class="title">4.1.1. Combined oral contraceptive pill plus antagonist versus progestogen plus antagonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in live birth or ongoing pregnancy rates (OR 0.60, 95% CI 0.12 to 2.89; 1 RCT; 44 women; very low quality evidence). </p> </section> </section> <section id="CD006109-sec-0192"> <h5 class="title">4.2. Pregnancy loss</h5> <section id="CD006109-sec-0193"> <h6 class="title">4.2.1. Combined oral contraceptive pill plus antagonist versus progestogen plus antagonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in rates of pregnancy loss (OR 1.11, 95% CI 0.14 to 8.64; 1 RCT; 44 women) </p> </section> </section> <section id="CD006109-sec-0194"> <h5 class="title">Secondary outcomes</h5> </section> <section id="CD006109-sec-0195"> <h5 class="title">4.3. Clinical pregnancy rate</h5> <section id="CD006109-sec-0196"> <h6 class="title">4.3.1. Combined oral contraceptive pill plus antagonist versus progestogen plus antagonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in clinical pregnancy rates (OR 0.71, 95% CI 0.19 to 2.73; 1 RCT; 44 women). </p> </section> </section> <section id="CD006109-sec-0197"> <h5 class="title">4.4. Multiple pregnancy rate</h5> <section id="CD006109-sec-0198"> <h6 class="title">4.4.1. Combined oral contraceptive pill plus antagonist versus progestogen plus antagonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in multiple pregnancy rates (OR 2.32, 95% CI 0.19 to 27.59; 1 RCT; 44 women). </p> </section> </section> <section id="CD006109-sec-0199"> <h5 class="title">4.5. Ovarian hyperstimulation syndrome rate</h5> <p>None of the studies reported OHSS.</p> </section> <section id="CD006109-sec-0200"> <h5 class="title">4.6. Number of oocytes retrieved</h5> <section id="CD006109-sec-0201"> <h6 class="title">4.6.1. Combined oral contraceptive pill plus antagonist versus progestogen plus antagonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in the mean number of oocytes retrieved (MD 1.40, 95% CI ‐3.24 to 6.04; 1 RCT; 44 women). </p> </section> </section> <section id="CD006109-sec-0202"> <h5 class="title">4.7. Days of gonadotrophin treatment</h5> <p>None of the studies reported days of gonadotrophin treatment.</p> </section> <section id="CD006109-sec-0203"> <h5 class="title">4.8. Amount of gonadotrophins administered</h5> <section id="CD006109-sec-0204"> <h6 class="title">4.8.1. Combined oral contraceptive pill plus antagonist versus progestogen plus antagonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in the mean quantity of gonadotrophin administered (MD 164.00 IU/L, 95% CI ‐249.03 to 577.03; 1 RCT; 44 women). </p> </section> </section> <section id="CD006109-sec-0205"> <h5 class="title">4.9. Ovarian cyst formation rate</h5> <p>None of the studies reported ovarian cyst formation.</p> </section> </section> <section id="CD006109-sec-0206"> <h4 class="title">5. Combined oral contraceptive pill versus oestrogen</h4> <p>Three trials compared COCP versus oestrogen (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0006" title="DalyDC , DalyCL , MayoD , JacobsA . Oocyte recruitment in IVF patients with limited ovarian reserve (LOR), maximizing quality of oocytes and embryos. Fertility and Sterility2002; Vol. Suppl 1, 78, issue 3:S148‐9. ">Daly 2002</a>; <a href="./references#CD006109-bbs2-0012" title="HauzmanEE , ZapataA , BermejoA , IglesiasC , PellicerA , Garcia‐VelascoJ . Cycle scheduling for in vitro fertilisation with oral contraceptive pills versus oral estradiol valerate: a randomised controlled trial. Reproductive Biology and Endocrinology2013;11:96. ">Hauzman 2013</a>). </p> <section id="CD006109-sec-0207"> <h5 class="title">Primary outcomes</h5> </section> <section id="CD006109-sec-0208"> <h5 class="title">5.1. Live birth or ongoing pregnancy</h5> <section id="CD006109-sec-0209"> <h6 class="title">5.1.1. Combined oral contraceptive pill plus antagonist versus oestrogen plus antagonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in live birth or ongoing pregnancy rates (OR 1.11, 95% CI 0.54 to 2.29; 2 RCTs; 146 women; I<sup>2</sup> = 0%; very low quality evidence). This finding was sensitive to the choice of statistical model, and was no longer statistically significant when a sensitivity analysis was conducted to examine the effect of calculating the RR rather than OR (RR 0.15, 95% CI 0.02 to 1.08). </p> </section> <section id="CD006109-sec-0210"> <h6 class="title">5.1.2. Combined oral contraceptive pill plus agonist versus oestrogen plus antagonist</h6> <p>There was a lower rate of live birth or ongoing pregnancy in women pretreated with COCP than in those who received oestrogen pretreatment (OR 0.08, 95% CI 0.01 to 0.79; 1 RCT; 25 women; very low quality evidence). </p> </section> </section> <section id="CD006109-sec-0211"> <h5 class="title">5.2. Pregnancy loss</h5> <section id="CD006109-sec-0212"> <h6 class="title">5.2.1. Combined oral contraceptive pill plus agonist versus oestrogen plus antagonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in rates of pregnancy loss (OR 1.09, 95% CI 0.06 to 19.63; 1 RCT; 25 women; very low quality evidence). </p> </section> </section> <section id="CD006109-sec-0213"> <h5 class="title">Secondary outcomes</h5> </section> <section id="CD006109-sec-0214"> <h5 class="title">5.3. Clinical pregnancy rate</h5> <section id="CD006109-sec-0215"> <h6 class="title">5.3.1. Combined oral contraceptive pill plus antagonist versus oestrogen plus antagonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in rates of clinical pregnancy (OR 1.19, 95% CI 0.60 to 2.37; 2 RCTs; 146 women; I<sup>2</sup> = 0%). </p> </section> <section id="CD006109-sec-0216"> <h6 class="title">5.3.2. Combined oral contraceptive pill plus agonist versus oestrogen plus antagonist</h6> <p>There was a higher rate of clinical pregnancy in women pretreated with oestrogen than in those who received COCP pretreatment (OR 0.13, 95% CI 0.02 to 0.82; 1 RCT; 25 women). </p> </section> </section> <section id="CD006109-sec-0217"> <h5 class="title">5.4. Multiple pregnancy rate</h5> <section id="CD006109-sec-0218"> <h6 class="title">5.4.1. Combined oral contraceptive pill plus antagonist versus oestrogen plus antagonist</h6> <p>There were no data on multiple pregnancies.</p> </section> </section> <section id="CD006109-sec-0219"> <h5 class="title">5.5. Ovarian hyperstimulation syndrome rate</h5> <p>None of the studies reported OHSS.</p> </section> <section id="CD006109-sec-0220"> <h5 class="title">5.6. Number of oocytes retrieved</h5> <section id="CD006109-sec-0221"> <h6 class="title">5.6.1. Combined oral contraceptive pill plus antagonist versus oestrogen plus antagonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in the mean number of oocytes retrieved (MD 0.90, 95% CI ‐3.59 to 5.39; 1 RCT; 46 women). </p> </section> </section> <section id="CD006109-sec-0222"> <h5 class="title">5.7. Days of gonadotrophin treatment</h5> <section id="CD006109-sec-0223"> <h6 class="title">5.7.1. Combined oral contraceptive pill plus antagonist versus oestrogen plus antagonist</h6> <p>There was no clear evidence of a difference in the number of days of gonadotrophin treatment between the two treatment groups (MD ‐0.60 days, 95% CI ‐1.23 to 0.03; 1 RCT; 100 women). </p> </section> </section> <section id="CD006109-sec-0224"> <h5 class="title">5.8. Amount of gonadotrophins administered</h5> <section id="CD006109-sec-0225"> <h6 class="title">5.8.1. Combined oral contraceptive pill plus antagonist versus oestrogen plus antagonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in the amount of gonadotrophin administered (MD 181.56 IU/L, 95% CI ‐344.73 to 707.86; 2 RCTs; 146 women; I<sup>2</sup> = 59%). There was no change in the evidence on sensitivity analysis using a random‐effects model (MD 113.73 IU/L, 95% CI ‐383.62 to 611.08). </p> </section> </section> <section id="CD006109-sec-0226"> <h5 class="title">5.9. Ovarian cyst formation rate</h5> <p>None of the studies reported ovarian cyst formation.</p> </section> </section> <section id="CD006109-sec-0227"> <h4 class="title">6. Progestogen versus oestrogen</h4> <p>One trial compared progestogen versus oestrogen (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>). This trial used a GnRH antagonist in both treatment groups. </p> <section id="CD006109-sec-0228"> <h5 class="title">Primary outcomes</h5> </section> <section id="CD006109-sec-0229"> <h5 class="title">6.1. Live birth or ongoing pregnancy</h5> <section id="CD006109-sec-0230"> <h6 class="title">6.1.1. Progestogen plus antagonist versus oestrogen plus antagonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in rates of live birth or ongoing pregnancy (OR 2.04, 95% CI 0.43 to 9.70; 1 RCT; 48 women). </p> </section> </section> <section id="CD006109-sec-0231"> <h5 class="title">6.2. Pregnancy loss</h5> <section id="CD006109-sec-0232"> <h6 class="title">6.2.1. Progestogen plus antagonist versus oestrogen plus antagonist</h6> <p>There were no pregnancy losses (1 RCT; 48 women).</p> </section> </section> <section id="CD006109-sec-0233"> <h5 class="title">Secondary outcomes</h5> </section> <section id="CD006109-sec-0234"> <h5 class="title">6.3. Clinical pregnancy rate</h5> <section id="CD006109-sec-0235"> <h6 class="title">6.3.1. Progestogen plus antagonist versus oestrogen plus antagonist</h6> <p>There was no evidence of a difference in clinical pregnancy rates between the two treatment groups (OR 2.30, 95% CI 0.57 to 9.22; 1 RCT; 48 women). </p> </section> </section> <section id="CD006109-sec-0236"> <h5 class="title">6.4. Multiple pregnancy rate</h5> <p>There were no multiple pregnancies (1 RCT; 48 women).</p> </section> <section id="CD006109-sec-0237"> <h5 class="title">6.5. Ovarian hyperstimulation syndrome rate</h5> <p>The study did not report OHSS.</p> </section> <section id="CD006109-sec-0238"> <h5 class="title">6.6. Number of oocytes retrieved</h5> <section id="CD006109-sec-0239"> <h6 class="title">6.6.1. Progestogen plus antagonist versus oestrogen plus antagonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in the mean number of oocytes retrieved (MD ‐0.50, 95% CI ‐4.55 to 3.55; 1 RCT; 48 women). </p> </section> </section> <section id="CD006109-sec-0240"> <h5 class="title">6.7. Days of gonadotrophin treatment</h5> <p>The study did not report days of gonadotrophin treatment.</p> </section> <section id="CD006109-sec-0241"> <h5 class="title">6.8. Amount of gonadotrophins administered</h5> <section id="CD006109-sec-0242"> <h6 class="title">6.8.1. Progestogen plus antagonist versus oestrogen plus antagonist</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in the mean quantity of gonadotrophin administered (MD 310.00 IU/L, 95% CI ‐32.30 to 652.30; 1 RCT; 48 women). </p> </section> </section> <section id="CD006109-sec-0243"> <h5 class="title">6.9. Ovarian cyst formation rate</h5> <p>The study did not report ovarian cyst formation.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006109-sec-0244" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006109-sec-0244"></div> <section id="CD006109-sec-0245"> <h3 class="title" id="CD006109-sec-0245">Summary of main results</h3> <p>This is the second update of a Cochrane Review that aimed to determine whether pretreatment with a COCP, a progestogen or an oestrogen in ovarian stimulation protocols affects outcomes in subfertile couples undergoing any form of ART. The first update was conducted in 2009. </p> <section id="CD006109-sec-0246"> <h4 class="title">Combined oral contraceptive pill versus no pretreatment</h4> <p>When COCP was compared with no pretreatment in antagonist cycles, there was a lower rate of live births or ongoing pregnancies in the pretreatment group. However, there was no clear evidence of a difference between the two groups in the rates of pregnancy losses, ovarian cyst formation, multiple pregnancies and OHSS. </p> <p>When COCP in antagonist cycles was compared with no pretreatment in agonist cycles, there was no evidence of a difference between the two groups in rates of live births or ongoing pregnancies. With respect to adverse effects, there was a lower rate of pregnancy loss in the pretreatment group while there was no clear evidence of a difference between the two groups in rates of ovarian cyst formation, multiple pregnancy or OHSS. </p> </section> <section id="CD006109-sec-0247"> <h4 class="title">Progestogen versus no pretreatment</h4> <p>When progestogen was compared with no pretreatment, with the same type of cycle (antagonist, agonist or gonadotrophins) in both groups, there was no clear evidence of a difference between the groups in rates of live births or ongoing pregnancies, pregnancy losses or multiple pregnancies. However, there was a lower rate of ovarian cyst formation among the progestogen pretreatment group that used agonist cycles in both groups. </p> </section> <section id="CD006109-sec-0248"> <h4 class="title">Oestrogen versus no pretreatment</h4> <p>When oestrogen in antagonist cycles was compared with no pretreatment in either antagonist or agonist cycles, there was no clear evidence of a difference between the groups in rates of live births or ongoing pregnancies, or in rates of pregnancy loss, multiple pregnancy or OHSS. </p> </section> <section id="CD006109-sec-0249"> <h4 class="title">Head‐to‐head comparisons</h4> <p>We compared COCP with progestogen and oestrogen plus progestogen with oestrogen, in all cases with an antagonist cycle in both groups. We compared COCP in an agonist cycle with oestrogen in an antagonist cycle. The evidence was scant but there was no clear evidence of a difference between the groups in rates of live births or ongoing pregnancies or pregnancy losses or other adverse events except in the small study comparing COCP in an agonist cycle versus oestrogen in an antagonist cycle, which reported lower rates of live birth or ongoing pregnancy in women in the COCP group. </p> <p>Overall, the evidence was insufficient to conclude whether or not pretreatment with COCPs, progestogens or oestrogens in ovarian stimulation resulted in better fertility outcomes. More studies are required for evidence‐based decision making regarding ART protocols. Besides this, there are a few other important aspects to consider when deciding if a pretreatment with a COCP, a progestogen or an oestrogen should be given. First, a pretreatment with one of these drugs may result in a longer duration and a higher amount of gonadotrophin treatment with considerable financial implications. Second, a pretreatment with one of these drugs means the need for a longer duration of the IVF/ICSI cycle and this might be a burden to the woman. In addition, if pretreatment with COCP, progestogen or oestrogen is given, this should be clearly explained to the woman, because the need for OCPs might be difficult to understand for some women trying to get pregnant. </p> <p>Our finding that pretreatment with progestogen in agonist cycles has a positive effect on clinical pregnancy rates is surprising, since pretreatment with a COCP seems to yield lower clinical pregnancy rates. We also found that pretreatment with progestogen results in the formation of fewer ovarian cysts. This is important, since ovarian cysts have a negative effect on the pregnancy rate, because ART cycles have to be cancelled. However, only one study that used a COCP pretreatment reported on ovarian cyst formation and this study also found a substantial difference in favour of the COCP group. Unless more research is done on the underlying mechanism that could explain these effects, no implications for practice can be suggested. </p> <p>If it is confirmed that pretreatment with progestogens results in a better IVF/ICSI outcome, this could be clinically and financially important. The administration of progestogen is easy, appears to be safe for the woman and it is less expensive than COCP pretreatment. </p> </section> </section> <section id="CD006109-sec-0250"> <h3 class="title" id="CD006109-sec-0250">Overall completeness and applicability of evidence</h3> <p>Although we were able to include 29 studies across six comparisons, many did not report on the primary outcomes of live births or ongoing pregnancies and pregnancy loss. Using subgroups of different GnRH antagonist and agonist protocols also limited the ability to pool data. There were also limited data for many of the secondary outcomes and almost all the other adverse events. </p> <p>This review included women with PCOS, but there was only one study of 56 randomized women that included a diagnosis of PCOS (<a href="./references#CD006109-bbs2-0016" title="HwangJL , SeowKM , LinYH , HuangLW , HsiehBC , TsaiYL , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. [DOI: 10.1093/humrep/deh375] ">Hwang 2004</a>). Eleven other studies used PCOS or ovarian cysts as an exclusion criteria. These studies randomized 2012 women, so almost half of all the women in this review were not diagnosed with PCOS. Because of the small proportion of women with PCOS included in this review, results might be less applicable to this group of women. </p> <p>With regard to poor responders, only one of the included studies used poor response to ovarian stimulation as an inclusion criterion in 120 women (<a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>). Therefore, the outcomes of this review might not be applicable to women with a history of poor response to controlled ovarian stimulation. </p> <p>In this review, we included 29 studies with 4701 women. These studies were included in six main comparisons each comprising different subgroups. However, most of the subgroups were reported in single trials. Also, some of the review's outcome measures were not reported in some of the comparisons because of the few number of studies in each subgroup. Thus reaching a robust conclusion regarding the objective of this review was difficult. </p> </section> <section id="CD006109-sec-0251"> <h3 class="title" id="CD006109-sec-0251">Quality of the evidence</h3> <p>The overall quality of the evidence for the main outcomes ranged from very low to moderate. The main limitations of the evidence were risk of bias (associated with poor reporting of study methods) and imprecision. Most of the studies did not describe their methods in adequate detail and many were at high or unclear risk of attrition bias or selective reporting. In several cases, important clinical outcomes or usable data were not reported. </p> </section> <section id="CD006109-sec-0252"> <h3 class="title" id="CD006109-sec-0252">Potential biases in the review process</h3> <p>A strength of this review was the grouping of the studies into subgroups regarding the type of agent used for downregulation (GnRH agonist or antagonist). Nonetheless, there was still some substantial heterogeneity in a few of the statistically significant outcomes, such as the number of days of gonadotrophin administration, but this may be explained by differences in treatment protocols between studies. The combination of live birth and ongoing pregnancy as a single outcome might have given the impression of higher live birth rates than the actual results, as some ongoing pregnancies could have ended in late abortion or intrauterine foetal death. However, there was no presence of significant heterogeneity between studies involved in such combinations. </p> <p>Furthermore, we were unable to construct a funnel plot, due to the small number of studies in each subgroup. Therefore, we could not examine if publication bias was present. </p> </section> <section id="CD006109-sec-0253"> <h3 class="title" id="CD006109-sec-0253">Agreements and disagreements with other studies or reviews</h3> <p>To our knowledge, there is one systematic review on COCP pretreatment available (<a href="./references#CD006109-bbs2-0130" title="GriesingerG , VenetisCA , MarxT , DiedrichK , TarlatzisBC , KolibianakisEM . Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta‐analysis. Fertility and Sterility2008;90(4):1055‐63. [DOI: 10.1016/j.fertnstert.2007.07.1354] ">Griesinger 2008</a>). The review investigated the effect of COCP pretreatment in a GnRH antagonist cycle versus no pretreatment, and included four studies (<a href="./references#CD006109-bbs2-0004" title="Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , DecanterC , et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre‐treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction2007;22(1):109‐16. [DOI: 10.1093/humrep/de1340] HuguesJN , Cédrin‐DurnerinI , BständigB , ParneixI , Bied‐DamonV , AvrilC , et al. Consequences of different steroid pre‐treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19‐22; Copenhagen, Denmark. 2005. ">Cédrin‐Durnerin 2007</a>; <a href="./references#CD006109-bbs2-0014" title="HuirneJAF , vanLoenenACD , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. VanLoenenACD , HuirneJAF , SchatsR , DonnezJ , LambalkCB . An open‐label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH‐antagonist in patients undergoing ART (IVF‐ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144‐5. ">Huirne 2006a</a>; <a href="./references#CD006109-bbs2-0018" title="KolibianakisEM , AlbanoC , TournayeH , CamusM , VanSteirteghemA , DevroeyP . Pre‐treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec‐FSH and GnRH antagonists. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S67. KolibianakisEM , PapanikolaouEG , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction2006;21(2):352‐7. [DOI: 10.1093/humrep/dei348] ">Kolibianakis 2006</a>; <a href="./references#CD006109-bbs2-0024" title="RombautsL , HealyD , NormanRJ , SpeirsA , WatkinsB , YovichJ , et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction2006;21(1):95‐103. [DOI: 10.1093/humrep/dei302] ">Rombauts 2006</a>). All of these studies are also included in our review, but we have included two more studies .<a href="./references#CD006109-bbs2-0017" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐J , AhnJ‐W , LeeJ‐I , KimS‐H , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD006109-bbs2-0021" title="ObrucaA , FischlF , HuberJ . Programming oocyte retrieval using oral contraceptive pretreatment before ovarian stimulation with a GnRH antagonist (Cetrotide) protocol. Human Reproduction. 2002; Vol. 17 Abstract Book 1:89. ">Obruca 2002</a>). Due to a lack of data, despite contacting the author, or differences in treatment protocols, we were unable to pool their results. Because the systematic review of Dr Griesinger included the same studies and investigated almost the same outcomes, it is not surprising that we reach the same conclusions. In his review, Dr Griesinger found no significant effects on ongoing pregnancies. Also, he found a significant difference in favour of the control group with regard to the number of days and amount of gonadotrophin administration. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006109-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD006109-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/full#CD006109-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD006109-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/full#CD006109-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Study PRISMA flow chart" data-id="CD006109-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Study PRISMA flow chart</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/full#CD006109-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Combined oral contraceptive pill (OCP) versus no pretreatment (Rx), outcome: 1.1 Live birth or ongoing pregnancy." data-id="CD006109-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Combined oral contraceptive pill (OCP) versus no pretreatment (Rx), outcome: 1.1 Live birth or ongoing pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/full#CD006109-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Combined oral contraceptive pill (COCP) versus no pretreatment (Rx), outcome: 1.2 Pregnancy loss." data-id="CD006109-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Combined oral contraceptive pill (COCP) versus no pretreatment (Rx), outcome: 1.2 Pregnancy loss. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/full#CD006109-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Oestrogen versus no pretreatment (Rx), outcome: 3.1 Live birth or ongoing pregnancy." data-id="CD006109-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Oestrogen versus no pretreatment (Rx), outcome: 3.1 Live birth or ongoing pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/full#CD006109-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Oestrogen versus no pretreatment (Rx), outcome: 3.2 Pregnancy loss." data-id="CD006109-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Oestrogen versus no pretreatment (Rx), outcome: 3.2 Pregnancy loss. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/full#CD006109-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Combined oral contraceptive pill (COCP) versus no pretreatment (Rx), Outcome 1 Live birth or ongoing pregnancy." data-id="CD006109-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Combined oral contraceptive pill (COCP) versus no pretreatment (Rx), Outcome 1 Live birth or ongoing pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Combined oral contraceptive pill (COCP) versus no pretreatment (Rx), Outcome 2 Pregnancy loss." data-id="CD006109-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Combined oral contraceptive pill (COCP) versus no pretreatment (Rx), Outcome 2 Pregnancy loss. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Combined oral contraceptive pill (COCP) versus no pretreatment (Rx), Outcome 3 Clinical pregnancy rate." data-id="CD006109-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Combined oral contraceptive pill (COCP) versus no pretreatment (Rx), Outcome 3 Clinical pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Combined oral contraceptive pill (COCP) versus no pretreatment (Rx), Outcome 4 Multiple pregnancy rate." data-id="CD006109-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Combined oral contraceptive pill (COCP) versus no pretreatment (Rx), Outcome 4 Multiple pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Combined oral contraceptive pill (COCP) versus no pretreatment (Rx), Outcome 5 Ovarian hyperstimulation syndrome rate." data-id="CD006109-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Combined oral contraceptive pill (COCP) versus no pretreatment (Rx), Outcome 5 Ovarian hyperstimulation syndrome rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Combined oral contraceptive pill (COCP) versus no pretreatment (Rx), Outcome 6 Number of oocytes retrieved." data-id="CD006109-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Combined oral contraceptive pill (COCP) versus no pretreatment (Rx), Outcome 6 Number of oocytes retrieved. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Combined oral contraceptive pill (COCP) versus no pretreatment (Rx), Outcome 7 Days of gonadotrophin treatment." data-id="CD006109-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Combined oral contraceptive pill (COCP) versus no pretreatment (Rx), Outcome 7 Days of gonadotrophin treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Combined oral contraceptive pill (COCP) versus no pretreatment (Rx), Outcome 8 Amount of gonadotrophins administered." data-id="CD006109-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Combined oral contraceptive pill (COCP) versus no pretreatment (Rx), Outcome 8 Amount of gonadotrophins administered. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Combined oral contraceptive pill (COCP) versus no pretreatment (Rx), Outcome 9 Ovarian cyst formation rate." data-id="CD006109-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Combined oral contraceptive pill (COCP) versus no pretreatment (Rx), Outcome 9 Ovarian cyst formation rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Progestogen versus placebo/no pretreatment (Rx), Outcome 1 Live birth or ongoing pregnancy." data-id="CD006109-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Progestogen versus placebo/no pretreatment (Rx), Outcome 1 Live birth or ongoing pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Progestogen versus placebo/no pretreatment (Rx), Outcome 2 Pregnancy loss." data-id="CD006109-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Progestogen versus placebo/no pretreatment (Rx), Outcome 2 Pregnancy loss. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Progestogen versus placebo/no pretreatment (Rx), Outcome 3 Clinical pregnancy rate." data-id="CD006109-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Progestogen versus placebo/no pretreatment (Rx), Outcome 3 Clinical pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Progestogen versus placebo/no pretreatment (Rx), Outcome 4 Multiple pregnancy rate." data-id="CD006109-fig-0020" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Progestogen versus placebo/no pretreatment (Rx), Outcome 4 Multiple pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Progestogen versus placebo/no pretreatment (Rx), Outcome 5 Number of oocytes retrieved." data-id="CD006109-fig-0021" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Progestogen versus placebo/no pretreatment (Rx), Outcome 5 Number of oocytes retrieved. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Progestogen versus placebo/no pretreatment (Rx), Outcome 6 Days of gonadotrophin treatment." data-id="CD006109-fig-0022" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Progestogen versus placebo/no pretreatment (Rx), Outcome 6 Days of gonadotrophin treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Progestogen versus placebo/no pretreatment (Rx), Outcome 7 Amount of gonadotrophins administered." data-id="CD006109-fig-0023" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Progestogen versus placebo/no pretreatment (Rx), Outcome 7 Amount of gonadotrophins administered. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Progestogen versus placebo/no pretreatment (Rx), Outcome 8 Ovarian cyst formation rate." data-id="CD006109-fig-0024" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Progestogen versus placebo/no pretreatment (Rx), Outcome 8 Ovarian cyst formation rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-003-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oestrogen versus no pretreatment (Rx), Outcome 1 Live birth or ongoing pregnancy." data-id="CD006109-fig-0025" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Oestrogen versus no pretreatment (Rx), Outcome 1 Live birth or ongoing pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-003-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oestrogen versus no pretreatment (Rx), Outcome 2 Pregnancy loss." data-id="CD006109-fig-0026" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Oestrogen versus no pretreatment (Rx), Outcome 2 Pregnancy loss.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oestrogen versus no pretreatment (Rx), Outcome 3 Clinical pregnancy rate." data-id="CD006109-fig-0027" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Oestrogen versus no pretreatment (Rx), Outcome 3 Clinical pregnancy rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oestrogen versus no pretreatment (Rx), Outcome 4 Multiple pregnancies." data-id="CD006109-fig-0028" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Oestrogen versus no pretreatment (Rx), Outcome 4 Multiple pregnancies.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oestrogen versus no pretreatment (Rx), Outcome 5 Ovarian hyperstimulation syndrome rate." data-id="CD006109-fig-0029" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Oestrogen versus no pretreatment (Rx), Outcome 5 Ovarian hyperstimulation syndrome rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oestrogen versus no pretreatment (Rx), Outcome 6 Number of oocytes retrieved." data-id="CD006109-fig-0030" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Oestrogen versus no pretreatment (Rx), Outcome 6 Number of oocytes retrieved.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oestrogen versus no pretreatment (Rx), Outcome 7 Days of gonadotrophin treatment." data-id="CD006109-fig-0031" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Oestrogen versus no pretreatment (Rx), Outcome 7 Days of gonadotrophin treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oestrogen versus no pretreatment (Rx), Outcome 8 Amount of gonadotrophins administered." data-id="CD006109-fig-0032" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Oestrogen versus no pretreatment (Rx), Outcome 8 Amount of gonadotrophins administered. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Combined oral contraceptive pill (COCP) versus progestogen, Outcome 1 Live birth or ongoing pregnancy." data-id="CD006109-fig-0033" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Combined oral contraceptive pill (COCP) versus progestogen, Outcome 1 Live birth or ongoing pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Combined oral contraceptive pill (COCP) versus progestogen, Outcome 2 Pregnancy loss." data-id="CD006109-fig-0034" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Combined oral contraceptive pill (COCP) versus progestogen, Outcome 2 Pregnancy loss. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Combined oral contraceptive pill (COCP) versus progestogen, Outcome 3 Clinical pregnancy rate." data-id="CD006109-fig-0035" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Combined oral contraceptive pill (COCP) versus progestogen, Outcome 3 Clinical pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Combined oral contraceptive pill (COCP) versus progestogen, Outcome 4 Multiple pregnancy rate." data-id="CD006109-fig-0036" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Combined oral contraceptive pill (COCP) versus progestogen, Outcome 4 Multiple pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Combined oral contraceptive pill (COCP) versus progestogen, Outcome 5 Number of oocytes retrieved." data-id="CD006109-fig-0037" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Combined oral contraceptive pill (COCP) versus progestogen, Outcome 5 Number of oocytes retrieved. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Combined oral contraceptive pill (COCP) versus progestogen, Outcome 6 Amount of gonadotrophins administered." data-id="CD006109-fig-0038" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Combined oral contraceptive pill (COCP) versus progestogen, Outcome 6 Amount of gonadotrophins administered. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Combined oral contraceptive pill (COCP) versus oestrogen (Oestr), Outcome 1 Live birth or ongoing pregnancy." data-id="CD006109-fig-0039" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Combined oral contraceptive pill (COCP) versus oestrogen (Oestr), Outcome 1 Live birth or ongoing pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Combined oral contraceptive pill (COCP) versus oestrogen (Oestr), Outcome 2 Pregnancy loss." data-id="CD006109-fig-0040" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Combined oral contraceptive pill (COCP) versus oestrogen (Oestr), Outcome 2 Pregnancy loss. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Combined oral contraceptive pill (COCP) versus oestrogen (Oestr), Outcome 3 Clinical pregnancy rate." data-id="CD006109-fig-0041" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Combined oral contraceptive pill (COCP) versus oestrogen (Oestr), Outcome 3 Clinical pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Combined oral contraceptive pill (COCP) versus oestrogen (Oestr), Outcome 4 Number of oocytes retrieved." data-id="CD006109-fig-0042" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Combined oral contraceptive pill (COCP) versus oestrogen (Oestr), Outcome 4 Number of oocytes retrieved. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Combined oral contraceptive pill (COCP) versus oestrogen (Oestr), Outcome 5 Days of gonadotropin treatment." data-id="CD006109-fig-0043" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Combined oral contraceptive pill (COCP) versus oestrogen (Oestr), Outcome 5 Days of gonadotropin treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Combined oral contraceptive pill (COCP) versus oestrogen (Oestr), Outcome 6 Amount of gonadotrophins administered." data-id="CD006109-fig-0044" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Combined oral contraceptive pill (COCP) versus oestrogen (Oestr), Outcome 6 Amount of gonadotrophins administered. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progestogen (Prog) versus oestrogen (Oestr), Outcome 1 Live birth or ongoing pregnancy." data-id="CD006109-fig-0045" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Progestogen (Prog) versus oestrogen (Oestr), Outcome 1 Live birth or ongoing pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progestogen (Prog) versus oestrogen (Oestr), Outcome 2 Clinical pregnancy rate." data-id="CD006109-fig-0046" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Progestogen (Prog) versus oestrogen (Oestr), Outcome 2 Clinical pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progestogen (Prog) versus oestrogen (Oestr), Outcome 3 Number of oocytes retrieved." data-id="CD006109-fig-0047" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Progestogen (Prog) versus oestrogen (Oestr), Outcome 3 Number of oocytes retrieved. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006109-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/urn:x-wiley:14651858:media:CD006109:CD006109-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_t/tCD006109-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progestogen (Prog) versus oestrogen (Oestr), Outcome 4 Amount of gonadotrophins administered." data-id="CD006109-fig-0048" src="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Progestogen (Prog) versus oestrogen (Oestr), Outcome 4 Amount of gonadotrophins administered. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/media/CDSR/CD006109/image_n/nCD006109-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006109-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Combined oral contraceptive pill compared to no pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Combined oral contraceptive pill compared to no pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> women undergoing ART </p> <p><b>Settings:</b> ART clinic </p> <p><b>Intervention:</b> COCP </p> <p><b>Comparison:</b> no pretreatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk<sup>1</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> No pretreatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> COCP</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth or ongoing pregnancy</b> </p> <p><b>(COCP + Ant vs Ant)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>270 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>215 per 1000</b> <br/> (177 to 260) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.74</b> <br/> (0.58 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1335<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth or ongoing pregnancy</b> </p> <p><b>(COCP + Ant vs Ag)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>296 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>273 per 1000</b> <br/> (212 to 345) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.89</b> <br/> (0.64 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>724<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pregnancy loss</b> </p> <p><b>(COCP + Ant vs Ant)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>64 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>85 per 1000</b> <br/> (53 to 134) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.36</b> <br/> (0.82 to 2.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>868<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pregnancy loss</b> </p> <p><b>(COCP + Ant vs Ag)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>103 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b> <br/> (25 to 76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.40</b> <br/> (0.22 to 0.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>780<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Multiple pregnancy rate (COCP + Ant vs Ant)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>98 per 1000</b> <br/> (25 to 313) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 2.21</b> <br/> (0.53 to 9.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>125<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Multiple pregnancy rate (COCP + Ant vs Ag)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>147 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>189 per 1000</b> <br/> (127 to 273) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.36</b> <br/> (0.85 to 2.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>546<br/> (4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OHSS rate</b> </p> <p><b>(COCP + Ant vs Ant)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>16 per 1000</b> </p> <p>(4 to 52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.98</b> </p> <p>(0.28 to 3.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>642</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OHSS rate</b> </p> <p><b>(COCP + Ant vs Ag)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>35 per 1000</b> </p> <p>(11 to 102)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.63</b> </p> <p>(0.20 to 1.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>290</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Ag:</b> agonist; <b>Ant:</b> antagonist; <b>ART:</b> assisted reproductive techniques; <b>COCP:</b> combined oral contraceptive pill; <b>CI:</b> confidence interval; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Mean baseline risk of control group.<br/> <sup>2</sup> Downgraded one level for serious risk of bias due to poor reporting of sequence generation and allocation concealment.<br/> <sup>3</sup> Downgraded one level for serious imprecision: effect estimate with wide confidence intervals or low event rate (or both).<br/> <sup>4</sup> Downgraded two levels for very serious imprecision: small sample size or very low event rate, and effect estimate with wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Combined oral contraceptive pill compared to no pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/full#CD006109-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006109-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Progestogen compared to placebo or no pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Progestogen compared to placebo or no pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> ovarian stimulation protocols for women undergoing ART </p> <p><b>Settings:</b> </p> <p><b>Intervention:</b> progestogen </p> <p><b>Comparison:</b> placebo or no pretreatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk<sup>1</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo or no pretreatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Prog</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth or ongoing pregnancy</b> </p> <p><b>(Prog + Ag vs Ag)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>170 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>217 per 1000</b> <br/> (124 to 352) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.35</b> <br/> (0.69 to 2.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>222<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth or ongoing pregnancy (Prog + Ant vs Ant)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>292 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>217 per 1000</b> <br/> (69 to 512) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.67</b> <br/> (0.18 to 2.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pregnancy loss</b> </p> <p><b>(Prog + Ag vs Ag)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b> <br/> (24 to 220) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.26</b> <br/> (0.67 to 7.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>222<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pregnancy loss</b> </p> <p><b>(Prog + Ant vs Ant)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>208 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>86 per 1000</b> <br/> (16 to 354) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.36</b> <br/> (0.06 to 2.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Multiple pregnancy rate</b> </p> <p><b>(Prog + Ag vs Ag)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Multiple pregnancy rate</b> </p> <p><b>(Prog + Ant vs Ant)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>42 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>44 per 1000</b> <br/> (3 to 438) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.05</b> <br/> (0.06 to 17.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OHSS rate</b> </p> <p><b>(Prog + Ag vs Ag)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OHSS rate</b> </p> <p><b>(Prog + Ant vs Ant)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Ag:</b> agonist; <b>Ant:</b> antagonist; <b>ART:</b> assisted reproductive techniques; <b>CI:</b> confidence interval; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>OR:</b> odds ratio; <b>Prog:</b> progestogen. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Mean baseline risk of control group.<br/> <sup>2</sup> Downgraded two levels for very serious imprecision: small sample size and effect estimate with wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Progestogen compared to placebo or no pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/full#CD006109-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006109-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oestrogen compared to no pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Oestrogen<b>compared to no p</b> retreat<b>ment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> ovarian stimulation protocols for women undergoing ART </p> <p><b>Settings:</b> </p> <p><b>Intervention:</b> oestrogen </p> <p><b>Comparison:</b> no pretreatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk<sup>1</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> No pretreatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Oestr</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth or ongoing pregnancy</b> </p> <p><b>(Oestr + Ant vs Ant)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>299 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>252 per 1000</b> <br/> (184 to 333) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.79</b> <br/> (0.53 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>502<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth or ongoing pregnancy</b> </p> <p><b>(Oestr + Ant vs Ag)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>350 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>322 per 1000</b> <br/> (215 to 447) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.88</b> <br/> (0.51 to 1.5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>242<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pregnancy loss</b> </p> <p><b>(Oestr + Ant vs Ant)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>208 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> <br/> (5 to 279) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.16</b> <br/> (0.02 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pregnancy loss</b> </p> <p><b>(Oestr + Ant vs Ag)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>72 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>110 per 1000</b> <br/> (46 to 240) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.59</b> <br/> (0.62 to 4.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Multiple pregnancy rate</b> </p> <p><b>(Oestr + Ant vs Ant)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Multiple pregnancy rate</b> </p> <p><b>(Oestr + Ant vs Ag)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not calculable ‐ see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 2.24</b> <br/> (0.09 to 53.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 2 events (both in oestrogen group)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OHSS rate</b> </p> <p><b>(Oestr + Ant vs Ant)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OHSS rate</b> </p> <p><b>(Oestr + Ant vs Ag)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>18 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>27 per 1000</p> <p>(5 to 147)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.54</p> <p>(0.25 to 9.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>220</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Ag:</b> agonist; <b>Ant:</b> antagonist; <b>ART:</b> assisted reproductive techniques; <b>CI:</b> confidence interval; <b>Oestr:</b> oestrogen; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Mean baseline risk of control group.<br/> <sup>2</sup> Downgraded one level for serious imprecision: effect estimate with wide confidence intervals.<br/> <sup>3</sup> Downgraded one level for serious risk of bias due to poor reporting on allocation concealment or high attrition (or both).<br/> <sup>4</sup> Downgraded two levels for very serious imprecision: small sample size and effect estimate with wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oestrogen compared to no pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/full#CD006109-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006109-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Combined oral contraceptive pill (COCP) versus no pretreatment (Rx)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth or ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 COCP + antagonist (Ant) vs Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.58, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 COCP + Ant vs agonist (Ag)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.64, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 COCP + Ant vs Ant, low response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.61, 4.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 COCP + Ant vs Ag, low response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.43, 2.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Pregnancy loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 COCP + Ant vs Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>868</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.82, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 COCP + Ant vs Ag</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.22, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 COCP + Ant vs Ant, low response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [0.18, 23.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 COCP + Ant vs Ag, low response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.13, 7.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinical pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 COCP + Ant vs Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.63, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 COCP + Ant vs Ag</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.59, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 COCP + Ant vs Ant, low response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [0.69, 4.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 COCP + Ant vs Ag, low response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.44, 2.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Multiple pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 COCP + Ant vs Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [0.53, 9.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 COCP + Ant vs Ag</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.85, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 COCP + Ant vs Ant, low response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.11 [0.36, 12.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 COCP + Ant vs Ag, low response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.29, 6.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Ovarian hyperstimulation syndrome rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 COCP + Ant vs Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.28, 3.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 COCP + Ant vs Ag</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.20, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number of oocytes retrieved <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Days of gonadotrophin treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 COCP + Ant vs Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 COCP + Ant vs Ag</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 COCP + Ant vs Ant, low response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 COCP + Ant vs Ag, low response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Amount of gonadotrophins administered <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 COCP + Ant vs Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>190.10 [134.91, 245.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 COCP + Ant vs Ag</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>496</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.96 [‐104.09, 124.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 COCP + Ant vs Ant, low response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>20.0 [‐165.39, 205.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 COCP + Ant vs Ag, low response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐349.0 [‐537.92, ‐160.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Ovarian cyst formation rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 COCP + Ant vs Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.08, 2.75]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Combined oral contraceptive pill (COCP) versus no pretreatment (Rx)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006109-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Progestogen versus placebo/no pretreatment (Rx)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth or ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Progestogen (Prog) + agonist (Ag) vs Ag</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.69, 2.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Prog + antagonist (Ant) vs Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.18, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Prog + gonadotrophin (Gon) vs Gon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.09, 4.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Pregnancy loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Prog + Ag vs Ag</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.26 [0.67, 7.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Prog + Ant vs Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.06, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Prog + Gon vs Gon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.06, 17.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinical pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Prog + Ag vs Ag</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [1.20, 3.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Prog + Ant vs Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.16, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Prog + Gon vs Gon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.14, 3.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Multiple pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Prog + Ant vs Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.06, 17.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of oocytes retrieved <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Prog + Ag vs Ag</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐2.07, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Prog + Ant vs Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [‐0.98, 6.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Prog + Gon vs Gon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.57, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Days of gonadotrophin treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Prog + Ag vs Ag</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.30, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Amount of gonadotrophins administered <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Prog + Ant vs Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>276.0 [‐75.53, 627.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Ovarian cyst formation rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Prog + Ag vs Ag</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.08, 0.32]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Progestogen versus placebo/no pretreatment (Rx)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006109-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Oestrogen versus no pretreatment (Rx)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth or ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Oestrogen (Oestr) + antagonist (Ant) vs Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.53, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Oestr + Ant vs agonist (Ag)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.51, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Pregnancy loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Oestr + Ant vs Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.02, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Oestr + Ant vs Ag</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.62, 4.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinical pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Oestr + Ant vs Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.66, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Oestr + Ant vs Ag</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.45, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Multiple pregnancies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Oestr + Ant vs Ag</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.24 [0.09, 53.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Ovarian hyperstimulation syndrome rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Oestr + Ant vs Ag</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.25, 9.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number of oocytes retrieved <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Oestr + Ant vs Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.23 [0.71, 3.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Oestr + Ant vs Ag</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐4.47, 5.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Days of gonadotrophin treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Oestr + Ant vs Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.58, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Oestr + Ant vs Ag</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.5 [‐4.07, ‐0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Amount of gonadotrophins administered <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Oestr + Ant vs Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>168.35 [111.53, 225.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Oestr + Ant vs Ag</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.0 [‐470.12, 438.12]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Oestrogen versus no pretreatment (Rx)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006109-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Combined oral contraceptive pill (COCP) versus progestogen</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth or ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 COCP + antagonist (Ant) vs progestogen (Prog) + Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.6 [0.12, 2.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Pregnancy loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 COCP + Ant vs Prog + Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.14, 8.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinical pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 COCP + Ant vs Prog + Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.19, 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Multiple pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 COCP + Ant vs Prog + Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.32 [0.19, 27.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of oocytes retrieved <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 COCP + Ant vs Prog + Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [‐3.24, 6.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Amount of gonadotrophins administered <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 COCP + Ant vs Prog + Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>164.0 [‐249.03, 577.03]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Combined oral contraceptive pill (COCP) versus progestogen</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006109-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Combined oral contraceptive pill (COCP) versus oestrogen (Oestr)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth or ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 COCP + antagonist (Ant) vs Oestr + Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.54, 2.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 COCP + agonist (Ag) vs Oestr + Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.01, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Pregnancy loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 COCP + Ag vs Oestr + Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.06, 19.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinical pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 COCP + Ant vs Oestr + Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.60, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 COCP + Ag vs Oestr + Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.02, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of oocytes retrieved <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 COCP + Ant vs Oestr + Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [‐3.59, 5.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Days of gonadotropin treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 COCP + Ant vs Oestr + Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐1.23, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Amount of gonadotrophins administered <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 COCP + Ant vs Oestr + Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>181.56 [‐344.73, 707.86]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Combined oral contraceptive pill (COCP) versus oestrogen (Oestr)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006109-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Progestogen (Prog) versus oestrogen (Oestr)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth or ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Prog + antagonist (Ant) vs Oestr + Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [0.43, 9.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Prog + Ant vs Oestr + Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.30 [0.57, 9.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Number of oocytes retrieved <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Prog + Ant vs Oestr + Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.5 [‐4.55, 3.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Amount of gonadotrophins administered <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Prog + Ant vs Oestr + Ant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>310.0 [‐32.30, 652.30]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Progestogen (Prog) versus oestrogen (Oestr)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006109.pub3/references#CD006109-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006109.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD006109-note-0002">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD006109-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006109-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD006109-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="pt#CD006109-note-0003">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD006109-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006109\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006109\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006109\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006109\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006109\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006109\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006109\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006109\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006109\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006109\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006109\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006109\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006109\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006109\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006109\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006109\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006109\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006109\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=STpJR8yz&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006109.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006109.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006109.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006109.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006109.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714640697"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006109.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714640701"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006109.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d739e5876937f',t:'MTc0MDcxNDY0MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 